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Abstract 
 
Introduction  
Breast cancer is the most common cancer in the world and environmental factors such as 
endocrine disrupting chemicals, as well as reproductive and hormone-related factors play a 
crucial role in the development of this disease. In order to assess causal pathways between 
these exposures and disease initiation, biomarkers based on DNA methylation measurements 
can be used.  
 
Methods 
The potential association between global and locus-specific DNA methylation and breast cancer 
risk was investigated in two prospective European nested case-control studies. The HM450 
array was used to generate epigenomic profiles of archived blood samples, collected from study 
participants before the onset of disease in 324 matched case-control pairs. The association 
between endocrine disrupting chemicals measured in blood samples (n=368), reproductive and 
hormone-related variables assessed by questionnaire (n=324), and hormone levels measured in 
blood(n=36), and DNA methylation was studied. The meet-in-the-middle approach was applied 
to identify DNA methylation markers related to both exposures and disease endpoint.  
 
Results 
Global hypomethylation was observed among breast cancer cases compared with controls and 
locus-specific analyses identified 26 CpGs whose DNA methylation was associated with breast 
cancer. Cadmium exposure was associated with DNA methylation at 62 CpGs but most 
associations did not survive adjustment for smoking status. In addition, numerous reproductive 
and hormone-related variables, as well as the hormones D4 and testosterone were associated 
with DNA methylation, and three potential meet-in-the-middle candidates were observed.  
 
Discussion 
Despite the relatively low power, results indicated that genome-wide hypomethylation among 
breast cancer cases may serve as a biomarker for disease risk. More research with bigger 
sample sizes is needed to disentangle the potential effect of cadmium and smoking on DNA 
methylation and to further explore possible effects of reproductive and hormone-related 
factors, as well as hormone levels, on DNA methylation. It is of interest to investigate what the 
biological consequences of these changes in methylation are.  
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Hypothesis, aims and outline of the thesis 
The use of DNA methylation arrays to characterise the global and locus-specific status of 
genome methylation is commonplace, and has proven useful in furthering understanding of 
mechanisms that underpin numerous diseases. There is considerable interest in applying such 
techniques to understand the contribution that environmental exposures make to the 
development of chronic diseases, including cancer, as little mechanistic evidence is available to 
support or refute existing hypotheses based on associations made in epidemiological studies. 
The work presented here describes the use of DNA methylation data to investigate the link 
between key environmental contaminants, alongside other exposures such as hormone-related 
variables and hormone levels, and breast cancer as outcome, using the meet-in-the-middle 
approach. 
 
Hypothesis 
Conducting combined analyses of exposure data and DNA methylation data will yield meet-in-
the-middle candidates that reflect the aetiology of breast cancer (i.e. methylation patterns that 
are significantly associated with both exposure and disease). 
 
Aims  
In order to address this hypothesis, the following aims were identified: 
 
 Conduct a literature review of environmental exposures (endocrine disrupting 
chemicals), DNA methylation and breast cancer applying the meet-in-the-middle 
approach 
 Investigate if DNA methylation (global as well as locus-specific), measured in peripheral 
blood, is associated with breast cancer risk 
 Examine whether certain exposures, mainly endocrine disrupting chemicals and 
reproductive/hormone-related factors, are associated with changes in DNA methylation  
 Identify possible associations between various hormone levels in blood and DNA 
methylation 
 Assess if DNA methylation lies on the pathway linking exposures to breast cancer 
development, using the meet-in-the-middle principle 
  
19 
 
Outline of the thesis 
Chapter 1 serves as a general introduction to the main area of study, breast cancer. It gives 
background information on the disease, biomarkers, and the meet-in-the-middle approach that 
will be applied in this thesis. In addition it includes a description of epigenetics, epigenomics 
and DNA methylation. 
Chapter 2 describes the results of a literature review in which the meet-in-the-middle approach 
is applied.  The first part summarizes studies that investigated the relation between endocrine 
disrupting chemicals (EDCs) and breast cancer. The second part describes studies that focused 
on the association between exposure to EDCs and DNA methylation, and the third part reviews 
literature reporting associations between DNA methylation and breast cancer. At the end of the 
chapter potential meet-in-the-middle candidates are identified and described. 
Chapter 3 describes the study design, criteria for inclusion of participants, and details of the 
statistical techniques used. An overview of the DNA methylation measurement platform 
(Infinium HumanMethylation450 BeadChip), and associated assay performance 
characterisation accompanies a rationale for the pre-processing and normalization steps taken 
prior to data analysis to ensure high data quality. 
Chapter 4 - 7 describe the main analytical results from analysis of exposure, DNA methylation 
status and other data; Chapter 4 describes the global DNA methylation analyses in relation to 
breast cancer; Chapter 5 focuses on locus-by-locus DNA methylation in relation to breast 
cancer; Chapter 6 describes replication of the analyses from Chapter 4, in an independent 
dataset. Chapter 7 describes analyses of exposures including a) EDC exposures measured in 
blood and the association with locus-specific DNA methylation, b) associations between 
reproductive and hormone-related exposures, measured using questionnaires, and locus-
specific DNA methylation, c) the relationship of hormone levels measured in blood and locus-
specific DNA methylation.  
Chapter 8 draws together the results described in the previous chapters in the context of a 
meet-in-the-middle approach to delineate biomarkers that are associated with both exposures 
and breast cancer outcome. It provides a summary of the main conclusion drawn from the work 
in relation to the central hypothesis and aims described. The strengths and limitations of the 
study are discussed, alongside implications of the findings and future work. 
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Chapter 1 – Introduction 
 
1.1 Breast cancer 
1.1.1 Incidence and mortality 
Breast cancer is the most common cancer 
worldwide (see Figure 1.1) and the most 
commonly diagnosed cancer in women 
with an estimated incidence of 1,676,633 
(age-standardised rate (ASR) = 43.3 per 
100.000) in 2012. It also has the highest 
mortality worldwide, estimated by 
GLOBOCAN to be 521,817 (ASR = 12.9).1  
However, the incidence and mortality rates 
vary internationally. In general, the ASR is 
highest among women in Western Europe 
(96.0), North America (91.6), Northern 
Europe (89.4), and Australia / New 
Zealand (85.8), and lowest in low resource countries such as Middle Africa (26.8), Eastern Asia 
(27.0), and South-Central Asia (28.2). The estimated ASR for more developed regions is 74.1 
compared to an estimated ASR of 31.3 in less developed regions.2 (see Figure 1.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Estimated age-standardised incidence and 
mortality rates for both sexes worldwide in 2012 
(Source: GLOBOCAN 2012, IARC) 
Figure 1.2 Estimated age-standardized rates (per 100.000) of breast cancer incidence worldwide 
in 2012 (Source: GLOBOCAN 2012, IARC) 
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Despite these rather large development related differential ASRs, mortality rates are almost 
equal: the estimated ASR in more developed countries is 14.9 (197,528 deaths) versus 14.3 
(324,289 deaths) in less developed countries. This means mortality rates are considerably 
higher in less developed countries.2;3 This is due to usually a later discovery of the disease and 
the inability to access appropriate treatment in less developed countries, but also to high 
survival rates in highly developed regions. Here, the survival rates can be as high as 80% 
compared to only 40% in developing countries, where 69% of breast cancer deaths occur.4 
Because of this, breast cancer is still the leading cause of cancer mortality among women in the 
world and now represents one in four of all cancers in women.3 
 
1.1.2 Trends in breast cancer incidence and mortality 
Between 1980 and 2010, an average increase of 3.1% in the rates of breast cancer cases per 
year has been observed worldwide and it now affects one in eight women.5;6 This increase was 
most apparent in developing countries where the incidence doubled for women aged 15-49 
years. The increase in developed countries is lower than the global average.6 Reasons for 
observed increasing incidence rates rely not only on the introduction of mammographic 
screening, meaning refined detection, but also on the adoption of a western lifestyle in 
developing countries. Until recently, it was thought that over the past 20 years, trends in breast 
cancer mortality showed decreases, especially in industrialized countries, which was believed to 
be due to earlier diagnosis and advances in treatment and management of the disease.5 In 
December 2013 however, the International Agency for Research on Cancer (IARC) stated in a 
press release that the incidence of cancer worldwide had increased significantly since 2008 to 
14.1 million (mortality: 8.2 million). Importantly, an increase of over 20% in breast cancer 
incidence had been observed since 2008 (mortality increased by 14%). This steep increase was 
mainly attributed to women in less developed countries experiencing fast changes both 
economically and socially and taking on Western lifestyles. In addition, not all women in 
developing countries have access to effective and affordable diagnostics and treatments.3  
 
1.1.3 Breast cancer risk factors 
Breast cancer is one of the most extensively studied malignancies and many studies focused on 
risk factors of the disease in an attempt to unravel the aetiology. To date, several risk factors 
have successfully been identified. Apart from the evident factor of sex (women in the United 
States are a 100 times more likely to develop the disease than men7), the risk of breast cancer 
also increases with age (until menopause, after which the risk levels off)8;9  
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Geographical differences in breast cancer incidence might partly be explained by women in 
Western countries having relatively high social status, delaying childbearing, having relatively 
few children, and (until recently) commonly using hormone-replacement therapy.9;10 Other risk 
factors include genetic/familial factors (about 5-10% of breast cancers in the general 
population have a hereditary basis11) reproductive/hormonal factors (such as high baseline 
levels of endogenous oestrogens, hormone therapy, and oral contraceptive hormones), lifestyle 
factors (such as obesity, physical activity, diet, alcohol consumption), and environmental 
factors.12;13 
 
1.1.4 Environmental factors  
Despite a great number of studies focusing on the aetiology of breast cancer it remains largely 
unknown. However the contribution of environmental factors (i.e. non-genetic) is firstly 
supported by clear geographic differences in incidence rates. Secondly, changes in incidence are 
occurring in relatively short periods of time and thirdly, studies have shown that migrants 
rapidly acquire the risk of disease that is typical of the population where they move.14 This is by 
far the most conclusive evidence for an environmental contribution because underlying genetics 
do not change but the gene-environment indicators do. 
 
An important challenge of environmental epidemiological studies that try to associate 
environmental factors to disease risk, is the exposure assessment methods, especially when 
considering chronic, low level exposures that may be multi-component. Some environmental 
exposures to pollutants such as cadmium (Cd) and polychlorinated biphenyls (PCBs) have been 
associated with the risk of breast cancer (Table 1.1).  
 
Table 1.1 Environmental pollutants associated with breast cancer risk 
Pollutant Characteristics Applications Exposure 
Cadmium Heavy metal, 
soluble in acids 
Batteries and industrial 
processes (e.g. smelting)  
Cigarette smoking. In non-smokers 
predominantly foods, mainly liver 
and kidneys of adult animals, also 
rice grown in cadmium contami-
nated irrigation water. Certain 
occupational exposures as well15 
PCBs Highly lipophilic, 
chemically stable 
Coolants and insulating fluids 
for transformers and capacitors, 
plasticizers in paint 
Mainly diet: fish from contaminated 
water, also inhalation and dermal 
contact16 
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The aforementioned pollutants have carcinogenic, immunotoxic and endocrine-disrupting 
properties. Their persistence in the environment has led to widespread, low-level chronic 
exposure and therefore poses a threat to human health.  
 
1.2 Biomarkers 
The associations between the pollutants described in the previous section and breast cancer 
have been established by classic epidemiological studies. An important addition to these classic 
studies that use disease endpoints, is the use of biological markers (biomarkers). A biomarker is 
defined as “A characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” by The Biomarkers Definitions Working Group.17 They can be environmental 
pollutants, chemicals, or metabolites that can be determined in body fluids or tissue, which 
strongly relate to the actual exposure to these pollutants or chemicals.  
In addition to biomarkers of exposure, intermediate biomarkers based on “-omics” technology, 
such as transcriptomics, proteomics, epigenomics and metabolomics (Table 1.2) (among others) 
directly or indirectly report on events that lie on the pathway linking exposure and disease.  
 
Table 1.2 Overview of main -omics technologies 
-Omics Example of 
platform  
Characteristics 
Transcriptomics Agilent 4x44k DNA 
microarrays 
Study of expression levels of mRNA molecules in a population of 
cells (gene expression profiling). The transcriptome is highly 
variable over time, between cell types and will change in response 
to environmental change 
Proteomics Luminex Multi-
analyte Profiling 
system 
Analysis of the total protein output encoded by the genome, mainly 
to identify proteins within the complex proteomic profile that 
discriminate between normal, benign, or disease status 
Epigenomics DNA microarrays or 
bisulfite sequencing 
Study of epigenetic processes, (mainly DNA methylation, histone 
modification, and microRNAs) on a genome-wide scale 
Metabolomics NMR spectroscopy 
or LC-mass 
spectrometry 
Study of a complete set of low molecular weight metabolites that 
are present in a cell or organism at any given time in order to 
define individual metabolic profiles (and responses) that can be 
used to predict the onset of common diseases 
 
Intermediate biomarkers can provide important mechanistic insight into the pathogenesis of 
diseases with a (suspected) environmental cause.18 In contrast to traditional molecular biology,   
“-omics” technologies allow the use of the same generic methodology for the detection of 
cellular responses to different categories of chemicals and types of toxicity and provide 
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mechanistic information at an exceptional scale. Moreover, these technologies can provide 
unique opportunities for the discovery of biomarkers of exposure to environmental pollutants 
as well as biomarkers capable of predicting susceptibility, disease risk, or effect of treatments.  
An example of the potential for risk prediction is the study by Lewis et al. They found promoter 
hypermethylation of specific genes more frequently in breast biopsies obtained from as yet 
unaffected women known to be at high risk of breast cancer (defined by using three breast 
cancer risk prediction models).19 Belinsky et al. investigated lymphocytes of smokers and 
observed hypermethylation of gene promoters also often found to be methylated in lung 
tumours. This is another example of the fact that epigenomic response to environmental 
exposures can provide molecular evidence of links with disease development.20  
These observations support the anticipation that use of omics-based biomarkers may facilitate 
the establishment of mechanistic links between environmental exposures and disease initiation 
and progression. Most of the reported intermediate biomarkers, however, still need to be 
validated and their role in the causal hypotheses is unclear.21 Two of the most important goals 
of validation of these new biomarkers are to characterize the ability of the marker to predict 
disease and to characterize biomarker variability.22 One of the main challenges is to understand 
whether intermediate biomarkers belong to the causal pathway between exposure and disease, 
whether they are a side effect of exposure or disease, or whether their measurement is 
confounded by some other exposure.  
 
1.3 Meet-in-the-middle approach 
Since epidemiological studies are often aimed at assessing the effect of a modifiable factor (such 
as exposure to endocrine disrupting chemicals) on disease risk, in order to implement health 
interventions or provide health advice, it is important to verify the causality of this (risk) factor. 
Vineis and Perera described an innovative approach to tackle the challenge of identifying causal 
relationships which is known as the ‘‘meet-in-the-middle” (MITM) approach.21 Unlike 
Mendelian23 randomization, this approach does not require a genetic measurement and will 
therefore be applied in this thesis. It is based on a combination, within a prospective study, of 
(a) a retrospective search for intermediate biomarkers which are elevated in subjects who 
eventually go on to develop disease and (b) prospective studies to search for links of such 
biomarkers to past environmental exposures (Figure 1.3). 
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Figure 1.3 The “meet-in-the-middle” approach (reproduced with permission from Vineis et al.18) Within a 
prospective study, a) a retrospective examination in the form of a nested-case-control study is performed to discover 
intermediate biomarkers, and b) the association between (biomarkers of) environmental exposures and intermediate 
biomarkers is assessed in a prospective manner. 
 
The first part of this approach consists of identifying associations between biomarkers of 
exposure and the disease. In this thesis the focus will be on endocrine disrupting chemicals, 
reproductive and hormone-related factors, and hormone levels as exposures and breast cancer 
as outcome. The next step consists of assessing the correlation between (biomarkers of) 
exposure and intermediate –omics biomarkers of early effects. The biomarkers in this thesis are 
serum concentrations of several environmental pollutants and the intermediate –omics 
biomarkers concerns DNA methylation. Thirdly, the relation between the disease outcome and 
intermediate –omics biomarker is assessed. Only when there is an association in all three steps 
it is possible to say that there is a causal association and new biomarkers can potentially be 
identified. These biomarkers would be more generic, provide mechanistic information 
simultaneously on multiple health endpoints, and would be suitable for assessing effects of low 
levels of environmental exposure. 
 
1.4 Epigenetics & epigenomics 
The biomarkers that are the focus of this thesis are part of the -omics technology of epigenomics 
(and epigenetics). There has been a dramatic increasing interest in epigenetic studies lately, 
however, the term epigenetics has been around since 1942, when Conrad Waddington 
introduced the word to describe the processes by which genotype determines how phenotypes 
arise during development.24 Over the years, this definition has been adjusted several times and 
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it is now generally accepted as (the study of) stable changes in gene expression and chromatin 
organization (that can be mitotically and/or meiotically heritable), without changes in the DNA 
sequence. Epigenetics is a naturally occurring and vital process in all humans (and many other 
organisms) and various types of epigenetic processes have been discovered, such as DNA 
methylation and histone methylation, acetylation, phosphorylation, ubiquitylation, and 
sumoylation. However, aberrant changes in these processes can lead to adverse health effects. 
 
Three main epigenetic mechanisms have been identified as DNA methylation (the focus of this 
thesis and described in more detail in section 1.5), chromatin modification, and microRNAs. 
Epigenomics refers to the study of epigenetic mechanisms on a genome-wide scale, which has 
led to the development of the Human Epigenome Project (HEP), which ‘aims to identify, 
catalogue, and interpret genome-wide DNA methylation patterns of all human genes in all major 
tissues’ (http://www.epigenome.org/). 
 
1.4.1 Chromatin modification 
Chromatin makes up the contents of the nucleus of a cell and is a combination of nucleosomes 
around which 147 base pairs of DNA are wrapped. One nucleosome exists of two copies of the 
four core histones (H2A, H2B, H3, and H4), and all these histones contain N-terminal ‘tails’.25 At 
least eight types of modifications have been found on histones, on more than 60 sites.26 When 
chromatin is condensed (heterochromatin) some DNA regulatory regions are hidden, which 
makes it impossible for them to interact with certain proteins, in turn inhibiting gene 
transcription.27 Heterochromatin is characterized by methylated cytosines and deacetylated 
histones, as well as suppressed histone modifications. When chromatin is ‘loose’ (euchromatin) 
gene transcription is eased: less cytosines of euchromatin are methylated, histones are 
acetylated and histone modifications are not suppressed.27 (See Figure 1.4). Chromatin 
modifications remodel the structure, composition and positioning of nucleosomes, which is 
called chromatin remodelling.26  
 
Besides the ‘unravelling’ of the chromatin, the ‘histone code’ hypothesis28 suggests that specific 
histone modifications or combinations of modifications recruit non-histone proteins. The 
binding of or not binding of these proteins to the chromatin causes further modification with 
eventual functional consequences for gene expression, DNA repair and DNA replication.26 
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Figure 1.4 Heterochromatin (A) and Euchromatin (B) (reproduced with permission from: Gioia et al.29) 
Heterochromatin contains methylated cytosines, deacetylated histones, and suppressed histone modifications 
(A).Euchromatin contains acetylated histones, histone modifications are unsuppressed and the DNA is more 
accessible for gene transcription (B).  
 
1.4.2 MicroRNAs 
MicroRNAs (miRNAs) are non-coding RNAs with a length of approximately 22 dinucleotides. 
They bind to specific sites on their target mRNAs by which they repress these mRNAs post-
transcriptionally.30 Some of the mechanisms that cause this repression include mRNA cleavage, 
mRNA deadenylation or alteration of mRNA stability.31;32 The online database miRBase 
(http://www.mirbase.org/index.shtml) is a growing database of newly discovered and 
published miRNA sequences and annotation.33  Research seems to indicate that approximately 
60% of human protein-coding genes are regulated by miRNAs34 and results of a study by Lim et 
al. imply that each miRNA can target 100 to 200 mRNAs.35 
Aberrant miRNA expression has been shown to be involved in the development of human 
cancers. They are often down-regulated in disease which suggests their role as tumour 
suppressors. Differential DNA methylation has been associated with this silencing of miRNA 
genes in breast cancer as well as other cancers.36-39  
 
1.5 DNA methylation 
DNA methylation is the most frequently studied and best understood epigenetic mechanism. It 
involves the covalent addition of a methyl group (CH3) to carbon 5 of the cytosine ring (forming 
5-methylcytosine), which in humans mainly occurs at CpG dinucleotides. It is vital for normal 
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development of mammals because of the key role DNA methylation plays in processes such as 
genomic imprinting40, X-chromosome inactivation41, and silencing of transposable elements42 
(which fall outside the scope of this thesis). It has also been shown as a key factor driving 
carcinogenesis.43 
 
1.5.1 DNA methylation in normal development 
As described above, DNA methylation is a significant regulatory factor in normal development. 
The first important event, in which DNA methylation is involved, takes place after fertilization; 
demethylation of the parental gametes. This happens in two separate steps (see Figure 1.5). 
Firstly, the paternal pronucleus gets rapidly demethylated by an active mechanism in the 
zygote, and secondly, the maternal genome gets demethylated by a passive mechanism, during 
several cell divisions. After this, re-methylation of the DNA starts again, in the inner cell mass 
(ICM) of the developing embryo. The primordial germ cells (PGC’s) inherit the epigenetic 
signature from the epiblast, which is epigenetically segregated from the inner cell mass (dashed 
line). Hereafter in the PGC’s, global demethylation of the DNA takes place again, simultaneously 
with the re-instatement of developmental potency. During development into completely 
specialized gametes, re-methylation of (part of) the DNA occurs again, together with a decrease 
in developmental potency. At differentially methylated regions of imprinted genes however, 
demethylation and re-methylation does not take place in the early embryo.44  
 
 
Figure 1.5 DNA methylation reprogramming in the mammalian life cycle (modified from Seisenberger et al. 44) 
(DPC = days post coitum, ICM = inner cell mass, ES cell = embryonic stem cell, EpiSC = post-implantation epiblast-
derived stem cells, PGC = primordial germ cell, EG cell = embryonic germ cell) Firstly after coitum, demethylation of 
the genome takes places (rapidly and actively for the paternal genome, more slowly and passively for maternal 
genome), after which re-methylation begins in the inner cell mass. After the primordial germ cells have inherited the 
epigenetic signature from the epiblast, global demethylation occurs once more (concurrently with increased 
developmental potency). Once completely specialized gametes have developed, re-methylation takes places, in 
combination with a restriction of the developmental potency. 
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DNA methyltransferases (DNMTs) regulate methylation patterns, by catalysing the transfer of a 
methyl group (CH3) from S-adenosyl-L-methionine (SAM) onto the carbon 5 of the cytosine ring, 
and can be classified into de novo methyltransferases (DNMT3a and DNMT3b), and maintenance 
methyltransferases (DNMT1).45;46 The main function of DNMT3a and DNMT3b are methylating 
cytosines of formerly unmethylated CpG sites while the task of DNMT1 is to copy pre-existing 
methylation patterns onto the new DNA strand during DNA replication.45;46 Another regulatory 
protein, DNMT3L, lacks catalytic activity but modulates the activity of the de novo 
methyltransferases.45;46 
In humans, approximately 70% of all CpG sites are methylated, except when they are part of a 
CpG island (see also section 3.2.4), which are usually unmethylated47 (unless it is located on the 
inactive X chromosome, or near imprinted genes48). CpG islands (CGI) are regions of at least 
200bp, with a CG percentage that is greater than 50%, and with an observed-to-expected CpG 
ratio that is greater than 60%.49 
CpG islands are often located on the promoter and/or first exons of genes50 (~70% of annotated 
gene promoters contain a CpG island51), and when these promoter or exon CGIs are 
(hyper)methylated, it leads to inhibition of gene expression.52;53 Recent work, however, shows it 
is mainly methylation of CpGs at the CpG island shores (sequences up to 2kb on either side of 
the CGI) that influences gene expression, rather than at the core of the CpG islands themselves.54 
In addition, it has been reported that even CpGs in intragenic and intergenic regions are 
associated with promoter function55;56, underlining the relationship between DNA methylation 
of CpG islands and transcription.51  
 
1.5.2 DNA methylation and cancer 
In the 1980s studies reported differences in DNA methylation between tumour tissue and 
normal tissue. Feinberg and Vogelstein found hypomethylation in colon cancer tissues, but not 
in cancer-free tissues, obtained from the same patient.57 In another study they described 
hypomethylation of 2 oncogenes58, and Gama-Sosa et al. observed DNA methylation loss in 
several carcinomas versus healthy tissues.59 Numerous studies since have established the image 
of hypermethylation, mainly of CpG islands on promoters (transcription region of the DNA) of 
tumour suppressor genes60;61 and global hypomethylation62 in tumours relative to non-
tumorous tissues in a wide variety of cancers (although this is not the same for all cell types or 
cancer types63).  
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1.5.2.1 Global DNA hypomethylation 
The exact mechanism by which hypomethylation increases the risk of cancer is still unknown 
but a possible mechanism is by increasing the expression of oncogenes that are located close to 
hypomethylated CpG islands. Other hypothesized processes involve mismatch repair and 
specific chromosomal instability.64;65 Loss of global methylation is mainly measured in repeated 
elements, such as tandem repeats (satellite DNA, minisatellite, and microsatellite) and 
interspersed repeats (among which short interspersed nuclear elements (SINEs), or long 
interspersed nuclear elements (LINEs)). Early estimates stated that about 45% of the human 
genome consists of repetitive elements66;67, but recently a study by De Koning et al. suggested 
approximately 78% of the human genome to be repetitive or repeat-derived.68 In humans, the 
majority of SINEs are Alu sequences (approximately 350 base pairs long, include no coding 
sequences, recognizable by the restriction enzyme Alul (hence Alu sequence), and comprise 
~10% of the human genome), and the majority of LINEs are LINE-1 (comprising ~15% of the 
human genome) hence many studies in humans have focused on these repetitive sequences. 
Hypomethylation of normally methylated LINE-1 and Alu repeats has been associated with 
several cancers, among which breast, ovarian, and colorectal cancers.69-74 
 
Despite the fact that most studies have measured global methylation in repetitive elements, 
other studies suggest that hypomethylation is not only limited to these areas but also occurs in 
gene regions.75-77 Irizarry et al. found hypomethylation of CpG shores but not of CpG islands in 
colon cancer tissue, and Hansen et al. reported hypomethylated blocks across the 
epigenome.54;78 In an attempt to answer the question if this was due to the repetitive sequences, 
they compared methylation levels inside and outside repetitive sequences, both inside and 
outside these blocks. They reported that it was not the presence of repetitive sequences that 
caused most of the overall hypomethylation, but the hypomethylated blocks.78 Also Ruike et al. 
described hypomethylation in breast cancer cell lines that was not restricted to repetitive 
elements but involved all regions of the epigenome.79 
Most DNA methylation studies have compared tumour tissue to healthy tissue but in the last few 
years, more interest has been shown in the possibility of using blood samples to measure DNA 
methylation differences between cases and controls. Choi et al. measured methylation of 
leukocyte DNA and reported global hypomethylation in breast cancer cases compared to 
controls.80 Another study described difference in methylation of repetitive elements measured 
in white blood cells (WBC) between breast cancer cases and healthy controls and suggested the 
potential for future biomarkers coming from studies investigating WBC methylation.81 In the 
following years a review and meta-analysis concluded that there could be great potential for 
DNA methylation of peripheral blood as biomarker for cancer risk, however factors such as 
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study design, study methods and data-analysis issues need to be optimized and taken into 
account.82;83 
 
1.5.2.2 Promoter and CpG island specific DNA hypermethylation 
The other key event in the development of cancer is hypermethylation of promoter CpG islands, 
which has been associated with inactivation of tumour suppressor genes.84 CpG islands on gene 
promoters are normally unmethylated in healthy cells (approximately 3% is methylated, 
including imprinted and X-chromosome inactivated genes) and methylated promoters are 
always repressed in normal conditions (despite the fact that absence of methylation does not 
necessarily indicate activation of the promoter).85 In 1986, the first site-specific 
hypermethylation with subsequent gene silencing was reported (although it did not concern a 
tumour-suppressor gene),86 and in 1989 and 1991 the first papers indicating the role of DNA 
methylation in tumour-suppressor silencing were published.87;88 Since then hypermethylation 
has frequently been observed in breast cancer, as well as various other types of cancer.89-92 
Besides this direct silencing of tumour suppressor genes, promoter hypermethylation, leading 
to inactivation of for example DNA repair genes can also lead to an increased risk of cancer.93 
The affected genes have been shown to be involved in important biological functions, such as 
cell cycle regulation, cell adhesion and invasion, and growth-inhibitory signalling.93  
Some studies, focussing on DNA methylation alterations in breast cancer tissue specifically have 
reported differential methylation between different molecular subtypes of breast cancer (basal-
like, HER2, luminal A and luminal B)94-97, or between breast cancers with different hormonal 
receptor status (i.e. oestrogen receptor-positive and oestrogen receptor-negative).98-100 
Similar to the global DNA methylation studies, the majority of these promoter and CpG island 
specific DNA methylation studies have used tumour cells or tumour tissues compared to cancer 
free cells or tissues, but recent studies indicate that epigenetic features in white blood cells 
(WBC) are encouraging biomarkers of disease risk.101-105 More detailed information about 
differential DNA methylation specifically in breast cancer is described in section 2.3. 
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Chapter 2 – Literature review 
 
This chapter describes the results of a literature review focused on the meet-in-the-middle of 
endocrine disrupting chemicals, DNA methylation and breast cancer. The overview of literature 
is stratified by the three steps of the meet-in-the-middle approach. First an overview is given of 
the studies investigating the association between various endocrine disrupting chemicals 
(cadmium, PCBs) and breast cancer (section 2.1). Next, literature describing relations between 
exposure to endocrine disrupting chemicals and DNA methylation is summarized (section 2.2), 
and finally papers reporting associations between DNA methylation and breast cancer are 
reviewed (section 2.3). 
 
2.1 Exposure and breast cancer 
The biomarkers of exposure assessed in this thesis are blood levels of endocrine disrupting 
chemicals (EDCs), more specifically cadmium and polychlorinated biphenyls. Many studies have 
focused on the association between exposure to EDCs and breast cancer risk. EDCs are synthetic 
and natural compounds in the environment that interfere with (i.e., mimic and/or antagonize) 
the actions of endogenous hormones by altering hormone synthesis, secretion, transport, 
binding, action or elimination and thereby disrupt the functions of the endocrine system. There 
are numerous ways in which exposures to EDCs can occur. While a few compounds are for 
medicinal use, exposures to the vast majority of these EDCs are through unintended exposure.  
 
2.1.1 Cadmium 
Cadmium (Cd) is a persistent heavy metal that occurs naturally in the environment but can also 
be found as a result of industry and agriculture.15 The two main sources of exposure are 
occupationally (occupations such as cadmium production and refining or Ni-Cd battery 
manufacturing) or via tobacco smoke. Non-occupationally exposed non-smokers are usually 
exposed to (considerably lower levels of) cadmium via consuming contaminated food, especially 
cereals, vegetable and potatoes.106 Cadmium has a half-live of approximately 10 years and after 
ingestion it accumulates primarily in the liver and kidneys which can lead to kidney 
dysfunction.15;107 The International Agency for Research on Cancer (IARC) classified cadmium 
and cadmium compounds as carcinogenic to humans (Group 1).108  
The endocrine disrupting properties of cadmium were discovered after studies reported 
increased oestrogen receptor(ER)α-mediated proliferation of breast cancer cells after cadmium 
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exposure.109-111 Moreover, it has been shown that cadmium influences the expression of the 
progesterone receptor (PgR),109;112 In addition, an in vivo study showed oestrogenic responses 
after environmentally relevant doses of cadmium in animals, and in utero exposure of these 
animals to cadmium lead to changes in the development of the mammary glands as well as an 
earlier start of puberty in the female offspring.112 Because of these endocrine disrupting 
characteristics, cadmium and other heavy metals are often referred to as metalloestrogens. 
Several mechanisms by which cadmium causes endocrine disruption, leading to breast cancer 
development, have been identified. Cadmium has been shown to block the binding of 17β-
oestradiol to ERα by binding to the receptor itself and to decrease the total number of available 
oestrogen binding sites.113 It has also been indicated that cadmium can activate GPR30, a 
membrane oestrogen receptor,114 leading to proliferation and migration of breast cancer 
cells.115;116 In addition, cadmium exposure can result in increased extracellular signal-regulated 
protein kinases 1 and 2 (ERK1/2) and Akt activation, which are both involved in cell 
proliferation and apoptosis.109;114;117;118 
Initial epidemiological studies focussed on highly exposed individuals such as occupationally 
exposed subjects or smokers, however in 2009 Jarup et al. stated that also much lower levels of 
environmental cadmium exposure can have adverse health effects.15 Recently, Cho et al. 
performed a meta-analysis on dietary cadmium intake and cancer risk, including 8 studies (2 
case-control studies and 6 cohort studies) and 309,103 participants (12,859 cancer cases). They 
concluded that chronic exposure to cadmium could be involved in the development of breast 
cancer, however a major limitation of the meta-analysis concerns the heterogeneity of the 
included studies and the validity of the assessment of cadmium exposure via dietary intake.119  
Rahim et al. conducted a meta-analysis on population-based studies, investigating the causal 
effect of cadmium on breast cancer risk. They included 13 studies and 2,257 subjects (978 
cadmium exposed breast cancer cases and 1,279 controls). They found no statistically 
significant difference of breast cancer frequency among subjects exposed to cadmium, 
compared to non-exposed individuals. However, after stratifying the analysis by ethnicity, 
higher frequencies of breast cancer were observed in an Asian population compared with a 
Caucasian population.120  
 
2.1.2 Polychlorinated biphenyls (PCBs) 
PCBs are classified into 209 congeners according to the number and position of the chlorine 
atoms in the biphenyl ring. Twelve are classified as dioxin-like PCBs (also coplanar) because of 
their strong affinity for the aryl hydrocarbon receptor (AhR).  
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They were widely used as coolants and insulating fluids in electrical equipment (among many 
other applications) until their production was banned in the 1970s. They are highly persistent 
organic pollutants (POPs) with carcinogenic (classified by the IARC as Group 1 carcinogen121), 
immunotoxic and endocrine-disrupting activities. Because of bioaccumulation in contaminated 
rivers in industrial areas, the primary source of exposure in general populations is from fish 
consumption. According to the International Council for the Exploration of the Seas (ICES), the 
presence of PCBs, especially of the congeners 101, 118, 138, and 153 can be considered as a 
marker for the degree of contamination by industry (European commission Decision. Decision 
99/788/EC. 1999, L 310, 62-70.) PCBs have a long half-life (10-15 years) and accumulate in 
human adipose tissue (including mammary tissues) and high levels have been found in human 
breast milk through which PCBs are transferred from mother to infant.122;123  
An exhaustive review of the epidemiological literature concluded that the evidence to date for 
an association between total PCBs and breast cancer in studies of general populations was 
inconsistent.124 However, some recent studies have investigated the effect of genetic 
polymorphisms on the association between exposure to PCBs and the risk of breast cancer and 
three studies have found a higher breast cancer risk associated with higher PCB exposures 
among postmenopausal white women with a polymorphism in the CYP1A1 gene.125-127 This gene 
is known to be involved in xenobiotic and drug metabolism. Another, more recent review by 
Golden et al. stated that there is growing evidence that environmental exposure to PCBs is not 
etiologically implicated in breast cancer risk. Furthermore they write that this conclusion is 
supported by the consistently negative findings for increased breast cancer mortality in 
occupational studies, which now involve almost 9,000 women.128 
 
2.2 Exposure and DNA methylation 
The next step consists of literature studying the association between biomarkers of exposure 
(EDCs) and –omics biomarkers, in this case: DNA methylation. The results from these studies 
can either concern changes in global methylation, or differential DNA methylation of certain 
genes, often tumour suppressor or oncogenes. 
 
2.2.1 Cadmium and DNA methylation 
Cadmium is the focus of many studies investigating the role of EDCs in relation to epigenetic 
changes. Several animal studies concerning this exposure have been performed as well as 
studies using animal cell lines. Takiguchi et al. reported DNA hypomethylation after exposing 
TRL1215 cells (rat liver) to a dose of 2.5μM of cadmium for 1 week, but hypermethylation after 
35 
 
exposure for 10 weeks (after which the cells are probably transformed).129 Another study 
showed that both a low (140mg/kg CdCl2) and high (210mg/kg CdCl2) dose of cadmium for 60 
days increased global methylation in both the liver and kidney of hens.130 Zhu et al. assessed 
LINE-1 methylation in the liver and testis of rats but found no difference between exposed and 
non-exposed rats after 8 days of post-natal exposure, nor after 70 days. Also no difference was 
detected in methylation level of the p53 promoter in the testis after cadmium exposure. 
However, cadmium exposure did seem to slow down the naturally occurring hypomethylation 
of part of the c-fos gene in the testis.131 Doi et al. demonstrated differential expression of 
DNMT3A and DNMT3B in chick embryos after cadmium exposure, and hypothesized this could 
lead to global de novo DNA hypomethylation, which could play a role in disturbed 
embryogenesis.132 
A genome-wide study was performed by Wang et al. in rat liver, assessing the methylation level 
of 385,000 CpGs after low dose, chronic cadmium exposure (compared to no exposure), using 
the MeDIP-Chip assay. They reported hypermethylation in the promoter region of 675 genes 
and hypomethylation in the promoter region of 899 genes. Looking at gene specific methylation 
of genes regulating the apoptotic process, they found hypermethylation of CASP8 (resulting in 
decreased expression) and hypomethylation of TNF (also resulting in decreased expression).133  
Studies involving human cells or cell lines include the study by Benbrahim-Tallaa et al. who 
reported global DNA hypermethylation after exposing human prostate epithelial cells to 
cadmium for 10 weeks. When they investigated methylation levels of CpG islands specifically in 
the promoter region of two tumour suppressor genes (RASSF1A and p16) they found 
hypermethylation compared to non-exposed cells, which led to reduced expression.134 Global 
hypermethylation was also found in a study by Jiang et al. in which human embryo lung 
fibroblast (HLF) cells were long-term (two months) exposed to cadmium. They observed a dose-
response relationship between increasing exposure and increasing methylation but only 
concentrations of 1.2 and 1.5 μmol/L led to a statistically significant increase compared to non-
exposed cells.135 In contrast, Huang et al. described a reduction in global DNA methylation of 
K562 cells (chronic myelogenous leukemia cell line) after exposure to 2.0 μM of cadmium 
during 24 and 48 hours.136 Recently, Yuan et al. exposed human lymphocyte cells to low levels of 
cadmium (<0.1µM) for 3 months and observed an increase in global DNA methylation (in a 
dose-response manner), and hypermethylation of the CpG island of p16.137 
These different results could be due to different model systems, however, it can also indicate 
that long-term exposure to cadmium leads to global hypermethylation, while acute, short-term 
exposure results in overall hypomethylation.138 
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One study measured cadmium levels in blood samples of 17 mother-child pairs and investigated 
the association with differences in DNA methylation of gene promoter regions. They found DNA 
methylation of 92 genes to be associated with cadmium exposure in maternal blood samples 
and 61 genes in blood samples of the offspring. No overlap was observed between these two 
gene sets. Gene enrichment analysis showed genes involved in cell cycle, cell death, and nervous 
system development to be enriched. The methylation levels for most of the identified genes 
were validated using q-PCR and the Illumina HM450 platform.139  
 
The only study that investigated epigenetic effects of dietary cadmium exposure in humans was 
performed by Hossain et al. Cadmium levels were measured in blood (reflecting short-term 
exposure) and urine (reflecting long-term exposure) samples and peripheral blood was drawn 
to assess LINE-1 methylation levels, as well as methylation of the promoters of p16 and MLH1. 
Higher levels of cadmium in urine were associated with hypomethylation of LINE-1 but no 
association was found between cadmium levels in blood and LINE-1 methylation, nor between 
cadmium concentrations in urine and blood and p16 or MLH1 methylation.140  
 
2.2.2 PCBs and DNA methylation 
Compared to cadmium, PCBs have not as frequently been studied in relation to DNA 
methylation. Bastos Sales et al. exposed N2A cells (murine neurobalstoma cells) and SK-N-AS 
cells (human neuroblastoma cells) to various chemicals, among which PCB-153. After exposing 
the N2A cells for 48 hours to 10 µM of PCB-153 a modest decrease of global methylation was 
observed, while no changes were seen after exposing SK-N-AS cells to the same amount of PCB-
153 for 72 hours. However, the changes in global methylation did not lead to any changes in 
adipocyte differentiation, which was hypothesized by the researchers.141  
Three studies recently investigated human serum levels of persistent organic pollutants (POPs) 
and the associations with global DNA methylation. Rusiecki et al. were the first to examine 
environmental POP exposure in relation to DNA methylation, in Greenlandic Inuits142, who are 
known to have the highest reported POP levels in the world due to their contaminated 
environment and their diet.143 They determined lipid-adjusted levels of PCB-118, PCB-138, PCB-
153, PCB-156, PCB-170 and PCB-180 concentrations (among other POPs) in 70 individuals and 
reported increasing hypomethylation levels with increasing POPs levels, both in Alu and in 
LINE-1 (although stronger associations were observed in Alu).142 Kim et al. studied global DNA 
methylation in whole blood samples from a Korean population (n=86), for which they expected 
lower POPs exposure levels.144 This expectation was correct for most exposures apart from 
beta-hyxachlorocyclohexane (β-HCH) and p,p’-DDT which were similar in both the Inuit and 
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Korean population. After lipid-standardizing the POPs concentrations they found lower Alu 
methylation levels with higher levels of exposure, mainly of organochloric pesticides, among 
which p,p’-DDT and p,p’-DDE, and BDE-47.144 Pesticides also seemed to be inversely associated 
with methylation, however, these associations did not reach significance. Moreover, 
hypomethylation was observed for all exposures measured by LINE-1 but also these 
observations were not statistically significant. When assessing quintiles of exposures, they 
observed several U-shaped associations, indicating lower levels of exposure were stronger 
associated with global hypomethylation.144 Finally, Lind et al. investigated the association 
between circulating levels of (lipid-adjusted) POP concentrations and global DNA methylation 
using the Luminometric Methylation Assay (LUMA), in blood samples of 1,016 Swedish 
subjects.145 They found higher levels of p,p’-DDE and Octachlorodibenzo-p-dioxin (OCDD) to be 
associated with increased levels of global DNA methylation.145 
Several factors can possibly have contributed to the different findings reported by these studies 
(hypomethylation with increasing POPs levels found by Rusiecki et al. and Kim et al., but 
hypermethylation observed by Lind et al.).  Firstly, the technique used to measure global 
methylation was different in the last study (luminometric methylation assay (LUMA)), 
compared to the previous two studies (repetitive elements LINE-1 and Alu), which means 
different parts of the genome have been measured in the different studies. Secondly, exposure 
levels of the Inuit individuals in the study by Rusiecki et al. are much higher than the subjects in 
the other two studies. If the hypothesized U-shaped or non-linear relationship between 
exposure and DNA methylation is true, higher exposures would possibly be part of a different 
part of the distribution, leading to different results. Finally, other (confounding) factors are 
perhaps different between the different populations, such as age. Age is associated with 
exposure levels (because of the accumulation during a lifetime) as well as with DNA 
methylation, which can explain (part of) the different findings.  
Various other endocrine disrupting chemicals have been described in relation to DNA 
methylation, such as diethylstilbestrol (DES) and bisphenol-A (BPA), but they fall out of the 
scope of this thesis.146  
 
2.3 DNA methylation and breast cancer  
The third and final step in the “meet-in-the-middle”-approach describes the association 
between –omics technology (here DNA methylation) and breast cancer. It is of vital importance 
that new biomarkers are found, not only for the detection of breast cancer, but also for typing 
and treatment. Breast cancer has been among the earliest and most intensely studied diseases 
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using various –omics technologies, among which DNA methylation, and many papers have been 
published. Especially during the last 5-10 years, the number of studies has increased 
exponentially, which makes it impossible to describe all individually detected genes with 
altered DNA methylation in breast cancer. For that reason it was decided to only summarize the 
recent reviews on DNA methylation and investigate a possible overlap between genes reported 
to be differentially methylated after exposure to endocrine disrupting chemicals and genes 
reported to be differentially methylated in breast cancer.  
In 2008, Lo et al. performed a literature search for studies reporting epigenetic changes, 
including DNA methylation, in breast cancer.147 They described 40 genes to be hypermethylated 
in subjects with this disease. Both Jovanovic et al. and Huang et al. have recently written 
extensive reviews of papers studying the epigenetics of breast cancer.148;149 They both report a 
list of hypermethylated and hypomethylated genes in human breast cancer cells. Jovanovic et al. 
listed a selection of the 43 most frequently differentially methylated genes in breast cancer: 6 
hypomethylated and 37 hypermethylated genes.149 Huang et al. reports many more genes 
commonly hyper- or hypomethylated in breast cancer, 186 in total.148  
Despite all these reviews, most of the identified genes cannot be used as potential biomarker 
because they have not been replicated and/or validated in subsequent studies, nor is their 
clinical utility tested. More recently performed studies have focused on this and both Wang et al. 
as well as Suijkerbuijk et al. reviewed the possibility of using the methylation status of certain 
genes as a biomarker for breast cancer. They reported 11 and 19 genes respectively, which can 
be found in supplementary Table 2.1.150;151 The study by Suijkerbuijk is more recent and almost 
all genes reported by Wang et al. are also reported by Suijkerbuijk, apart from BRCA2. 
The most recent reviews of potential biomarkers for breast cancer based on DNA methylation 
have been performed by Tang et al. (2012) and Ma et al. (2013).152;153 Tang et al. focused on 
potential diagnostic biomarkers of breast cancer and reported 16 genes. Nine of these genes 
have been identified by various independent studies, which makes them more credible as 
biomarkers (RASSF1A, HIN1, cyclin D2, TWIST, RAR3, RUNX3, BRCA1, BRCA2 and p16). Ma et al. 
summarized 18 genes whose methylation status was associated with breast cancer risk.152 Some 
of these genes had been studied in combination with others81;154, and Radpour et al. showed that 
the sensitivity and specificity for the detection of breast cancer was higher than 90% for a group 
of eight genes together (APC, BIN1, BRCA1, CST6, GSTP1, p16, p21, and TIMP3).154 Ten genes 
reported by Tang et al. and Ma et al. overlap (APC, BIN1, BRCA1, CST6, GSTP1, p16, p21, RARB, 
RASSF1A, and TIMP3), while six genes are reported by Tang et al. but not by Ma et al. and eight 
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are reported by Ma et al. but not by Tang et al. Both lists can be found in supplementary Table 
S2.1. 
 
In addition to these reviews, the online database Pubmeth was explored to identify genes whose 
DNA methylation is altered in breast cancer. Pubmeth is an annotated and reviewed database of 
methylation in cancer (www.pubmeth.org)155. For this review, a cancer centric search was 
performed which resulted in a list of genes reported as being methylated in breast cancer. Only 
genes which had been identified by two or more independent studies were added to the list of 
genes differentially methylated in breast cancer. These genes can also be found in 
supplementary Table S2.1. After combining the genes from the four studies and the online 
database, 52 unique genes remained.   
 
2.4 Meet-in-the-middle candidates derived from the literature 
Most studies that have investigated the association between exposure to EDCs and DNA 
methylation (described in section 2.2) reported changes in global DNA methylation. Only a few 
studies investigating cadmium exposure and DNA methylation reported altered methylation of 
specific genes. Combining the genes reported in these studies results in a list of 1,719 unique, 
differentially methylated genes. When comparing these genes to the genes in supplementary 
Table 2.1 (n=52) seven genes (BRCA1, ESR1 (ERα), FHIT, ID4, CDKN2A (p16), RASSF1A, SCGB3A1 
(HIN-1)) overlapped and were identified as potential meet-in-the-middle candidates. A 
description of the genes, including the function, is given below. 
 
BRCA2 
Wang et al. found the promoter region of the BRCA2 gene to be hypermethylated after cadmium 
exposure and several studies investigated DNA methylation levels of BRCA2 in breast cancer.133 
Lee et al. reported 8-33% of hypermethylation of the promoter of the gene in ductal carcinoma 
in situ (DCIS)156, which is comparable to methylation levels in invasive breast cancer reported 
by Collins et al.157 Cucer et al. studied methylation levels of the 1st exon of the BRCA2 gene and 
reported methylation for half of the women with breast cancer. This methylation was observed 
in their normal tissue, as well as in their tumour tissue. The percentage of women with sporadic 
breast cancer and archival breast tumours in which methylation of the BRCA2 gene was found, 
was 58.33% and 66.67% respectively. More recently, Moelans et al. reported differential 
methylation in 50% or more of DCIS as well as adjacent invasive ductal carcinoma (IDC) lesions 
for BRCA2, amongst other genes. They showed higher methylation frequencies than previous 
studies and stated that hypermethylation of the promoter region of the BRCA2 gene was often 
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observed as an early event in breast cancer development.158 Ben Gacem et al. studied DNA 
methylation changes of BRCA2 in Tunisian subjects and reported promoter hypermethylation of 
BRCA2 (and BRCA1) in 69.2% of the tumour tissues and only 4.6% of the paired normal breast 
tissues. This indicates the significance of BRCA2 promoter methylation in the development of 
the disease.159  
The breast cancer 2, early onset (BRCA2) gene is a large gene (10,254 base pairs, 27 exons) 
located on the long arm of chromosome 13 (13q12-13). As a tumour suppressor gene it is 
involved in the maintenance of genome stability (specifically double strand DNA repair) and 
carriers of mutations in BRCA2 (or BRCA1) gene have 40-80% chance of developing breast 
cancer, which makes it the strongest predictor for the disease to date.160 In addition to an 
increased risk of breast cancer in women, BRCA2 mutations are associated with an increased 
risk of breast cancer in men, as well as increased risk of ovary, fallopian tube and other forms of 
cancer.161 
 
ESR1 
The oestrogen receptor 1 (ESR1) gene, or ERα, was reported to be hypomethylated after 
cadmium exposure by Wang et al. and many studies have reported DNA methylation of this gene 
in breast cancer.133 A study by Lapidus et al. observed DNA methylation of the 5’ UTR region of 
the oestrogen receptor gene in 25% of the ER-negative breast cancer cell lines, which was not 
found in ER-positive breast cancer cell lines.162 A study performed in a Chinese population 
observed higher frequencies of methylation (60.1% of tumours were methylated) and in an 
Indian population, even higher frequencies were reported (66%).163;164 Gaudet et al. assessed 
methylation levels at two CpG islands located on the ESR1 gene and reported only low levels of 
methylation in most breast cancer tumours. In addition, they measured methylation levels of a 
CpG island shore on the ESR1 gene and found a great variety of methylation levels, which were 
weakly associated with reduced expression of ERα.165 Among Iranian women with sporadic 
breast cancer, methylation of ESR1 was observed in 98% of the ER-negative tumours and 65% 
of the ER-positive tumours.166 A study among Brazilian women reported hypermethylation of 
the promoter region of the ESR1 gene in 41% of tumours. They observed lower expression of 
ERα protein with higher levels of ESR1 methylation. Moreover, they showed concurrent 
methylation of ESR1 and CXCL12, another gene that is frequently hypermethylated in breast 
tumours. This was associated with advanced forms of breast cancer, as well as with metastases 
and death.167 An association between ERα expression and methylation of the promoter region of 
the ESR1 gene was also reported by Wei et al. for familial breast cancer in Chinese women168 
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and by Prabhu et al. for triple negative breast cancers in Indian women.169 It seems the level of 
methylation is different among various populations and various types of breast cancer. 
The ESR1 gene is located on chromosome 6 (6q25.1) and encodes an oestrogen receptor which 
is activated by the sex hormone oestrogen. It plays an important role in various cellular 
processes and functions, such as sex development and reproduction. In women, predominantly 
the ovaries, uterus, vagina and mammary glands are targeted by oestrogen, and in men mainly 
the testes, prostate and epididymis. In addition it is vital for the human skeleton, cardiovascular 
system and nervous system. In addition to DNA methylation studies, genetic studies have also 
identified SNPs near ESR1 that are associated with breast cancer risk.170  
 
FHIT 
The fragile histidine triad gene (FHIT) is a tumour suppressor gene which was reported by 
Wang et al. to be hypomethylated after cadmium exposure.133 Methylation levels of this same 
gene were studied by Zöchbauer-Müller et al. in 39 breast tumours and 22 breast cancer cell 
lines. They observed 31% methylation of the breast tumours and 86% methylation of the breast 
cell lines and reported a correlation with FHIT expression.171  Yang et al. found methylation of 
the FHIT gene in 48% (22 out of 46) breast tumour samples but observed no association 
between methylation and expression. When only investigating tumour samples with loss of 
heterozygosity (LOH), 88% methylation (7 out of 8 samples) was found.172 LOH is often 
observed in breast cancer.173 A study by Naqvi et al. investigated 232 breast cancer samples and 
observed higher frequencies of FHIT methylation among locally advanced breast cancers and 
metastases, compared to early tumours, which could indicate FHIT methylation plays a role in 
progression of the disease, rather than in the initiation.174 Raish et al. studied methylation of 
FHIT in relation to clinical and pathological factors among women with breast cancer. They 
observed methylation in 36.8% of the tumour samples, while methylation was only found in 
1.6% of normal tissue of the same patients. They also reported an association between FHIT 
methylation and menopausal status, TNM stage, age at diagnosis, differentiation, and stage of 
the tumours.175 Finally, Syeed et al. studied 130 breast cancer cases and found 
hypermethylation of the FHIT promoter in 59 (45.3%) women. In addition, an association 
between hypermethylation and age, menopausal status, smoking status, nodal status, and 
tumour stage was observed. Moreover, in 30 samples both hypermethylation of the promoter 
region, as well as a mutation in one or more exons of the FHIT gene was observed, indicating 
both events play a role in the development and progression of breast cancer.176   
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The FHIT gene is located on chromosome 3 (3p14.2), belongs to the histidine triad superfamily 
and encodes a diadenosine 5',5'''-P1,P3-triphosphate hydrolase. It is often inactivated in breast 
cancer, as well as in various other cancers such as cervical and lung cancer.177-182 
 
ID4 
The ID4 gene was found to be hypomethylated after cadmium exposure by Wang et al.133 Few 
papers have investigated DNA methylation of this gene in relation to breast cancer. Umetani et 
al. investigated eight breast cancer cell lines and found two (T-47D and HBL-100) to be fully 
methylated, four (MCF-7, BT20, BT549, and BR2) to be partially methylated, and two (734B and 
MDA-MB23) to be unmethylated. In addition they assessed methylation of the ID4 promoter 
among 24 node-positive breast cancer cases and 36 node-negative breast cancer cases (matched 
on age and tumour size) and found 67% and 19% of the samples to be methylated, respectively. 
Moreover, hypermethylation was associated with a decreased mRNA expression of ID4.183 
Noetzel et al. analysed methylation of the ID4 promoter in 170 breast cancer cases and found 
68.9% of the samples to be methylated. Thirteen normal breast samples did not show any ID4 
promoter methylation. They also reported and association between promoter methylation and 
ID4 gene silencing. In addition, hypermethylation of the ID4 promoter was associated with 
positive lymph node status, loss of ID4 mRNA expression, and a higher risk of recurrence of the 
disease.184 
The ID4 gene (Inhibitor Of DNA Binding 4, Dominant Negative Helix-Loop-Helix Protein), 
encodes a member of the inhibitor of DNA binding (ID) protein family. They lack DNA binding 
activity but can form heterodimers with other proteins to perform their functions, such as 
tumour suppression. Promoter hypermethylation of ID4, leading to inactivation of the gene, has 
been observed in several other types of cancer, among which gastric cancer185, colorectal 
cancer186, and leukaemia.187  
 
CDKN2A (p16) 
Both Benbrahim-Tallaa et al. and Yuan et al. observed hypermethylation of the p16 promoter 
after exposing prostate epithelial cells and lymphocyte cells, respectively, to cadmium.134;137 
Various studies have investigated DNA methylation levels of the p16 gene in relation to breast 
cancer. Hui et al. reported methylation of the p16 promoter in 24 out of 120 primary breast 
cancer samples (20%)188, Jing et al. in 13 out of 38 (34%) samples189, Silva et al. in 8 out of 35 
(23%) samples190, while Nielsen et al. only detected methylation in 4-8% of the samples191. 
Dominguez et al. reported hypermethylation in 19% of tumour samples, and found an 
association between p16 hypermethylation and aging.192 Sharma et al. measured methylation of 
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p16 in invasive ductal carcinoma samples and paired serum samples of 36 breast cancer cases. 
In 44% of the tumours, p16 was methylated and in 36% of the paired serum samples. In four 
control samples from healthy females, p16 was not methylated in tumour samples or in serum. 
Methylation of p16 was not associated with any clinico-pathological features.193 Liu et al. 
showed that methylation of CpG islands on the p16 gene was associated with decreased 
expression of the p16 protein and increased expression of cyclinD1, which was associated with 
progression of breast cancer.194 Raish et al. investigated the association between p16 
methylation and clinico-pathological characteristics among Indian female breast cancer cases. 
They reported methylation in 31.9% of the tumour samples, versus 1.4% of normal tissue of the 
same patients. They also reported an association between p16 methylation and menopausal 
status, ER status, and histological grade.175 Vallian et al. used two different methods 
(methylation-specific PCR (MSP) and restriction enzyme-related PCR (REP)) to assess 
methylation of the p16 gene among sporadic breast cancer cases from Iran and reported similar 
results; 37.5% methylation using MSP and 40% methylation using REP. Samples from control 
subjects without the disease did not show any evidence of methylation of the p16 promoter.195 
More recently, Lee et al. studied p16 methylation among 231 invasive breast cancers and 90 
intraductal cancers and found 52.8% and 57.8% of the samples to be methylated, respectively. 
They did not observe an association between methylation and p16 expression. In addition, they 
investigated methylation levels in peripheral blood plasma from 200 women with invasive 
breast cancer and 189 controls and observed 34.5% and 1% methylation, respectively. These 
results support the potential for p16 methylation in blood samples as possible breast cancer 
biomarker.196   
Quite a wide range of percentages of methylation have been reported by these studies, which 
might be explained by the different techniques used to measure DNA methylation, the small 
numbers, the different ethnicities, the various types of breast cancer and the different stages 
and grades of the disease. However, a recent meta-analysis also concluded that p16 
hypermethylation is associated with a higher risk of breast cancer, which can potentially be 
used as a tool for diagnosis and/or treatment of the disease.197 
 
The Cyclin-Dependent Kinase Inhibitor 2a, CDKN2A or p16, is a tumour suppressor gene located 
on chromosome 9, at a locus (9p21) which is frequently deleted in several human cancers, 
among which breast, ovarian, pancreatic cancers and melanomas.198-202 It can bind to CDK4, 
CDK6 and D-type cyclins to inhibit progression of the cell cycle from the G1 to the S phase.175;194  
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RASSF1A  
Benbrahim-Tallaa et al. observed hypermethylation of the RASSF1A promoter, and associated 
reduced expression, after cadmium exposure.134 The association between RASSF1A promoter 
DNA methylation and breast cancer has been the focus of many studies. Agathanggelou et al. 
measured methylation of breast cancer cell lines and found four out of five cell lines to be 
completely methylated, while the fifth one was completely unmethylated. In addition, they 
studied methylation of the RASSF1A promoter in tumour tissue and reported four out of 44 
samples to be methylated (10%). Moreover, they found none of the matched control breast 
tissue to be methylated.203 Burbee et al. assessed methylation of the RASSF1A promoter in 22 
breast tumour cell lines and 39 breast tumours and found methylation in 64% and 49% 
respectively. In the breast cancer cell lines, hypermethylation of CpG islands in the promoter 
was associated with decreased expression of RASSF1A.204 Dammann et al. analysed 16 CpGs on 
the RASSF1A gene in five breast cancer cell lines (MCF7, MDAMB157, MDAMB231, T47D, and 
ZR75-1) and reported all CpGs in all five cell lines to be completely methylated. Moreover, they 
measured methylation of the promoter region of the RASSF1A gene in 45 mammary tumour 
tissues and found 28 (62%) to be methylated. Furthermore, they reported methylation in 100% 
(3 out of 3) of the grade I tumours, 53% (8 out of 15) of the grade II tumours, and 60% (9 out of 
15) of the grade III tumours. In addition, three out of 40 matched, control tissue samples were 
found to be methylated, albeit at a lower level than the tumour samples.205 Dulaimi et al. 
evaluated methylation of the RASSF1A promoter in tumour tissue of 34 breast cancer cases and 
observed hypermethylation in 22 out of 34 (65%) samples. They did not find hypermethylation 
of this gene in serum samples from 20 healthy, age matched controls, nor in serum samples 
from eight females with benign breast disease.206 Lehman et al. investigated methylation levels 
of the RASSF1A gene in intraductal papillomas (n=7), epithelial hyperplasia (n=10), normal 
epithelium (n=6), breast stromal tissue (n=2), and one sample of apocrine metaplasia. They 
found methylation of RASSF1A frequently and for some samples heavily (mainly in epithelial 
hyperplasia and papilloma). The gene is methylated in most samples of DCIS, however in blood 
samples of healthy subjects they observed no methylation of the RASSF1A gene, nor in DNA 
from normal lymph nodes.207 Honorio et al. studied RASSF1A promoter methylation in 20 trios 
of breast samples (each trio consisting of invasive ductal breast carcinoma, adjacent ductal 
carcinoma, and healthy breast tissue) and found methylation in 65% of invasive breast 
carcinomas, 42% of ductal carcinoma, and 0% of healthy breast tissue.208 Also Fackler et al. 
studied RASSF1A methylation in different types of breast cancer. Their study included 32 
lobular carcinomas (13 lobular carcinoma in situ (LCIS), 19 invasive lobular carcinoma (ILC)), 
44 ductal carcinoma in situ (DCIS), and 27 invasive ductal carcinomas. They reported RASSF1A 
to be methylated in 62% of LCIS, 84% of ILC, 88% of DCIS-1, 58% in DCIS-2, 78% in DCIS-3, and 
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70% of IDC.209 Two studies investigated RASSF1A methylation and clinic-pathological features in 
breast cancer cases. Shinozaki et al. investigated tumour tissues of 151 breast cancer cases and 
reported RASSF1A methylation in 122 (81%) primary breast cancer samples and in 59% of the 
sentinel lymph node metastasis (no methylation was observed in 10 control samples from 
healthy women). Furthermore, they found an association between RASSF1A methylation and 
ER-positive tumours.210 A more recent study by Xu et al. used tumour tissue from 193 breast 
cancer cases to assess the association between RASSF1A methylation and several clinical 
characteristics. They reported an association with ER-positive and PR-positive tumours. Using a 
multivariate model adjusting for these factors, plus age, tumour size, and S-phase, they showed 
an association between higher methylation of the RASSF1A gene and worse time to first 
occurrence, as well as worse overall survival. They concluded that the methylation status of this 
gene potentially could serve as a biomarker for disease prognosis.211  Two studies measured 
DNA methylation in blood samples. Yazici et al. assessed methylation frequency of the RASSFA1 
gene in blood of 61 breast cancer cases, 28 unaffected siblings from high risk families and 29 
population-based controls and found 18%, 20% and 0% respectively. Blood was collected two 
weeks – 83 months before diagnosis. They observed no association between methylation of 
RASSF1A and age at diagnosis, age at blood collection, ER status, menopausal status, histology 
grade or BRCA1 and 2 mutations.212 Also Kloten et al. used blood samples to measure RASSF1A 
methylation levels of 250 breast cancer cases, 237 women without breast cancer, and 59 
women with benign breast disease. The frequency of methylation was 47.1% among breast 
cacner cases, 25.9% among healthy control women, and 15.4% among women with benign 
breast disease. They also reported an association between RASSF1A methylation and 
postmenopausal status.213  
 
The RASSF1A gene, or Ras Association (RalGDS/AF-6) Domain Family Member 1, is located on 
chromosome 3 (3p21.3) and is a tumour suppressor gene. It encodes for a protein which is 
involved in DNA repair and which has in addition been shown to influence the G1-S cell cycle 
checkpoint by regulating the level of cyclinD1.214 Besides breast cancer, methylation and 
inactivation of the RASSF1A gene has also been shown to be involved in lung, prostate, pancreas, 
kidney, liver, cervical, thyroid, and many other cancers.215  
 
SCGB3A1 (HIN-1) 
Wang et al. reported hypermethylation of the SCGB3A1 gene after cadmium exposure. Fackler et 
al. studied methylation of the same gene (among others) in 32 lobular carcinomas (13 lobular 
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carcinoma in situ (LCIS), 19 invasive lobular carcinoma (ILC)), 44 ductal carcinoma in situ 
(DCIS), and 27 invasive ductal carcinomas (IDC). They reported SCGB3A1 to be methylated in 
46% of LCIS, 79% of ILC, 79% of DCIS-1, 58% in DCIS-2, 67% in DCIS-3, and 60% of IDC.209 Two 
studies investigated SCGB3A1 methylation in metastatic breast cancer. Mehrotra et al. reported 
methylation of HIN-1 in 40% of primary breast cancer samples, in 90% of bone metastasis and 
in 100% of both brain and lung metastasis. In addition, they observed higher methylation of 
HIN-1 in lymph node metastasis and no hypermethylation in normal, healthy tissue of the same 
individuals. This hypermethylation was associated with decreased expression of the mRNA in 
77% of the samples and with loss of HIN-1 expression in 66% of the samples. Furthermore, they 
showed an association between HIN-1 methylation and ER-positive and PR-positive status.216 
Feng et al. also reported an association between hormone receptor (HR) status and HIN-1 
methylation (both ER-status and PR-status were positively associated with high HIN-1 
methylation) in addition to the finding that HIN-1 was frequently methylated in breast cancer 
tissues (lower methylation in poorly differentiated tumours compared with well- and 
moderately differentiated tumours), but not in healthy breast tissues of the same subjects.217 
The other study that investigated methylation of SCGB3A1 in breast cancer metastasis was 
performed by Feng et al. in 2010. They studied tissues of 38 breast cancer pairs and reported a 
methylation frequency of HIN-1 in 73.7% in tissue of primary tumours and 68.4% in tissue of 
metastases, and a Pearson correlation coefficient of 0.624 between the two. In addition, they 
found higher methylation levels of HIN-1 in subjects with a positive ER and PR status in both 
primary tumours as well as metastasis lymph nodes.218 Park et al. studied 30 atypical ductal 
hyperplasia/flat epithelial atypia (ADH/FEA) samples, 35 DCIS samples, and 50 IDC samples, 
and reported a HIN-1 methylation frequency of 23%, 34% and 35%, respectively. In normal 
breast tissue, they found a methylation frequency of only 3%. They hypothesize their results 
suggest HIN-1 methylation (among other genes) is an event that occurs early in breast cancer 
development. In contrast to previous studies, they did not observe an association between HIN-
1 methylation and ER status.219 Two more studies investigated HIN-1 methylation in relation to 
clinical characteristics. Wang et al. included 32 African American (AA) and 33 European 
American (EA) female breast cancer cases in their study and reported HIN-1 (among other 
genes) often to be hypermethylated in breast tumours compared to healthy tissue from the 
same women. They observed no difference in AA or EA women, nor any association between 
HIN-1 methylation and any of the clinical characteristics.220 The study by Xu et al. from 2012 is 
already mentioned in the previous section, but in addition to RASSF1A methylation, they also 
studied HIN-1 methylation in 193 breast cancer cases and reported a median methylation level 
of 13.6%. In addition they found an association between HIN-1 methylation and ER-positive and 
PR-positive tumours, but not with any other clinical characteristics.211 Sturgeon et al. were the 
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only study using blood samples (serum DNA) from post-menopausal women to investigate 
promoter methylation of several genes, among which HIN-1.  They included 241 breast cancer 
cases with lymph node-positive disease, 63 with lymph node-negative disease and 234 control 
women with benign breast disease. For the first group (lymph node-positive) they found the 
highest methylation levels, followed by intermediate levels for the second group (lymph node-
negative) and lowest levels in the third group (control subjects). The difference between the 
lymph node-positive and control subjects was statistically significant, however, because of the 
relative small differences between the two groups, the researchers are of the opinion it cannot 
be used to differentiate cases from controls in clinical practice.221 Finally, Tisserand et al. 
studied HIN-1 methylation in ductal breast tumours (n=20) and in a small subtype (3-5%) of 
breast cancers: medullary carcinoma (MC) (n=22). They reported HIN-1 methylation in 15 out 
of 20 ductal carcinomas and only in two out of 22 MCs. However, MC accounts for 13% of breast 
cancers among BRCA1 families. Among 10 samples with a BRCA1 germline mutation, they found 
only one sample of which the HIN-1 promoter was methylated.221 This is in agreement with a 
study by Krop et al. who observed almost completely unmethylated promoters of the HIN-1 
gene in BRCA1 tumours, and much higher methylation levels among sporadic breast cancer 
cases.222  
The Secretoglobin, Family 3A, Member 1 gene (SCGB3A1 (HIN-1)), is located on chromosome 5 
(5q35.3) and is an inhibitor of cell growth, cell migration, and cell invasion and it induces 
apoptosis in breast cell lines. The HIN-1-mediated growth inhibition potentially takes place via 
the AKT signalling pathway.223 The gene is known to be associated with breast cancer, as well as 
various other cancers such as prostate, lung, pancreatic, and gastric cancer, testicular germ cell 
tumours (TGCT), ovarian clear cell adenocarcinoma (OCCA), and oesophageal squamous 
cancer.224-229 
 
Some of the differences in results reported by the various studies can be due to the relatively 
small sample sizes and differences in methylation analysis techniques. In addition, the different 
subtypes and stages of breast cancer are associated with different levels of methylation.230 
Despite these differences it seems there is a lot of evidence that DNA methylation of the above 
mentioned genes is involved in breast cancer development and progression. Because most 
genes, apart from CDKN2A (p16), are only reported by one study, it requires more research to 
confirm the association between cadmium exposure and DNA methylation of these genes.  
Breast cancer is a very complex disease, with multiple factors being involved in the aetiology, 
however, the results described above seem to indicate it is possible that cadmium exposure 
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causes changes in DNA methylation of several genes, which increases the risk of (certain types 
of) breast cancer. More studies, investigating this pathway between cadmium exposure, DNA 
methylation and breast cancer are needed to prove and strengthen this hypothesis.  
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Chapter 3 – Methods 
3.1 Study design and subjects 
The European Prospective Investigation into Cancer and Nutrition (EPIC) is a prospective, multi-
centre, epidemiological cohort study aimed at investigating the association between nutritional, 
lifestyle, and environmental factors and cancer, and other chronic diseases.231 Enrolment of 
volunteers took place between 1992 and 2000 and currently 519,978 participants (366,521 
women and 153,457 men) have been included. These individuals are distributed over 23 
centres in 10 European countries (Greece, France, Italy, Spain, the United Kingdom, the Nether-
lands, Germany, Sweden, Denmark, and Norway), which form the sub-cohorts (Figure 3.1).  
 
 
 
 
Figure 3.1 Geographical distribution of the EPIC sub-cohorts Participants from the EPIC cohort are 
recruited from 23 centres in 10 European countries (Greece, France, Italy, Spain, the United Kingdom,  
the Netherlands, Germany, Sweden, Denmark, and Norway) 
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Participants signed an informed consent agreement and completed a questionnaire on diet 
(with country-specific questions) and lifestyle. Topics included education, socio-economic 
status, employment, physical activity, reproductive history, disease history, alcohol 
consumption and tobacco use. In addition, a blood sample was taken (and stored in liquid 
nitrogen within 2-5 hours), anthropometric factors (height, weight, waist and hip 
circumference) were assessed, and blood pressure was measured. Furthermore, 24-hour 
dietary recalls were collected for randomly selected individuals (~7%).232 These data form one 
of the principal sources in the world which can be used to perform biochemical and 
epidemiological investigations into the mechanistic causes of cancer and other diseases. 
 
The Northern Sweden Health and Disease study (NSHDS) comprises questionnaire data 
(exposure and health related topics) and blood samples from three different projects: the 
Västerbotten Intervention program (VIP), the Västerbotten Mammary Screening Program, and 
the Northern Sweden MONICA project.  
VIP started out as a long-term project with the purpose of promoting health of the inhabitants of 
Västerbotten. Enrolment started in 1985, when all individuals who were living in the county and 
were aged 40, 50, and 60 years old, were invited for screening, asked to complete a 
questionnaire and to give a blood sample. Ten years later, a second blood sample and 
questionnaire was taken of all individuals in the cohort. 
Since 1995 blood samples and questionnaire data from approximately 29,000 subjects were 
included in the NSHDS, made available through the Västerbotten Mammary Screening program. 
In this project, a blood sample was taken every 2 years, resulting in 54,400 blood samples which 
were added to the NSHDS. 
Finally, the Northern Sweden MONICA project increased the number of participants with 8,900 
new subjects and the number of blood samples by 14,200 resulting in a total of 95,000 unique 
individuals and 172,600 blood samples for the NSHDS cohort in January 2008. 
All three projects collected information about lifestyle and environmental exposures, while the 
Mammary Screening Cohort also obtained data on hormonal status. Blood samples within the 
NSHDS cohorts were collected in a uniform way and stored at -80˚C within two hours of 
collection. 
 
3.1.1 Human Genetics Foundation (HuGeF) Study 
Participants for this nested case-control study were selected from the Italian cohort of the 
European Prospective Investigation into Cancer and Nutrition (EPIC). This sub-cohort consists 
of 46,857 volunteers (including 32,157 women), recruited from five different centres within 
Italy (Varese, Turin, Florence, Naples, Ragusa). The DNA methylation analyses were performed 
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separately in the laboratory for 2 groups that hereafter will be referred to as ‘Breast I’ and 
‘Breast II’. For Breast I, 95 incident breast cancer cases were identified, for each of whom 95 
healthy controls (matched on date of birth (± 5 years), date of recruitment and study centre) 
were selected, resulting in 190 subjects for whom DNA methylation data was available. Six of 
these subjects were excluded because they were men, three because they were diagnosed with 
another cancer before they developed breast cancer, and 11 because the matched pair was not 
located on the same chip, leaving 170 subjects for the analyses. For Breast II, 166 female 
incident breast cancer cases were selected and matched to 166 healthy female controls (using 
the same matching variables as for the Breast I study), resulting in 332 subjects with 
information on DNA methylation. Here, two subjects had to be excluded because of a diagnosis 
with a different cancer prior to breast cancer, and another two because of incompletely matched 
pairs. The final analyses thus included 328 subjects (164 matched case-control pairs).  
  
Data on anthropology, lifestyle, reproductive, hormone-related, disease history, and dietary 
factors were available through questionnaire data and used for the analyses. In addition, levels 
of 13 hormones were measured in blood, and were available for a small subset of subjects (see 
Table 3.1) Despite not all measures actually being hormones they are all referred to as such 
throughout this thesis for convenience. 
 
Table 3.1 – Hormone levels and number of measurements 
Name Abbreviation N  
Connecting peptide C-peptide 57 
Insulin-like growth factor 1 IGF-1 58 
Insulin-like growth factor-binding protein 1 IGFBP1 23 
Insulin-like growth factor-binding protein 2 IGFBP2 23 
Insulin-like growth factor-binding protein 3 IGFBP3 56 
Testosterone Testosterone 35 
Dehydroepiandrosterone sulfate DHEAS 34 
Sex hormone-binding globulin SHBG 35 
Androstenedione D4 35 
Estrone  E1 31 
Estradiol E2 31 
Progesterone  Progesterone 14 
Glycated hemoglobin HbA1c 23 
 
All hormone assays were performed by the laboratory of the Hormones and Cancer group at the 
International Agency for Research on Cancer (IARC) in Lyon, France. Serum samples were 
thawed once and all hormone measurements were done on the same day to avoid additional 
freeze-thaw cycles. Connecting peptide (C-peptide), estrone (E1), estradiol (E2), sex hormone 
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binding globulin (SHBG), and dehydroepiandrostenedione (DHEAS) concentrations were 
measured using double-antibody radioimmunoassay (RIA) kits (Diagnostic System Laboratories 
Inc., Webster, TX, USA). Concentrations of progesterone and testosterone were measured with 
the radioimmunoassay IM1188 and IM1119, respectively (Beckman Coulter). Serum 
concentrations of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding 
protein 3 (IGFBP-3) were measured by enzyme-linked immunosorbent assays (ELISA), insulin-
like growth factor-binding protein 1 (IGFBP-1) by immunoradiometric assay and insulin-like 
growth factor-binding protein 2 (IGFBP-2) by radioimmunoassay, all from Diagnostic System 
Laboratories (Webster, TX, USA). Androstenedione (D4) was measured by direct 
radioimmunosorbent array (Diagnostic System Laboratories Inc., Webster, TX, USA). 
Measurements of glycated haemoglobin (HbA1c) were done on erythrocyte hemolysate using 
the high-performance liquid chromatography method with BioRad variant II instrument.  
 
All participants signed an informed consent form and the ethical review boards of the 
International Agency for Research on Cancer (IARC) and of local participating centres approved 
the study protocol.  
 
3.1.2 EnviroGenoMarkers (EGM) study 
Subjects within the EGM project were recruited from both EPIC and NSHDS, and include 600 
breast cancer cases and 600 matched controls, and 300 non-Hodgkin lymphoma (NHL) cases 
and 300 matched controls. Matching was performed on age, sex, year of recruitment and 
country. DNA methylation is available for 684 subjects, among which 190 breast cancer subjects 
(95 cases and 95 controls), and 494 lymphoma subjects (247 cases and 247 controls). 
Depending on the type of analysis, different numbers of subjects were included in the different 
sections of this thesis. At the start of each section, the specific numbers used will be outlined.  
Besides DNA methylation, data on seven environmental exposures, measured in blood (PCB-
118, PCB-138, PCB-153, PCB-156, PCB-170, PCB-180, cadmium) were made available for the 
analyses in this thesis. Serum concentrations were used for the assessment of PCBs, while 
exposure to the heavy metal cadmium was evaluated using erythrocyte concentrations.  
The PCB analyses were performed in the National Institute for Health and Welfare, Chemical 
Exposure Unit, in Kuopio, in Finland, using an Agilent 7000B gas chromatograph triple 
quadrupole mass spectrometer (GC-MS/MS). Pretreatment of serum samples for GC-MS/MS 
analysis has been described by Koponen et al.233 Samples below the limit of quantification (LOQ) 
were excluded from analyses. LOQ was 6pg/ml for PCB118 and PCB156; 10pg/ml for PCB138, 
PCB153, PCB170, and PCB180.  
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The concentrations of cadmium in erythrocytes were determined by Hannu Kiviranta from the 
Department of Environmental Health at the National Public Health Institute (KTL), Kuopio, in 
Finland, by inductively coupled plasma-mass spectrometry (ICP-MS; Thermo X7, Thermo 
Elemental, Winsford, UK) in samples diluted with an alkaline solution according to a method 
described by Barany et al.234 The detection limit, calculated as 3 times the standard deviation 
(SD) of the blank was 0.03 µg/L. The analytical accuracy was checked against human blood 
reference material from Centre de Toxicologie du Quebec, International Comparison Program, 
Canada. All samples were prepared in duplicate and the method imprecision (calculated as the 
coefficient of variation for duplicate preparation measurements) was 5%. To reduce the impact 
of technically-induced variation, matched pairs were analysed in the same batch on the same 
day. As matching was performed by sample date each case therefore had the same storage time 
as its matched control. 
 
A summary of the available number of cases and controls per cohort are displayed in Table 3.2. 
 
Table 3.2 – Final number of breast cancer cases and controls, per cohort to include in the analyses  
 Disease endpoint Cases Controls Total 
HuGeF     
     Breast I Breast cancer 85 85 190 
     Breast II Breast cancer 164 164 328 
     Total (HuGeF)  249 249 518 
EGM     
     EPIC Breast cancer 49 48  
 Lymphoma 0* 80 (46 female)  
     NSHDS Breast cancer 46 47  
 Lymphoma 0* 167 (76 female)  
     Total (EGM)  95 342 (217 female) 437 (312 female) 
*Due to potential bias in case of inclusion of lymphoma cases, only lymphoma controls were used in the analyses 
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3.2 The Infinium HumanMethylation450 BeadChip 
3.2.1 Laboratory analysis 
DNA was extracted from buffy coats or blood cell fractions using the 
QIAsymphony DNA Midi Kit (Qiagen, Crawley, UK). 500 ng of DNA 
was treated with sodium bisulfite, using the EZ-96 DNA Methylation-
Gold™ Kit (according to the manufacturer’s protocol (Zymo Research, 
Orange, CA, USA)), which converted unmethylated cytosines (C) to 
uracile (U) whereas methylated cytosines remained unchanged. Next, 
the bisulfite converted DNA (BCD) samples were denatured, 
neutralized and isothermally amplified. After whole genome 
amplification (WGA), the samples were fragmented (using end-point 
fragmentation) and isopropanol-precipitated, after which the DNA 
was collected by centrifugation at 4˚C. Next, the DNA was re-
suspended in hybridization buffer and applied to BeadChips. Each 
BeadChip contained 12 samples and was incubated in the Illumina 
Hybridization Oven at 48˚C for 17 hours, followed by single 
nucleotide extension. The incorporated nucleotides were labelled 
with biotin (ddCTP and ddGTP) and 2,4-dinitrophenol (DNP) (ddATP 
and ddTTP). After the extension step and staining, the BeadChip was 
washed and scanned using the Illumina HiScan SQ scanner. The 
intensities of the images were extracted using the GenomeStudio 
(v.2011.1) Methylation module (1.9.0) software, which normalizes 
within-sample data using different internal controls that are present 
on the HumanMethylation450 BeadChip (HM450) and internal background CpGs. These lab-
analyses were performed in the laboratory of the Human Genetics Foundation (HuGeF), by Dr. 
Silvia Polidoro (for more information about the protocol used by Dr. Polidoro, see the document 
“Infinium HD Assay Methylation Protocol Guide (15019519)” on the Illumina support website:  
http://support.illumina.com/array/array_kits/infinium_humanmethylation450_beadchip_kit/d
ocumentation.html). 
 
3.2.2 The Infinium probe design 
The Infinium HumanMethylation450 BeadChip array (HM450) can be used for the assessment 
of genome-wide DNA methylation patterns. When a probe successfully binds to DNA, a single 
fluorescent labelled nucleotide extends off the probe and this signal is read by an Illumina 
reader, however, the signal depends on the type of assay.  The array consists of two types of 
Figure 3.2 Infinium 
HumanMethylation450 
BeadChip 12 samples can 
be processed in parallel 
and >450.000 methyla-
tion sites across the 
genome can be assayed 
per sample 
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assay designs: the Infinium I assay, which was used for the previous Illumina array (Illumina 
Infinium HumanMethylation27 BeadChip (HM27)), and for 135,501 probes on the HM450 array, 
and the Infinium II assay, which was used for the remaining 350,076 probes that are included 
on the HM450 array.  
3.2.2.1 Infinium I 
The design of the Infinium I assay 
consists of two bead types for each 
CpG site (locus) of interest: an 
unmethylated bead (U) and a 
methylated bead (M). Each Infinium 
I bead is paired with a 50-base 
oligonucleotide of which only the 3’ 
terminus is different. One strand 
matches the methylated ‘C’ 
(cytosine) and the other strand 
matches the unmethylated ‘C’ 
(thymine). Thus, for example, at an 
unmethylated locus, the un-
methylated bead can bind to the 
DNA, while the methylated bead 
cannot. Also, the opposite is true: at 
a methylated locus the methylated 
bead can bind to the DNA, while the 
unmethylated bead cannot. The colour channel is either green (Cy  for ‘C’) or red (Cy5 for ‘A’ or 
‘T’), which is the same for both the methylated as well as the unmethylated bead. As a result of 
this design, both beads fluoresce at the same wavelength. Subsequently, the ratios of 
fluorescence intensity between the two bead types are calculated, where 0 indicates no 
methylation and 1 indicates total methylation (see Figure 3.3). 
The assumption behind this design is that there exists high correlation between the methylation 
levels of the CpGs within the 50bp span, therefore the methylation of all CpGs within the 50bp is 
reported to be equally methylated or unmethylated as the query site. This assumption is 
supported by a study which found high correlation in methylation levels of CpGs within 50bp of 
each other, located on chromosome 6, 20 and 22.235 
 
Figure 3.3 Infinium I and Infinium II assays on the 
HumanMethylation450 BeadChip (from technical note244) Infinium 
I utilizes two bead types (one for the unmethylated and one for the 
methylated state) for each CpG locus. The Infinium II utilizes one 
bead type for each CpG locus, an M+U bead. 
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3.2.2.2 Infinium II 
Only one bead type for each CpG locus that is being queried is used for the Infinium II design; an 
M+U bead. This bead binds to a 50-base oligonucleotide directly upstream of the query site and 
is either extended with a G, to complement a “methylated” C (Cy  in the green channel) or with 
an A, to complement an “unmethylated” T (Cy5 in the red channel) at the CpG locus of interest. 
These probes fluoresce at different wavelengths, depending on the methylation state. (see 
Figure 3.3.) A reason why Infinium II probes would be preferred is that Infinium II probes can 
have up to three CpGs within the 50bp span with a different methylation status from the CpG of 
interest.236 Another reason why type II probes would be favoured is because of the single bead 
type, which means more CpGs can be queried.  
Out of the 485,577 CpG sites that are being assessed by the array 135,501 are of the Infinium I 
type and 350,076 are of the Infinium II type. 
 
3.2.3 Control probes 
For quality control, the HM450 array includes control probes. These can either provide 
information about the quality of the various steps that have been taken while following the 
protocol, or they can help in identifying samples that form outliers in order for them to be 
(potentially) excluded from further analyses. 
The control probes can be divided in sample independent probes, which are used to assess the 
performance of the chip, and sample dependent probes, which evaluate the performance of the 
assay across samples, in addition to the quality of the DNA that was used. A brief overview of 
the different types of control probes and their function is given in Table 3.3. 
 
Table 3.3 – Different types of control probes and their functions 
Type of control probe Function 
Sample independent Staining To assess sensitivity and efficiency of the staining in the 
green (biotin) and the red (DNP) channel 
 Extension To test the efficiency of single base extension in both the 
green (extension with A or T) and the red (extension 
with C or G) channel 
 Target removal To test the efficiency of stripping off the DNA template 
after the extension reaction 
 Hybridization To evaluate assay performance using synthetic targets 
(instead of amplified DNA) that complement the probe 
sequence  
Sample dependent Bisulfite conversion To test efficiency of bisulfite conversion of genomic DNA 
by query of the C/T polymorphism (separate for 
Infinium I and Infinium II) 
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 Specificity To monitor potential non-specific detection of 
methylation signal over unmethylated background 
(separate for Infinium I and Infinium II) 
 Negative To measure background ‘noise’ (they do not match to 
any part of the genome). GenomeStudio uses them for 
background correction 
 Non-polymorphic To test the overall performance of the assay, from 
amplification to detection, by querying a particular base 
in a non-polymorphic region of the genome 
 
These quality control steps were assessed by Dr. Silvia Polidoro at HuGeF and judged to be of 
good quality. 
 
3.2.4 Array content  
The Infinium HumanMethylation450 BeadChip from Illumina is an array that allows the 
assessment of the methylation levels of 485,577 cytosine positions on the human genome. It is 
the successor of the Illumina GoldenGate DNA Methylation BeadArray (covering 1,505 CpGs), 
and the Illumina Infinium HumanMethylation27 BeadChip (covering >27,000 CpGs). The CpGs 
on the array are distributed over all 22 autosomal chromosomes and the X and Y chromosomes. 
The array also includes 65 SNPs that were included to confirm the identity of samples from the 
same individual, as an added level of quality control. The regions and locations of the queried 
CpGs were selected by a Consortium which was formed by 22 experts in the field of methylation. 
They focused on CpGs located on RefSeq genes (http://www.ncbi.nlm.nih.gov/RefSeq/)237, or 
on CpG islands, shores and shelves, on CpG islands that were defined by use of Hidden Markov 
Models238;239, CpGs located on FANTOM4 promoters (identified through the Functional 
Annotation of the mammalian Genome consortium)240, or in major histocompatibility complex 
(MHC) regions241. They also concentrated on biologically significant and informative positions of 
the genome, differentially methylated regions242;243, non-CpG sites244;245 and other regions.236  
The array assesses methylation levels of 98.9% of the total 21,474 UCSC RefGenes, with an 
average of 17.2 probes per gene region. In addition, genes that are not covered by the UCSC 
database are included on the array. 
The CpGs on the array can be divided based on the different parts of the gene, into CpGs located 
at the TSS200 (n=52,283), TS1500 (n=68,984), 5'UTR (n=42,685), 1st Exon (n=22,737), Body 
(161,677), and 3'UTR (n=17,494). This categorization relates to the functional regions of the 
gene where the probes are located. TSS200 is the region from the transcription start site (TSS) 
to -200 nucleotides (nt) upstream of the TSS, and TSS1500 comprises the area -200 to -1500 
nucleotides upstream of the TSS. The five prime untranslated region (5'UTR) extends from the 
TSS to one nucleotide before the start codon. The first exon is the first part of the section that 
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contains information required for protein synthesis and all exons together are found in the 
mature transcript (messenger RNA). The gene body is the sequence between the transcriptional 
start site to the end of the transcript (the termination site). Finally the three prime untranslated 
region (3'UTR) is defined as the section directly following the translation termination codon. 
(see Figure 3.4)  
 
 
Figure 3.4 The gene body and related locations on the genome (figure reproduced with permission from 
Bibikova et al.236) The functional regions of the gene: TSS (transcription start site), TSS200 (region from TSS to -
200nt upstream of TSS), TSS1500 (-200 to -1500 nt upstream of TSS), 5’UTR (region from TSS to 1nt before start 
codon), 1st exon, gene body, and 3’UTR (region after the translation termination codon) 
 
Furthermore, a distinction can be made based on the location of the probes on the genome, into 
CpG island (n=150,254), CpG north shore (n=62,870), CpG south shore (n=49,197), CpG north 
shelf (n=24,844), CpG south shelf (n=22,300), and CpGs located at open sea (regions outside the 
shelves) (n=176,112). A CpG island is defined as a region of at least 200bp, with a CG percentage 
that is greater than 50%, and with an observed-to-expected CpG ratio that is greater than 
60%.49 A CpG shore is defined as the area 2kb on either side of a CpG island, and a CpG shelf is 
defined as the area 2kb on either side of a CpG shore (or 2-4kb from a CpG island).54;236 (see 
Figure 3.5). On average, each CpG islands contains 5.63 probes, each north and south shore 2.93 
and 2.81 probes, and each north and south shelf 2.07 and 2.03 probes, respectively. 
 
 
Figure 3.5 The CpG Island and related locations on the genome (figure reproduced with permission from 
Bibikova et al.236) CpG islands (separated in sections of 500bp), CpG island north and south shores (regions 2kb 
upstream and downstream of the CpG island), CpG island north and south shelves (regions 2kb upstream and 
downstream of the CpG island shores) 
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The major histocompatibility complex (MHC) is located on chromosome 6 in humans and is one 
of the most gene-dense and polymorphic regions in the human genome. It plays a role in the 
immune function and has been associated with many varying and complex diseases, which 
makes it an extremely interesting area to study.241;246 For these reasons, 12,334 probes on the 
array are located on the MHC. 
3,091 loci on the array are non-CpG sites. These are of importance because they are only found 
in stem cells and have not been detected in differentiated cells. The mechanism and functional 
significance of non-CpG methylation is still unknown, however it has been hypothesised to play 
a central role in the establishment and maintenance of the pluripotent stage.244;245 
Finally, the CpGs on the array can be classified according to the associated RNA transcript into 
coding (361,766), non-coding (4,168), and intergenic (119,830).247  
 
3.2.5 Reliability and reproducibility, precision and accuracy 
Several studies have assessed the performance of the array. Sandoval et al. used the array to 
measure methylation levels in two healthy colorectal tissue samples and compared this to a 
frequently used colorectal cancer cell line (HCT-116). They observed high correlation between 
the two healthy samples and major differences between the healthy samples and the cancer cell 
line. Moreover, they compared the methylation levels in the cell lines to findings from previous 
studies assessing methylation of HCT-116 cells using various other methods and found 
comparable results. In addition, a comparison was made between methylation levels in HCT-
116 cells measured with the HM450 array and measured with the recognized and standardized 
predecessors: Illumina GoldenGate DNA Methylation BeadArray (covering 1,505 CpGs), and the 
Illumina Infinium HumanMethylation27 BeadChip (covering >27,000 CpGs). The HM450 
includes more than 90% of the CpGs measured by the Golden Gate array and the HM27. High 
correlations were observed between the HM450 and Golden Gate and HM27 arrays (Pearson 
correlation coefficient R2=0.87 and R2=0.94, respectively). Based on these results Sandoval et al. 
judged the array to be biologically, functionally, and technically reliable and robust.247   
The group who developed the array have also described its performance in a paper. They 
mention different beta-value distributions for the Infinium I and Infinium II assay but claim this 
has no consequences for the detection of differences in methylation.236 In addition, they 
assessed the reproducibility of the array by measuring beta-values of technical replicates in 
three different cell lines, as well as in healthy and tumour tissue. They reported an average 
correlation of R2=0.992, which makes the array highly reproducible. Moreover, they showed a 
correlation of R2>0.95 between the HM450 and HM27 array. Finally, the group evaluated the 
correlation of methylation levels measured by the HM450 array and methylation levels obtained 
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from another method (whole genome bisulfite sequencing (WGBS) using a HiSeq2000 by 
Illumina). They calculated the correlation in healthy tissue and in tumour tissue and reported R2 
of 0.95 and 0.96 respectively. 236  
 
3.2.6 Strengths and limitations of the HM450 array 
As with any technical method, there are strengths or benefits and limitations or disadvantages 
that can be identified for the HM450 array.  
 
Strengths 
Firstly, the array offers a genome-wide coverage with the assessment of >480,000 cytosine 
positions, chosen based on several criteria by methylation experts resulting in highly 
informative data.236 The 12 samples per chip provide high throughput capacity, which makes 
the array ideal for studies with large sample sizes. The relatively easy workflow offers user 
friendly and time efficient analysis, and compared to other methods the HM450 array is 
relatively affordable. The input of biological material on the array is low (500ng bisulphite 
converted DNA), which is perfect for cohort studies and biobanks which make their valuable 
samples available for epigenetic studies. Another advantage of the HM450 array is the fact that 
there exists high overlap with other platforms by Illumina, such as gene expression arrays and 
microRNA profiling, which offers the potential of integrating these data. The high level of 
reproducibility (mentioned in the previous section) is combined with a high level of sensitivity. 
The developers of the array have demonstrated that the array is able to reliably detect a 
difference in beta-value of 0.2 (this refers to tissue samples and not to blood samples) with a 
false positive rate <1%.248  
 
However, despite these strengths, some limitations have been described by several studies. 
 
Limitations 
Differences in Infinium I and Infinium II probes 
Despite the fact that Bibikova et al. mentioned the difference in beta-value distribution between 
Infinium I and Infinium II (hypomethylated probes for Infinium II do not reach beta-values of 0 
and hypermethylated probes for the same Infinium type do not reach 1), they did not recognize 
this as a potential point of concern and did not measure possible consequences of this 
discrepancy.236 Dedeurwaerder et al. focused on the consequences of using these two different 
Infinium types and confirmed that Infinium II probes are less sensitive for the measurement of 
extreme methylation values. In addition, they found larger variance as well as lower efficiency 
for the Infinium II probes compared to the Infinium I probes.249 Moreover, the average 
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Table 3.4 – Percentage of CpG sites covered by 
Infinium I and Infinium II in different regions 
 
intensities in the red and the green channel are different. They developed a technique called 
peak-based correction (PBC) to deal with these issues. 
 
Furthermore, the two Infinium types do not 
measure the same regions on the genome. 
Out of all CpG sites on CpG islands, 51.7% is 
of Infinium type I and 48.3% is of Infinium 
type II probes, which is fairly equal. For 
probes on shores however, these 
percentages are 20.0% (type I) and 80.0% 
(type II), and for probes outside shores 
15.9% and 84.1% for type I and type II, 
respectively. Also for different genomic 
locations the percentage of type I and type 
II probes are not equal (see Table 3.4). For 
these reasons some studies have argued it is 
best to not use PBC but analyse Infinium I 
and Infinium II probes separately (if no 
other correction technique is used).  
 
Batch effects 
Similar to gene expression studies, DNA methylation experiments have been shown to be prone 
to batch effects.250-253 Since 12 samples are analysed on one chip, eight chips (96 samples) form 
one plate, and two plates can be placed in the hybridization oven at the same time, it is likely for 
batch effects to occur. These technical artefacts are not correlated with any biological variables 
but are systematic differences associated with factors related to, for example, laboratory 
conditions. This potentially leads to incorrect conclusions or a loss of power if correction is not 
applied properly.254  
However, it needs to be emphasized that the design of the experiment can prevent certain batch 
effects from having a major impact on the results. If the cases and controls are randomized 
(keeping the matched case-control pairs on the same chip but randomizing the position on the 
array) and all DNA samples (if possible) are processed together at the same time, then ‘chip’-
effect, ‘position on the array’-effect and ‘plate’-effect are likely to be eliminated. The importance 
of this has also been shown for microarray studies using Illumina BeadChips.255 There is nothing 
that can be done with correction or normalization that replaces careful experimental design. 
 Infinium I 
(%) 
Infinium II 
(%) 
Relation to CpG Island   
   CGI 51.7 48.3 
   Shores 20.0 80.0 
   Distant 15.9 84.1 
   
Genomic location   
   1st Exon 44.9 55.1 
   5'UTR 24.4 75.6 
   Gene body 22.8 77.2 
   3'UTR 15.1 84.9 
   TSS200 48.9 51.1 
   TSS1500 25.3 74.7 
   Intergenic 38.9 61.1 
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Nevertheless, some confounding factors cannot be avoided and rigorous quality control is 
always necessary.  
 
Non-specific probes  
Despite claims of high specificity, a large percentage of probes are not mapped to unique loci on 
the human genome. This was already observed in the HM27 array (as well as genotyping and 
expression arrays), where around 1,000 non-specific probes were found to be ambiguously 
mapped to multiple genomic locations.256 Recently, several studies investigated this problem in 
relation to the HM450 array.257-259 One reason why this takes place is because the beads bind to 
an oligonucleotide which is only 50bp long, and therefore may map to multiple genomic 
locations. Another reason for its occurrence are repeated sequences. The methylation levels of 
these non-specific probes are probably amalgamations of methylation signals at more than one 
location, but because there is most likely no correlation between these locations, their 
methylation levels are not interpretable. If this issue is not dealt with appropriately, it can 
potentially lead to incorrect conclusions and an inability to validate these signals in 
downstream analyses.257 
 
SNP probes 
The HM450 array is based on measuring C/T SNPs introduced after bisulfite conversion. 
Considering this, it becomes clear that bias in methylation signals may occur when a SNP is 
present at the CpG of interest, and it may be possible that a difference in genotype, rather than a 
difference in DNA methylation, is being measured. When the query site includes a SNP it can 
lead to an incorrect DNA methylation signal due to hybridization of the wrong probe (possible 
for Infinium I probes) or to no or very limited extension of the target site (possible for both 
Infinium I and II probes). Therefore, careful interpretation of methylation levels at SNPs is 
important.258 
 
Because of the limitations pointed out above, the data need to be pre-processed before the 
actual analyses can start. 
 
3.3 Pre-processing & normalization of the data 
3.3.1 Pre-processing 
To date, there is no consensus in the field of DNA methylation analysis using the HM450 array 
as to which pre-processing steps should be taken and which forms of normalization should be 
performed. These steps are intended to remove sources of technical bias between 
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measurements, without removing or losing true biological differences between samples and 
probes. Currently, studies are ongoing trying to determine the optimal methods of pre-
treatment of the data before the actual analyses can take place. Deciding which pre-processing 
and normalization to use has been one of the biggest challenges of this PhD. Below is an 
overview of possible techniques and their rationale.    
 
3.3.1.1 Background subtraction 
The purpose of background subtraction is to remove the non-speciﬁc signal from the total 
signal, or in other words to remove background noise. This background noise translates to a 
reduced dynamic range of beta-values. Background subtraction is an option given by 
GenomeStudio, however, the method suffers from truncation of the data at low intensity 
levels.260 Therefore it was decided that it was preferable for bio-informatician colleague 
Gianluca Campanella to perform this subtraction manually rather than relying on 
GenomeStudio. First, per-sample means were calculated of negative control probes in the green 
and red channel separately. Next, means were subtracted from probe intensities in the A and B 
channel according to the type and colour of each probe. If intensities became negative after this 
subtraction, they were set to missing.  
 
3.3.1.2 Detection p-values 
Each beta value is accompanied by a detection p-value, which indicates the confidence or 
reliability of the methylation reading. To calculate detection p-values a normal distribution was 
fitted to a set of negative control probes, in the green and red channel separately. Subsequently 
the normal quantile function was used to compute detection p-values for probe intensities in the 
unmethylated (A) and methylated (B) channel according to the type and colour of each probe. 
This step was also performed by Gianluca Campanella. All probes whose detection p-value was 
higher than 0.05 were considered as non-detected, and samples with >5% non-detected probes 
were excluded. In addition, probes that were not detected in >20% of all samples were excluded 
from the analyses. 
 
3.3.1.3 Dye bias correction 
Because of the different average intensities in the red and green channels, it is proposed to 
perform dye bias correction. For Infinium I probes, the unmethylated and methylated probe are 
always measured in the same colour channel; however, for Infinium II probes, the methylated 
signal is measured in the green channel and the unmethylated signal is measured in the red 
channel, hence methylated and unmethylated Infinium II probes are not comparable. Therefore, 
dye bias of Infinium II probes was corrected by equalising the intensities in the green and red 
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channel to the average intensities across the two colours as measured by normalization control 
probes present on the BeadChip. This method is similar to the method Triche et al. suggested 
after comparing different correction techniques.260 This was done with the help of Gianluca 
Campanella. GenomeStudio has an implemented approach of dye bias correction but there is no 
option to select a different array as the reference. 
 
In addition, it became apparent that there was a “position-on-the-array”-effect (also mentioned 
in section 3.2.6 under ‘batch effects’) in our data. Figure 3.6 shows two box-and-whisker plots 
(before and after dye bias correction) of the mean methylation values grouped and coloured by 
chip position. It clearly highlights the benefits of this method, as the “position on the array”-
effect is minimized which results in samples that are much more comparable. 
 
 
Figure 3.6 Box-and-whisker plots of mean β-values for each position on the chip, before and after dye bias 
correction Each box-and-whisker plot shows the mean β-value (horizontal black line), the first and third quartile 
(bottom and top of the box) and the minimum and maximum (end of the whiskers). The red box includes all samples 
on the first row and the first column of all chips, the orange box includes all samples on the first row and the second 
column of all chips, the yellow box includes all samples on the second row and the first column of all chips etc. Before 
dye bias correction a clear ‘position on the chip’ effect is visible, which largely disappears after dye bias correction. 
 
β-values and M-values 
After these correction steps, actual methylation values were calculated for each probe, using the 
average intensities of unmethylated (U) and methylated (M) signals, and expressed as a β-value: 
β = M / (U + M + α) where α is an arbitrary offset (usually 100) intended to stabilize β-values 
where fluorescent intensities are low.  
Alternatively, M-values instead of β-values can be used to perform the analyses. M = log2 ((M + 
α) / (U + α)), which is basically a logit transformation of the β-values.261 They are not restricted 
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to values between 0 and 1, which creates the possibility of performing other types of analyses. 
Often M-values are transformed back to β-values after the analyses because β-values are easier 
to biologically interpret. 
These β-values and M-values were used to analyse the data in this thesis. 
 
3.3.4 Normalization 
After obtaining the beta-values, it is of key importance to perform normalization techniques 
before any analysis will be performed and various techniques have been proposed with respect 
to the HumanMethylation 450BeadChip. There are three aims of using normalization methods: 
1) reduction of between-sample technical variability, 2) correction of probe design type bias 
(Infinium I and Infinium II difference), and 3) reduction of batch effect. 
 
3.3.4.1 Technical variability 
Quantile normalization (QN) is a method which is often used for high throughput data, in order 
to reduce between-sample variation, without losing true biological differences between 
samples. It is a non-linear transformation that replaces each intensity score with the mean of 
the features with the same rank from each array.262 Studies use various QN approaches. Some 
studies chose to quantile normalize the intensities of the methylated signal and unmethylated 
signal separately, after which they re-calculate the average β-value, or quantile normalize 
Infinium I and II separately.251;262;263 Other groups have experimented with quantile normalizing 
each probe type and colour channel separately (Type I Red (M), Type I Green (M), Type I Red 
(U), Type I Green (U), Type II Red, Type II Green). Relatively many studies use the same strategy 
as gene expression studies and quantile normalize the average beta values which equalizes the 
distribution of the beta values for each sample, a technique that has been shown to be successful 
for this type of study.264 However, when this technique is performed on DNA methylation data, it 
is likely that valuable information is lost when intensity distributions are equalized across all 
arrays. A disadvantage of QN is the fact that, for parts of the distributions where there are few 
values (for DNA methylation data this concerns values of around 0.5), substantial changes may 
arise. Large changes could potentially lead to an increase in variance across samples for 
individual features, instead of a decrease, which was aimed for.262 Since the current study 
involved blood samples, the expected differences in methylation between cases and controls is 
quite small, which makes it even more important to not overcorrect or dilute any results.   
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3.3.4.2 Probe design type bias 
As described in section 3.2.6 under the heading ‘limitations, Dedeurwaerder et al. observed 
differences in sensitivity, variance and efficiency between Infinium I and Infinium II probes and 
developed a peak-based correction method to minimize these differences.249 This was done by 
rescaling the distribution of type II probes on the basis of Infinium I probes, which resulted in a 
smaller variance and higher precision of the type II probes. In addition, using PBC increased the 
number of significant associations that the researchers were able to detect. However, the 
authors already touched upon a potential problem of applying PBC to clinical tissue samples. In 
addition, other studies have recently questioned this method and described possible problems. 
Maksimovic et al. and Touleimat et al. have both applied the method to their data but observed 
only moderate results. In order to make it possible to analyse both Infinium types at the same 
time both groups have developed another method (SWAN and subset quantile normalization 
(SQN)), optimizing peak-based correction.265;266  
 
In order to provide an accurate normalization of Infinium I and II probes and to correct for the 
difference between the two probe types, subset quantile normalization uses Infinium I 
methylation signals as anchor to estimate a reference distribution of quantiles. This reference is 
subsequently used to estimate a target distribution of quantiles for Infinium II probes.266 This is 
done separately for probes in the different ‘relation to CpG’ categories (north and south shore, 
north and south shelve and distant), as well as ‘relation to gene sequence’ categories (body, 5´-
UTR, 3´-UTR, 1st exon, intergenic, TSS200 and TSS1500) to take into account the fact that 
probes on different parts of the genome will measure different methylation levels. This method 
was first developed for normalization of gene expression signals.267 The approach was applied 
to DNA methylation data and compared to other methods such as no normalization, classic QN, 
and PBC and it performed best in completely correcting the shift between Infinium I and II 
probes. In addition, pyrosequencing was used to validate the findings, and also in comparison to 
pyrosequencing results, SQN was preferred over the other methods. However, large batch 
effects might not be as easily controlled by this technique.266 
 
Likewise, Subset-quantile Within Array Normalization (SWAN) aims at normalizing Infinium I 
and II probes by performing two steps.265 Firstly, a subset of randomly selected probes that are 
biologically similar based on CpG content is defined and used to determine an average quantile 
distribution. This is done for probes with one, two, or three CpGs in the probe body, for the 
Infinium I and II probes separately, and subsequently the subsets are sorted by increasing 
intensity and the mean intensity for Infinium I and Infinium II probes is calculated for each 
‘quantile’. Secondly, the intensities of the remaining probes is adjusted (again separately for 
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Infinium I and II), using linear interpolation of the subset probes. Results showed a reduction in 
technical variation using SWAN and an increased capability of detecting methylation differences 
between samples. However, despite the fact that SWAN resulted in equal distributions of the 
subset, the intensity distribution between the two probe types is still very different.265 
 
Recently, a study by Teschendorff et al. proposed yet another method, a beta-mixture quantile 
normalization (BMIQ) method, to address this problem.268 BMIQ is assumption free, unlike PBC 
which assumes a bimodal shape of the methylation density profiles, and SQN and SWAN, which 
both require separate normalization of the subsets of probes because of the assumption of 
methylation differences at different genomic regions and CpG density. BMIQ is an intra-array 
normalization method which aims to adjust the beta-values of Infinium II probes into a 
statistical distribution which is similar to Infinium I probes. Firstly, probes are categorized into 
different methylation states by means of a three-state beta-mixture model; unmethylated, hemi-
methylated, and methylated, for Infinium I and II probes separately. Next, for Infinium II probes 
which are categorized into the unmethylated state, the probabilities of belonging to this 
category are transformed to quantiles using the inverse of the cumulative beta-distribution with 
beta parameter estimates from the Infinium I probes in the same (unmethylated) category. The 
same is done for the probes assigned to the methylated category. Quantiles for the probes in the 
hemi-methylated category are obtained by performing a dilation (scale) transformation. This is 
done is a way that does not affect the biological variation of the two probes types (related to 
their location on the genome), or reduces the bias and the difference in distribution between 
Infinium I and II probes, while the relative ranking of beta values remains the same under the 
transformation.268 
Teschendorff et al. showed some weaknesses of PBC when applied to their data and they 
compared performance of their BMIQ method to PBC, and SWAN in ten independent dataset. 
Firstly, they showed that BMIQ performed well when analysing tumour tissues samples, where 
PBC failed to produce excellent results. Subsequently, they reduced technical variation and bias 
of Infinium II methylation values, and observed an elimination of Infinium I enrichment bias 
using BMIQ. The method was favoured over PBC and SWAN, based on several criteria.268  
 
Despite the fact that the difference between Infinium I and II probe distributions might be 
expected since the different probes measure different parts of the genome, and it is known that 
different parts of the genome are differently methylated269-271;271, there are several arguments 
for the importance of making the distributions of Infinium I and II probes comparable. Firstly, 
the different range for the two probe types might introduce enrichment bias towards Infinium I 
probes. Secondly, when aiming to identify differentially methylated regions, the assumption is 
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made that there are no technical differences between the different probes in the region.272 
Thirdly, it is important when clustering, classification, or reduction algorithms are to be applied, 
that these can be applied to one dataset and not two different subsets of Infinium I and II probes 
seperately.273-275 
 
3.3.4.3 Batch effect 
The last aim of normalization methods is to reduce batch effects. The normalization methods 
described above are not sufficient to remove batch effects, because they can affect different 
probes in different ways. Techniques to identify batch effects include principal component 
analysis, clustering techniques, or linear models to measure the level of confounding between 
the outcome of interest (for example case-control status) and potential variables related to 
batch effect (such as analysis date or laboratory factors). 
When a batch effect has been identified, it can be adjusted for by including variables such as 
processing date of the sample in the model, or it can be correct by using statistical methods such 
as ComBat or Surrogate Variable Analysis (SVA).252  
SVA is especially useful when attempts to identify the true sources of batch effects have failed.254 
This can happen when it is impossible to measure certain factors or when they are unknown. 
Briefly, the method identifies variables in the data with more variability than expected by 
chance and identifies a subset of probes that drives this variation. Next, a surrogate variable is 
built for each subset of probes and all significant surrogate variables are included in further 
statistical models as covariates. The surrogate variables are built on the original DNA 
methylation data and take into account the fact that a surrogate variable may have a different 
effect on each gene. It has been shown to have advantages over other techniques254, but one of 
the disadvantages comprises its need for >25 samples per batch. An adjustment to this method 
is the independent surrogate variable analysis (ISVA), which uses independent component 
analysis (ICA) to model confounding factors as statistically independent variables. For ISVA, the 
variables need to be non-linearly uncorrelated, which is more robust than the linear 
uncorrelated variables in the case of SVA.276 It was demonstrated to be applicable to both the 
HM27 and HM450 array and to improve the identification of confounding factors, compared to 
other techniques.276 
ComBat is an Empirical Bayes (EB) method which was originally developed to reduce batch 
effects in gene expression (microarray) studies.277 The method uses parametric empirical priors 
to estimate batch effect parameters (after first standardizing the data). Subsequently, the data 
are adjusted for these identified batch effects which results in a more robust adjustment.277 The 
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main advantages of ComBat are the fact that it deals with outliers and that it can be applied to 
data with small batch sizes (n<10), unlike many other methods.277  
One of the biggest discussions in the area of DNA methylation analysis remains to be the 
question of which pre-processing method to use in order to correctly identify differentially 
methylated probes. Marabita et al. recently published a paper evaluating six different pipelines 
for DNA analyses using the Infinium HumanMethylation 450 BeadChip.263 The first conclusion 
concerned the necessity to adjust for the probe design type bias using dye bias correction. 
Secondly, it was concluded that BMIQ (individually or in combination with QN), was most 
effective in reducing technical bias. Finally, it was advised to use ComBat to adjust for batch 
effects.263 Because of these conclusions, it was decided to perform the same pre-processing 
steps in the current work, in summary: 
- Sample and probe filtering: 
o Exclusion of samples with >5% non-detected probes 
o Exclusion of probes not detected in >20% of all samples 
- Background subtraction 
- Dye bias correction 
- Normalization using BMIQ  
- Correction for batch effect using ComBat 
 
3.3.5 Additional probe exclusions 
The final step, before the actual analyses can commence, consists of exclusion of additional 
probes. As described in section 3.2.6, several probes map to multiple locations on the genome, 
and since the methylation values at these probes are not informative, it is best to exclude them 
from the analysis. Price et al. expanded Illumina’s annotation file, adding cross-hybridizing 
probes among others, which is publicly available from the National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus (GEO) website, under the accession GPL16304 
(http://www.ncbi.nlm.nih.gov/geo). 
In the annotation file from Illumina, SNPs located within 10bp of the query site (n=36,535) and 
SNPs located within the remainder of the probe (n=59,892) were already included. Price et al. 
added SNPs at the actual target CpG to this annotation, and, given their demonstrated potential 
bias of a SNP at the queried CpG, suggested to exclude these probes from the analyses.258 The 
effect of SNPs at other locations of the probe are most likely not as severe, although it has been 
demonstrated to influence the binding of probes in mRNA expression arrays, which used probes 
of the same length as the HM450 array.278  
Another important point to take into account regarding SNPs in the probe body is the minor 
allele frequency. If the SNP is very rare in the study population, it is better not to exclude the 
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probe from the analyses. For these reasons, it was decided to include probes with SNPs in the 
analyses, in order to avoid naively excluding a large part of the data. After obtaining statistically 
significant results, they will be checked against the annotation file by Price et al.258 in order to 
confirm true biological variation.   
Excluding the above mentioned probes from the analyses does not only result in a less stringent 
FDR correction, because fewer probes will be tested, but it will probably also lead to more valid 
biological signals.259 
 
3.4 Statistical analyses 
The different analyses are either performed in the HuGeF study or the EGM cohort. More 
detailed information is given in the sections below. The HuGeF study consists of DNA 
methylation measured for 190 subjects of the Breast I cohort, and 332 subjects of the Breast II 
cohort. Unfortunately, due to a technical problem during the lab analyses, the quality of the 
Breast I samples was judged as very poor. Figure 3.7 gives an overview of the mean signal 
intensity in the Breast I, Breast II, and EGM samples.  
 
Figure 3.7 Box-and-whisker plots of mean signal intensities in the Breast I (B1), Breast II (B2), and 
EnviroGenoMarkers (EGM) studies. Each box-and-whisker plot shows the mean signal intensity (horizontal black 
line), the first and third quartile (bottom and top of the box) and the minimum and maximum (end of the whiskers). 
The mean signal intensity of the Breast I study is low for many of the samples, with large variability among samples 
above the third quartile. The mean signal intensities of the Breast II study and EGM study are higher and more 
comparable, although the EGM samples have a larger variability of the mean signal intensities. 
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It was feared that the Breast I methylation data could dilute any possible signal we were trying 
to obtain. After careful evaluation and discussion with both the senior laboratory scientist (Dr. 
Silvia Polidoro) and the bio-informatician (Gianluca Campanella), it was concluded that the data 
was of such low quality that the Breast I samples should be excluded from any further analyses.  
 
3.4.1 Global DNA methylation 
The global DNA methylation analyses were performed using samples from the HuGeF (Breast II) 
cohort. This cohort consisted of 164 incident female breast cancer cases and 164 healthy female 
controls (matched on date of birth (± 5 years), date of recruitment, and study centre).  
As a measure for global methylation, the mean β-value over all CpGs was computed for each 
subject. A paired Wilcoxon test was performed to estimate the crude difference in mean 
between cases and controls. An adjusted estimate was obtained by running a conditional logistic 
regression model with case-control status as the outcome and the global methylation 
measurement as continuous predictor while adjusting for age. Despite the fact that cases and 
controls are matched on age (± 5 years), it was decided to adjust for it because of potential 
residual confounding. Next, the global methylation levels (beta-values) were divided into 
quartiles based on the distribution in controls. As a quantitative measure of the overall 
methylation, each quartile was allocated its median value. To ease comparison with the 
corresponding methylation distribution in controls, medians were centred and standardized 
using the observed means and standard deviations over all CpGs investigated. Conditional 
logistic regression including these quantitative measures was performed by time to diagnosis 
(defined as the time interval between date of recruitment and date of diagnosis of breast 
cancer), and breast cancer risk factors such as oestrogen receptor (ER)-status, and 
characteristics of the tumour such as grade and stage. The odds ratios (OR’s), 95% confidence 
intervals (95% CIs) and p-values are reported, and p-values <0.05 were considered to be 
statistically significant. 
Potential confounding factors were assessed by running linear regression models of global 
methylation versus baseline variables and breast cancer risk factors. In addition, variables that 
showed an association with breast cancer in our dataset, or in the literature, were identified as 
potential confounding factors and adjusted analyses were performed.  
 
Subsequently, the CpGs of the HM450 array were categorized into different classes, according to 
their physical location or the functionality of the region where the CpG is located. Illumina’s 
manifest file was used for the definition of the classes of the following groups: ‘Regulatory 
Feature Category’, ‘Gene Region Category’, and ‘Associated RNA Transcript Category’. Finally, 
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information about repetitive elements was obtained from the RepeatMasker track of the UCSC 
Genome Browser279. (http://www.repeatmasker.org). Mean methylation values across all CpGs 
in each category were computed for each subject, and the OR, 95% CI and p-value for the 
association between global methylation and breast cancer were calculated using a conditional 
logistic regression model.  
 
3.4.2 Locus-by-locus analysis 
The locus-by-locus analyses, investigating the association between DNA methylation at 
>480.000 CpGs on the human genome and breast cancer, were performed using samples from 
the HuGeF study.  
 
The median β-value among cases and controls was calculated for each CpG and Wilcoxon non-
parametric tests on median methylation levels within case-control pairs were performed to 
assess whether each CpG was significantly discriminating cases and controls. Possible 
associations between case-control status (outcome) and methylation level (M-values) 
(continuous predictor), adjusting for the pair identifier (i.e. accounting for age, chip) were 
evaluated by means of conditional logistic regression models. Stratified analyses were 
performed by menopausal status and MTHFR genotype. In order to assess the possibility of 
reverse causality, the analyses were repeated excluding all cases (and their matched controls) 
who were diagnosed within one year of enrolment. 
Q-values, measuring the maximum FDR from the Benjamini and Hochberg method were 
derived, and the overall type I error was controlled by conservatively applying Bonferroni 
multiple testing correction: the per-test significance cut-off value was set to 1.03x10-7.  
The observed versus the expected number of CpGs on the genes of the top hits was calculated, 
and the direction of the effect was evaluated, in combination with the location of the CpGs on 
the genome. 
 
In order to identify potential subgroups of CpGs among the CpGs with q-values<0.05 obtained 
from the conditional logistic regression analysis, two types of cluster analyses were performed.  
 
Firstly, principal component analysis was performed on all CpGs with a q-value<0.05 using the 
“prcomp” function from the default stats packages in R. Since this function cannot handle 
missing data, they were imputed using the KNN (k-nearest neighbours) method implemented in 
the impute.knn function from the R package ‘impute’. The variance explained for each of the 
principal components (PCs) was calculated, and score plots depicting the first, second, or third 
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PC on the X-axis and Y-axis were produced in order to visually investigate potential subgroups 
among the CpGs. 
Next, consensus clustering280 was performed (using the ConsensusClusterPlus package from 
Bioconductor281), in an attempt to classify CpGs with similar characteristics into groups. This 
was performed on the same CpGs with 80% samples resampling, 80% CpGs resampling, a 
maximum evaluated k of 10,  100 resamplings, a kmeans algorithm and Manhattan distance.282  
 
3.4.3 Exposure analyses 
Chapter 7 describes the results of the analyses between EDC exposures, hormone-related and 
reproductive variables from questionnaire data, and hormone levels in blood as predictive 
variables, and DNA methylation as outcomes.  
 
3.4.3.1 Endocrine disrupting chemicals and DNA methylation 
Section 7.1 shows the results of the analyses evaluating the association between EDCs and DNA 
methylation, for which data of the EGM cohort were used. 
Summary descriptive statistics for the cohort were calculated for all variables. Medians and 
ranges of cadmium and PCB exposures were reported for the entire EGM cohort, as well as for 
the EPIC-Italy and NSHDS cohort separately. Equally, all subsequent analyses were performed in 
the EGM, EPIC-Italy and NSHDS cohort. After assessing the normality of the distribution of the 
exposure levels, it was decided to log-normalize them. Besides single exposures, the total PCB 
concentrations were summed and analysed, as well as the following mixtures of PCBs, based on 
the properties of the congeners: dioxin-like congeners (PCB118 and PCB156), non-dioxin-like 
PCBs (PCB138, PCB153, PCB170, and PCB180), immunotoxic PCBs (PCB118, PCB138, PCB156, 
and PCB170). A linear model was run with DNA methylation (M-values) as the outcome and the 
exposure as predicting variable, adjusting for age, sex, chip, case-control status, and centre. The 
number of CpGs reaching a genome-wide significance level were summarized per exposure, as 
well as the number of CpGs with a q-value<0.05 and the smallest observed p-value. Significant 
top hits for each exposure were summarized, and an overlap in affected CpGs by all PCBs was 
investigated.  
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3.4.3.2 Hormone-related and reproductive variables from questionnaire data and DNA 
methylation 
Questionnaire data were used from the HuGeF Breast II cohort to assess the association 
between several hormone-related and reproductive variables and DNA methylation. The results 
of these analyses are described in section 7.2. 
Summary descriptive statistics for cases and controls were calculated for all variables and a 
linear model was run with DNA methylation (M-values) as the outcome, and the hormone-
related or reproductive variable as predicting variable, adjusting for age, chip, case-control 
status, and centre. The number of CpGs reaching a genome-wide significance level were 
summarized per assessed variable, as well as the number of CpGs with a q-value<0.05 and the 
smallest observed p-value. Significant top hits for each exposure were summarized. 
 
3.4.3.3 Blood hormone levels and DNA methylation 
The last section of Chapter 7, section 7.3, describes the results of the analysis of hormone levels 
in blood and DNA methylation. Summary descriptive statistics for cases and controls were 
calculated for all variables and a linear model was used, assessing the effect of hormone levels 
(continuous predictor) on methylation levels (M-values) (outcome), adjusting for age and case-
control status. Because of the small numbers it was not possible to adjust for chip and position 
on the chip but as described in section 3.3.1.3 these biases have been minimized. These analyses 
were run on HuGeF samples, and the number of CpGs reaching a genome-wide significance level 
were summarized per assessed hormone level, as well as the number of CpGs with a q-
value<0.05 and the smallest observed p-value. Significant top hits for each exposure were 
summarized. 
 
3.4.4 Validation and Replication 
Even after strict quality control, pre-processing, elaborate analyses and adjustment for 
confounders and multiple testing, it is still possible that false positive results arise. Obviously 
the study design is important in increasing the chances of findings being real and meaningful, 
but other ways of confirming the observations is by validating and/or replicating the results. 
Ideally, both validation and replication are performed, although this is not always possible 
because of factors such as high costs or limited access to studies with the correct study designs 
and tissue available.  
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3.4.4.1 Validation 
After finding results, it is important they are validated using a different method (laboratory 
technique) in the same samples, to verify that results are accurate and reliable. This is mainly 
advisable when a method is not yet established or has limitations. Since the HM450 array has 
been evaluated by Sandoval et al. (see also section 3.2.5) and concluded it to be reliable and 
reproducible, it was decided that validation, for example using pyrosequencing, was not 
necessary for the results presented in this thesis. 
 
3.4.4.2 Replication  
In addition to validation, it is important to replicate results in an independent dataset, i.e. the 
same methods are used on different samples. The EnviroGenoMarkers (EGM) dataset was used 
in an attempt to do this for the global methylation analyses (Chapter 4) and results are 
presented in Chapter 6. The same pre-processing was applied, after which identical analyses 
were performed. The results are more reliable once they have been replicated in independent 
samples and can be extrapolated and generalized to a broader population. Given the necessity to 
adjust for multiple testing, it was not attempted to replicate the locus-by-locus (genome-wide) 
analyses (Chapter 5) because the sample size of the EGM dataset was deemed too small to yield 
genome-wide significant results. 
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Chapter 4 – Global DNA methylation and breast cancer 
 
4.1 Samples and study population 
The global DNA methylation analyses were performed using samples from the HuGeF study 
(n=332). DNA methylation was measured at 485,577 loci on the genome in all subjects: 166 
cases and 166 matched controls. 65 of these loci were SNPs, which were excluded from the 
analyses. Out of all 332 subjects, two subjects had to be excluded because of a diagnosis with 
another cancer prior to developing breast cancer, and another two subjects because their 
matched pair was not located on the same chip. 
Following these initial sample exclusions, pre-processing of the DNA methylation data excluded 
36,655 CpGs from the analyses because of missing values in >20% (66) of the samples, and 
another three samples because of missing values for >5% (22,443) of the remaining CpGs. 
Finally, one sample (which formed an incomplete match-pair), and 40,108 non-specific CpGs 
were excluded, resulting in 324 samples in which DNA methylation was measured at 408,749 
CpGs.  
 
Median follow-up (cases and controls combined) was 11.3 years and median time to diagnosis 
(the interval between date of recruitment and date of breast cancer diagnosis) was 3.8 years. 
Baseline characteristics and breast cancer risk factors of the study population, stratified by 
case-control status are reported in Table 4.1. The p-value refers to the significant level of the 
student’s t-test (or Wilcoxon test) or chi2 test for differences between cases and controls.  
Cases and controls are similar for most variables, however, differences were observed for 
physical activity (more inactive cases compared with controls, p-value = 0.04), smoking status 
(more never smokers in cases and more former smokers in controls, p-value = 0.02), and age at 
menopause (cases being older at menopause than controls, p-value = 0.03). 
 
Table 4.1 – Baseline characteristics and breast cancer risk factors of the study population  
Characteristic  Cases (n=162) Controls (n=162) p-value& 
Centre n (%)   1.00 
   Florence  28 (17.3) 28 (17.3)  
   Varese  29 (17.9) 29 (17.9)  
   Ragusa  6 (3.7) 6 (3.7)  
   Turin  88 (54.3) 88 (54.3)  
   Naples  11 (6.8) 11 (6.8)  
Age at recruitment mean (range), years 52.4 (35.0 – 70.0) 52.4 (34.0 – 70.0) 0.95 
Height mean (range), cm 158.6(141.5 – 177.5) 159.1 (139.5 – 175.5) 0.48 
Weight mean (range), kg 64.5 (44.3 – 106.0) 66.1 (42.8 – 104.6) 0.20 
BMI n (%)   0.49 
   Underweight  2 (1.2) 2 (1.2)  
   Normal  65 (40.1) 77 (47.5)  
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   Overweight  68 (42.0) 55 (34.0)  
   Obese  26 (16.1) 27(16.7)  
   Missing  1(0.6) 1 (0.6)  
Physical activity  n (%)   0.04 
   Inactive  24 (14.8) 9 (5.6)  
   moderately inactive  35 (21.6) 39 (24.1)  
   moderately active  87 (53.7) 101 (62.3)  
   Active  14 (8.7) 13 (8.0)  
   Missing  2 (1.2) 0 (0.0)  
Smoking status    0.02 
   Never  106 (65.5) 85 (52.5)  
   Former  23 (14.2) 41 (25.3)  
   Current  31 (19.1) 36 (22.2)  
   Missing  2 (1.2) 0 (0.0)  
Educational level n (%)   0.75 
   None  3 (1.9) 5 (3.1)  
   Primary  88 (54.3) 97 (59.9)  
   Technical/professional 16 (9.9) 16 (9.9)  
   Secondary  38 (23.4) 30 (18.5)  
   College/University  15 (9.3) 14 (8.6)  
   Missing  2 (1.2) 0 (0.0)  
Alcohol consumption  median (gr/d) 0.91 (0.00 – 68.0) 2.78 (0.00 – 85.9) 0.35 
Folic acid intake median (µr/d) 268.2 (97.4 – 637.8) 262.4 (50.8 – 599.0) 0.82 
Fat consumption median (gr/d) 77.6 (26.6 – 15.2) 79.4 (19.0 – 208.7) 0.61 
Age at menarche mean (range), years   0.16 
   <12   26 (16.1) 35 (21.6)  
   12-14  121 (74.7) 107 (66.1)  
   ≥15  13 (8.0) 20 (12.3)  
   missing  2 (1.2) 0 (0.0)  
Age at menopause mean (range), years 50.2 (38.0 – 57.0) 49.1 (39.0 – 59.0) 0.03 
Menopausal status n (%)   0.99 
   Premenopausal  60 (37.0) 62 (38.3)  
   Postmenopausal  99 (61.1) 100 (61.7)  
   missing  3 (1.9) 0 (0.0)  
Ever pregnant n (%)   0.67 
   Yes  16 (9.9) 13 (8.0)  
   No  144 (88.9) 149 (92.0)  
   Missing  2 (1.2) 0 (0.0)  
Age first birth mean (range), years 26.0 (17.0 – 44.0) 25.4 (17.0 – 39.0) 0.23 
Parity n (%)   0.25 
   0  23 (14.2) 19 (11.7)  
   1  52 (32.1) 38 (23.5)  
   2  62 (38.3) 77 (47.6)  
   3  16 (9.9) 24 (14.8)  
   4  4 (2.4) 2 (1.2)  
   5  3 (1.9) 2 (1.2)  
   missing  2 (1.2) 0 (0)  
Ever OC use* n (%)   0.48 
   Yes  59 (36.4) 67 (41.4)  
   No  101 (62.3) 95 (58.6)  
   Missing  2 (1.2) 0 (0.0)  
Ever HRT use# n (%)   0.56 
   Yes  23 (14.2) 28 (17.3)  
   No  137 (84.6) 133 (82.1)  
   missing  2 (1.2) 1 (0.06)  
&Missing values category is omitted from the analyses 
*OC: oral contraceptive  #HRT: hormone replacement therapy 
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The estimated difference in mean beta values (calculated over all CpGs) between matched 
breast cancer cases and controls was 0.002 representing a 0.2% drop in mean methylation 
difference in cases overall (p-value paired Wilcoxon test = 1.82e-05). Conditional logistic 
regression analysis was used to measure the potential association between average methylation 
levels and breast cancer risk using categorical methylation values as quartiles (Table 4.2). The 
cut-offs for the quartiles were based on the distribution in the controls and the corresponding 
number of cases within each quartile shows a difference in methylation levels between the two 
groups. Fewer cases (n=26) compared with controls (n=41) in the highest methylation quartile 
and more cases (n=75) compared with controls (n=41) in the lowest quartile indicate global 
hypomethylation in breast cancer cases. In addition, the p-values for Q2, Q3, and Q4 versus Q1 
respectively suggest a statistically significant association between decreased methylation levels 
and breast cancer risk. Furthermore, the analysis of the median methylation within each 
quartile provided an estimate of the OR for one SD change in methylation of 0.61, suggesting a 
2-fold lower methylation in cases compared to controls (OR = 0.61, 95% CI 0.47 – 0.80, p-value 
= 0.0004) (Table 4.2). 
 
Table 4.2 – Association between average methylation and breast cancer risk 
  Cases  
(n) 
Controls 
(n) 
OR  (95% CI) p-value 
By quartiles Q1  [0.520 – 0.530) 75 41 1.00   
 Q2  [0.530 – 0.532) 30 40 0.44 (0.24 – 0.81) 0.008 
 Q3  [0.532 – 0.534) 31 40 0.42 (0.23 – 0.79) 0.007 
 Q4  [0.534 – 0.543) 26 41 0.34 (0.18 – 0.66) 0.001 
       
 Per 1 SD   0.61 (0.47 – 0.80) 0.0004 
       
Time to Diagnosis <3.7  79 - 0.66 (0.46 – 0.95) 0.03 
(years) >3.7 83 - 0.56 (0.37 – 0.84) 0.005 
       
Menopausal status Premenopause 60 62 0.65 (0.43 – 0.99) 0.04 
 Postmenopause 99 100 0.56 (0.39 – 0.80) 0.002 
       
ER status Negative  18 - 0.49 (0.20 – 1.24) 0.18 
 Positive 56 - 0.59 (0.36 – 0.96) 0.02 
  Missing*  88 -    
       
PR status Negative 27 - 0.95 (0.45 – 2.01) 0.88 
 Positive 44 - 0.47 (0.26 – 0.83) 0.01 
  Missing* 91 -    
       
HER2 status Negative  20 - 0.77 (0.36 – 1.64) 0.50 
 Positive 6 - 4.69e+14 (0.00 – inf) 1.00 
  Missing* 136 -    
       
Tumour behaviour 
 
Borderline 
malignancy 
23 - 0.62 (0.31 – 1.23) 0.18 
 In situ 119 - 0.64 (0.47 – 0.87) 0.005 
 Missing* 20     
       
Grade Well differentiated 15 - 0.11 (0.01 – 0.93) 0.04 
 
Moderately 
differentiated 
38 - 0.61 (0.32 – 1.14) 0.12 
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Poorly 
differentiated 
20 - 0.88 (0.43 – 1.78) 0.72 
 Undifferentiated 1 - 31.85   (0.00 – inf) 1.00 
 Missing* 88 -    
       
Stage In situ 8 - 0.77 (0.26 – 2.27) 0.63 
 Localised 45 - 0.41 (0.24 – 0.73) 0.002 
 Metastatic 16 - 1.83 (0.73 – 4.58) 0.20 
 
Metastatic 
regional 
11 - 1.40 (0.46 – 4.31) 0.56 
 Metastatic distant 3 - 2848.41 (0.00 – inf) 1.00 
 missing* 79 -    
*missing values category is omitted from the analyses 
 
The results were further investigated by performing stratified analyses by time to diagnosis and 
various tumour characteristics. Time to diagnosis was stratified above and below the median of 
3.7 years and did not seem to influence the association between hypomethylation and breast 
cancer (Table 4.2, Figure 4.1). A Kolmogorov-Smirnov test was performed to test for equality of 
distributions in cases and controls and the results confirmed a difference in mean methylation 
in both strata (p=0.02 for below 3.7 years, p=0.02 for above 3.7 years).  
 
 
Figure 4.1 Density plots of the mean β-values for cases and controls stratified below and above the median of 
time to diagnosis (3.7 years) Both density plots (below and above the median of time to diagnosis) show lower 
mean β-value densities among cases (red line) compared with controls (black line) 
 
After stratifying the analysis according to menopausal status we observed global 
hypomethylation in cases in both strata (strongest in postmenopausal women: p-value=0.002). 
Global hypomethylation was also observed in ER-positive (OR = 0.59, 95% CI = 0.36 – 0.96, p-
value = 0.02) and PR-positive (OR = 0.47, 95% CI = 0.26 – 0.83, p-value = 0.01) breast cancer 
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cases. No significant results were observed for HER2 status. Lower levels of methylation were 
also found for tumours with an in situ tumour behaviour (OR = 0.64, 95% CI = 0.47 – 0.87, p-
value = 0.005), well differentiated tumours (OR = 0.11, 95% CI = 0.01 – 0.93, p-value = 0.04), 
and tumours with a localized stage (OR = 0.41, 95% CI = 0.24 – 0.73, p-value = 0.002). However, 
these results should be interpreted with caution because of the high number of missing values 
in these tumour characteristic variables. 
  
4.2 Confounding 
Potential confounding factors were assessed by running linear regression models of global 
methylation versus baseline characteristics and breast cancer risk factors (identified in 
literature8-13) and results are shown in Table 4.3.  
 
Table 4.3 – Association between global methylation and breast cancer risk factors 
Characteristic  Estimate§ p-value 
Centre Varese -2.75e-05 0.97 
 Ragusa -7.47e-04 0.54 
 Turin -4.64e-04 0.43 
 Naples 1.02e-04 0.92 
Age at recruitment years 6.17e-06 0.93 
Height cm -1.83e-05 0.58 
Weight kg -2.71e-05 0.16 
BMI  underweight -0.0011 0.56 
 overweight 0.0001 0.81 
 obese -0.0007 0.25 
Physical activity moderately inactive 0.0008 0.32 
 moderately active 0.0013 0.08 
 active 0.0017 0.09 
Smoking status former 0.0012 0.08 
 current 0.0005 0.35 
Educational level primary 2.93e-04 0.83 
 technical/professional -1.74e-04 0.91 
 secondary -8.09e-05 0.96 
 college/university -7.01e-04 0.65 
Alcohol consumption gr/d -2.28e-06 0.89 
Folic acid intake µg/d 4.84e-06 0.04 
Fat consumption gr/d 1.45e-05 0.08 
Age at menarche  12-14 years -0.0003 0.53 
 ≥15 years 0.0006 0.49 
Age at menopause  years -1.69e-04 0.02 
Menopausal state pre/post-menopausal 0.0003 0.45 
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Ever pregnant yes/no -5.08e-05 0.95 
Age first birth years -4.54e-06 0.93 
Parity 1 -0.0006 0.41 
 2 -0.0001 0.86 
 3 0.0002 0.84 
 4 0.0010 0.56 
 5 -0.0016 0.37 
Ever OC use* yes/no -0.0005 0.21 
Ever HRT use# yes/no -0.0004 0.47 
§estimate from linear regression model *OC: oral contraceptive  #HRT: hormone replacement therapy 
 
From Table 4.1 it becomes apparent that physical activity, smoking, and age at menopause are 
associated with breast cancer and in Table 4.3 a significant association is reported between age 
at menopause and folic acid intake and methylation. In order for any variable to have a potential 
confounding effect, an association needs to be observed between both the exposure and the 
outcome. This is the case of age at menopause, hence, additional analyses were performed 
adjusting for this potential confounder (Table 4.4). After adjustment, an overall loss of 
significance was observed. The p-values for the second, third, and fourth methylation quartiles 
versus the first methylation quartile became 0.01, 0.01, and 0.03 respectively, compared with 
0.008, 0.007, and 0.001 before adjustment. Also the p-value for 1SD change became less 
significant with 0.01, but still statistically significant. In addition, time to diagnosis less than 3.7 
years lost significance (p-value = 0.29), as did ER-positive (p-value = 0.17) and PR-positive 
status (p-value = 0.10). The number of samples with available information on tumour grade and 
tumour stage was too small to perform adjusted analysis on, but in situ tumour behaviour 
remained statistically significantly associated with hypomethylation. Additionally adjusting for 
folic acid intake, physical activity, and smoking did not change the results substantially. This 
indicates that the results are robust; even after adjusting for potential confounding factors, 
global hypomethylation is observed in cases compared with controls.  
 
Table 4.4 – Association between average methylation and breast cancer risk, adjusted for age at 
menopause 
  Cases  
(n) 
Controls 
(n) 
ORadj* (95% CI)* p-value* 
By quartiles Q1  [0.520 – 0.530) 47 23 1.00   
 Q2  [0.530 – 0.532) 17 27 0.28 (0.10 – 0.78) 0.01 
 Q3  [0.532 – 0.534) 18 24 0.29 (0.11 – 0.74) 0.01 
 Q4  [0.534 – 0.543) 17 26 0.36 (0.14 – 0.93) 0.03 
       
 Per 1 SD   0.61 (0.41 – 0.90) 0.01 
       
Time to Diagnosis <3.7  43 - 0.76 (0.45 – 1.27) 0.29 
(years) >3.7 56 - 0.48 (0.26 – 0.87) 0.02 
       
ER status Negative  12 - 0.52 (0.17 – 1.58) 0.25 
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 Positive 40 - 0.64 (0.33 – 1.22) 0.17 
  Missing*  47 -    
       
PR status Negative 22 - 1.10 (0.41 – 2.98) 0.85 
 Positive 27 - 0.54 (0.25 – 1.13) 0.10 
  Missing* 50 -    
       
HER2 status Negative  14 - 0.88 (0.28 – 2.77) 0.83 
 Positive 2 - 8.55e+14 (0.00 – inf) 1.00 
  Missing* 83 -    
       
Tumour behaviour 
 
Borderline 
malignancy 
9 - 0.52 (0.17 – 1.57) 0.24 
 In situ 78 - 0.59 (0.38 – 0.93) 0.02 
 Missing* 12     
* Adjusted for age at menopause 
 
4.3 Stratified analyses based on location or function 
In order to investigate which CpGs are contributing most to the difference in methylation 
between cases and controls, the association between global methylation and breast cancer risk 
was stratified for different groups of CpGs based on their location (e.g. in relation to CpG island 
or gene) or function (e.g. coding or non-coding and according to their ‘functional’ regions 
TSS1500, TSS200, 1st exon, 3’URT, 5’URT, body). Table 4.5 displays the crude and adjusted ORs 
and 95% CIs.  
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Table 4.5 – Association between global methylation and breast cancer risk by CpG genomic feature per 1 SD 
      # CpGs ORcrude (95% CI) p-value ORadj* (95% CI)* p-value* 
All Including SNP probes 408,749 0.61 (0.47 – 0.80) 0.0004 0.61 (0.41 – 0.90) 0.01 
 Excluding SNP probes 360,342 0.62 (0.47 – 0.81) 0.0004 0.63 (0.43 – 0.92) 0.02 
         
CpG Island Island 124,962 0.76 (0.57 – 0.99) 0.04 0.82 (0.57 – 1.20) 0.31 
 Shores 98,890 0.72 (0.55 – 0.93) 0.01 0.76 (0.53 – 1.10) 0.14 
 Shelves 38,755 0.50 (0.37 – 0.68) 8.93e-06 0.54 (0.36 – 0.81) 0.003 
 None 146,142 0.50 (0.38 – 0.68) 7.44e-06 0.55 (0.36 – 0.82) 0.003 
         
Regulatory feature  Gene   2,974 0.62 (0.47 – 0.82) 0.001 0.60 (0.40 – 0.91) 0.02 
category NonGene 1,237 0.81 (0.59 – 1.12) 0.20 0.83 (0.52 – 1.33) 0.44 
 Promoter 82,006 0.92 (0.64 – 1.32) 0.66 0.93 (0.56 – 1.54) 0.77 
 Unclassified 60,615 0.70 (0.53 – 0.92) 0.01 0.75 (0.51 – 1.09) 0.14 
 None 261,917 0.53 (0.39 – 0.71) 1.84e-05 0.57 (0.38 – 0.86) 0.007 
         
 Promoter 82,006 0.92 (0.64 – 1.32) 0.66 0.93 (0.56 – 1.54) 0.77 
 Other 326,743 0.56 (0.42 – 0.75) 0.0001 0.58 (0.39 – 0.86) 0.007 
         
Gene Region Feature  TSS1500 59,494 0.70 (0.53 – 0.92) 0.01 0.77 (0.53 – 1.12) 0.17 
category TSS200 43,506 0.92 (0.69 – 1.24) 0.60 0.99 (0.66 – 1.48) 0.96 
 5’UTR 36,778 0.72 (0.54 – 0.95) 0.02 0.82 (0.55 – 1.22) 0.33 
 1st Exon 19,024 0.85 (0.65 – 1.12) 0.25 1.13 (0.62 – 1.28) 0.52 
 Body 138,499 0.51 (0.38 – 0.69) 1.58e-05 0.49 (0.31 – 0.77) 0.002 
 3'UTR 15,065 0.40 (0.29 – 0.57) 2.90e-07 0.37 (0.22 – 0.61) 0.0001 
         
Associated RNA  Coding 303,202 0.65 (0.50 – 0.84) 0.001 0.68 (0.67 – 0.99) 0.04 
Transcript NonCoding 9,164 0.60 (0.46 – 0.79) 0.0002 0.63 (0.43 – 0.92) 0.02 
 Intergenic 96,383 0.57 (0.43 – 0.75) 6.86e-05 0.65 (0.45 – 0.94) 0.02 
         
Repetitive elements Rmsk 72,325 0.50 (0.37 – 0.68) 1.00e-05 0.56 (0.37 – 0.85) 0.006 
 NoRmsk 36,424 0.63 (0.48 – 0.82) 0.0006 0.65 (0.45 – 0.95) 0.03 
         
Type of repetitive  Rmsk.Sat_SimRep 5,528 0.73 (0.56 – 0.94) 0.01 0.73 (0.51 – 1.06) 0.10 
element Rmsk.LTR 11,134 0.51 (0.38 – 0.69) 8.35e-06 0.57 (0.39 – 0.85) 0.005 
 Rmsk.LINE 19,213 0.53 (0.40 – 0.70) 1.17e-05 0.58 (0.39 – 0.85) 0.006 
 Rmsk.SINE 21,928 0.48 (0.35 – 0.65) 2.31e-06 0.48 (0.32 – 0.74) 0.0009 
 Rmsk.OtherRep 14,522 0.72 (0.55 – 0.94) 0.01 0.75 (0.51 – 1.10) 0.15 
* Adjusted for age at menopause
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Across all 408,749 CpGs, a decreased risk of breast cancer was observed with increasing 
methylation, i.e. cases overall have lower methylation levels than controls (OR = 0.61, 95% CI = 
0.41 – 0.90, p-value = 0.01). Excluding SNP probes did not substantially change the results. 
After adjustment for confounding factors, no association was detected between CpGs located on 
CpG islands and breast cancer risk (OR = 0.82, 95% CI = 0.57 – 1.20, p-value = 0.31), and CpG 
island shores and breast cancer (OR = 0.76, 95% CI = 0.53 – 1.10, p-value = 0.14), while CpGs 
located at CpG shelves (OR = 0.54, 95% CI = 0.36 – 0.81, p-value = 0.003) were hypomethylated 
in cases compared with controls. The mean methylation level of CpGs located on gene 
promoters was not associated with breast cancer risk (p-value = 0.77), which is possibly due to 
a strong overlap with CpG islands (i.e. CpG islands are found on many promoters). However, 
CpGs on gene bodies or at the 3’UTR were both significantly hypomethylated in cases compared 
to controls (p-value = 0.002 and 0.0001, respectively). This significance was also found for the 
‘gene’ class of the Regulatory Feature Category (p-value = 0.02). Finally, hypomethylation in 
cases was consistently observed in different types of repetitive elements. The OR for SINEs was 
0.48 (95% CI = 0.32 – 0.74), with a p-value of 0.0009. The p-values for LTR and LINE, whose 
methylation has been measured in a number of studies examining global methylation, were 
found to be similar, albeit a little less significant (p-value = 0.005 for LTR and p-value = 0.006 for 
LINE). 
 
4.4 Cell types 
Previous studies have highlighted the importance of taking into account the type of different 
white blood cells (WBC) in each sample, when analysing DNA methylation in whole blood283;284. 
Unfortunately, WBC compositions of the blood samples were not available for this study. In an 
attempt to address this problem, we used HM450 methylation data obtained from purified CD4 
T-cells, CD8 T-cells, CD19 B-cells, monocytes, natural killer (NK) cells, neutrophils and 
eosinophils and whole peripheral blood mononuclear cells (PBMCs)284. These data were 
available for six subjects. The CpGs that differed significantly between each individual cell type 
and PBMC (linear regression using β values, p<1x10-7 and delta-β >0.05) were identified, which 
resulted in n=11,196 unique CpGs. These CpGs were subsequently removed from the statistical 
analyses, assuming as a first approach that blood composition only marginally affected 
methylation patterns at other sites (n=397,553 remaining CpGs). Results did not change 
substantially however, with and without such removal (see supplementary Table S4.1 – S4.2). 
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4.5 Discussion 
In this chapter, global hypomethylation was found among breast cancer cases compared with 
matched controls using a prospective, nested case-control design. This was observed when 
performing a matched Wilcoxon test with global methylation as a continuous outcome, as well 
as by comparing the lowest to highest methylation quartiles using conditional logistic 
regression. In addition, estimating the OR for one SD change in methylation confirmed these 
findings.  
Stratifying the analyses by time to diagnosis and different tumour characteristics showed 
significant associations with a time to diagnosis of more than 3.7 years, which cannot be 
explained by reverse causation. Despite the large number of missing values for several variables 
related to tumour characteristics, hypomethylation was also found in tumours with in situ 
tumour behaviour.  
When focussing on different functional and physical locations on the genome, breast cancer 
associated hypomethylation was found in various categories, among which CpG island shelves, 
gene bodies, the 3’UTR regions and repetitive elements (strongest effect observed for SINE).  
 
Previous studies assessing the association between global DNA methylation measured in 
peripheral white blood cells (WBC) and breast cancer risk have produced inconsistent results. 
However, almost all earlier studies assessing global methylation were of a retrospective or 
cross-sectional design and did not derive global methylation from genome-wide data but from 
various repetitive elements (such as LINE-1, Alu, and Sat2), using different types of assays and 
methods, which makes the comparison with our results difficult. 
Widschwendter et al. measured DNA methylation of peripheral blood cells in Alu elements of 
169 breast cancer cases and 180 controls and reported no differences in median and 
interquartile range between the two groups.285 Choi et al. measured methylation in 5-
methyldeoxycytosine (5-mdC) as well as in LINE-1 of leukocyte DNA, in women with early stage 
breast cancer (n=179) and matched, healthy controls (n=180). They observed no difference 
between cases and controls in methylation measured in LINE-1, but hypomethylation of 5-mdC 
in cases compared to controls, in a dose-dependent matter. They reported no correlation 
between the two measurements which can possibly be explained by the fact that LINE-1 is a 
repetitive element while 5-mdC measurements include different DNA sequence elements such 
as both CpG island and non-CpG island regions.70 
Xu et al. also studied global methylation in peripheral blood DNA of 1,055 breast cancer cases 
and 1,101 healthy controls using both luminometric methylation assay (LUMA) and LINE-1 and 
reported an increased risk of breast cancer with promoter hypermethylation measured by 
LUMA, but no difference in methylation between cases and controls measured in LINE-1, nor an 
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association between LUMA and LINE-1. They validated their finding of promoter 
hypermethylation in cases using the HumanMethylation27 BeadChip (which includes CpG sites 
located on 307 promoters) in a subset of 24 subjects (12 case-control pairs).286 
Some other studies investigated methylation of LINE-1, as well as Alu and Sat2 in blood samples 
of breast cancer cases and disease free controls. Cho et al. studied genomic methylation levels of 
all three repetitive elements in WBC DNA of 40 women who were diagnosed with invasive 
ductal carcinoma and compared them to levels in healthy controls with similar ethnic 
backgrounds. After adjustment for age, they only found significantly lower methylation levels of 
Sat2M1 in cases compared to controls but the study was limited by a small sample size and 
missing information for part of the participants on demographic and clinicopathologic 
variables.81  
Wu et al. analysed methylation in the same three repetitive sequences (LINE-1, Alu, and Sat2) in 
both WBC and granulocytes of 282 breast cancer cases and 347 controls (healthy sisters of the 
cases) and reported an association with Sat2 methylation and breast cancer (lower methylation 
in cases compared with controls) in total WBC, but no association in granulocytes, or for both 
cell types in LINE-1.287 The fact that there was an effect observed in WBC but not in granulocytes 
emphasized the relevance of taking into account cell types when using blood samples to 
investigate methylation. This importance has been highlighted by other studies as well, also 
because changes in the percentages of cell types can be a result of the disease process.283;284  
In another study, the same group used [3H]-methyl acceptance assay and LUMA to measure 
global methylation levels in WBC and granulocytes of women affected by breast cancer and 
again compared them to levels in their unaffected sisters. They reported lower DNA methylation 
in cases than controls using the [3H]-methyl acceptance assay but did not find any associations 
between methylation levels using LUMA in granulocytes, total WBC, or when both sources were 
pooled together.288 Like other studies, they stress the significance of the choice of assay, and the 
different results the various methods can produce because of different parts of the epigenome 
that are being assessed, as well as the type of cells in which DNA methylation is measured.289 
 
One of the few large, prospective studies has been performed by Brennan et al. They assessed 
global levels of LINE-1 DNA methylation in three independent cohort studies (each consisting of 
>200 cases and >200 controls) using pre-diagnostic blood samples and concluded that there 
was no difference between cases and controls, even after adjustment for confounding.290 Finally, 
another prospective study by Xu et al. recently measured methylation differences in breast 
cancer cases and controls using the HM27 array by Illumina. They found 250 CpG sites to be 
differentially methylated between 289 cases and 612 controls in pre-diagnostic blood samples, 
of which 75.2% were hypomethylated in cases, compared to 50.5% of hypomethylated CpG sites 
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on the complete array.291 This indicates hypomethylation among cases; however no replication 
or validation of their results has been performed.  
 
As mentioned before, inconsistencies between previous studies and this current chapter are 
possibly due to the fact that this chapter is one of the few prospective studies, with blood 
samples collected years before diagnosis of the disease. Since global hypomethylation can be a 
cause or consequence of the disease it is necessary to have a correct study design; a cross-
sectional or case-control study will not be able to establish the direction of associations.  
The different types of repetitive elements that have been measured, and the different 
techniques used to measure this, form another important factor to take into account when 
comparing different studies. Until today, there is no consensus on the best methods or assays 
for measuring global DNA methylation. Alu and LINE-1 are often used as surrogate measures for 
global methylation but studies which describe limitations of these elements, such as varying 
sequences that have been measured in LINE-1 and different LINE-1 contents across individual 
genomes are emerging.292;293 In addition, it appears that there is not a strong correlation 
between methylation levels of LINE-1 and Alu, for which the reason is still unknown. It is 
possible that the two repetitive elements are measuring something different.293 Other studies 
assessing global methylation have already stated that 5-mdC measurement and LUMA do not 
measure repetitive elements, which again, makes it difficult to compare these results. Therefore, 
besides the study design, the actual genome-wide global measurement forms another major 
strength of this chapter. Methylation levels of >400,000 CpG sites were assessed in different 
physical locations and functional regions of the genome and associations between methylation 
and tumour behaviour were observed. Breast tumour DNA shows an incremental 
hypomethylation in benign to malignant tumours294, which is in agreement with the findings in 
this chapter where in situ tumour behaviour was associated with hypomethylation, while 
borderline malignant tumours were not. To my knowledge, no other studies have investigated 
the association between peripheral blood DNA methylation and breast cancer risk stratified by 
tumour behaviour. 
When assessing methylation levels at categories related to physical and functional locations 
across the genome, hypomethylation was observed for CpGs located on shelves of CpG islands 
(shores were no longer significant after adjustment for confounding), but not on the islands 
themselves. This was also found by Irizarry et al.54 In addition, hypomethylation was also 
observed among breast cancer cases at gene bodies and 3’UTR, but not at promoter regions of 
genes.  
Like many previous studies, in this current study, hypomethylation was observed in various 
categories of repetitive elements, such as LINE, SINE, and LTR. However, the observation of 
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increasing hypomethylation across the whole genome with increasing breast cancer risk, 
measured both continuously and categorically, supports the hypothesis that hypomethylation is 
not restricted to repetitive elements but includes regions spread across the genome.78;79 It is 
unlikely that these results can be explained by a different WBC composition among cases and 
controls because the CpGs that were differentially methylated in different cell types were 
removed from the analyses, which did not lead to a great change in the findings. 
 
In conclusion the results of this chapter indicate that global hypomethylation, measured in pre-
diagnostic blood samples using the HM450 array may be able to predict breast cancer risk. 
From these results it appears that hypermethylation of tumour suppressor genes is only part of 
the mechanism of carcinogenesis and the effect of global hypomethylation may involve an 
additional important mechanism. Methylation levels can potentially be used as clinical 
biomarker for breast risk and progression. However, additional studies with larger sample sizes 
and cell type count information, as well as additional breast cancer risk factor information, 
should be performed to test the sensitivity and specificity of such a potential biomarker. 
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Chapter 5 – Locus-by-locus DNA methylation and breast cancer 
 
The locus-by-locus analyses, investigating the association between DNA methylation and breast 
cancer, were performed in the HuGeF (Breast II) study. In summary, 324 subjects were included 
in the analyses, 162 cases and 162 matched controls. DNA methylation was measured at 
408,749 CpGs across the genome of these subjects (see for more information about exclusion of 
samples and probes see section 4.1). 
 
Demographic and lifestyle features of the study participants, stratified by case-control status, 
are summarized in Table 5.1. The p-value refers to the significance of the t-test (or Wilcoxon 
test) or the chi2-test, testing differences in baseline variables between cases and controls. No 
significant differences were observed between cases and controls for height, weight, BMI, and 
educational level (as proxy for socio-economic status). Smoking status was significantly 
different between cases and controls (p-value = 0.02), with more never smokers among cases 
compared to controls (65.5% and 52.5% respectively) and fewer former smokers among cases 
compared to controls (14.2% and 25.3% respectively). Differences between cases and controls 
were also observed for physical activity level: more cases were inactive compared to controls 
and more controls were moderately active compared to cases (p-value = 0.04). Finally the mean 
age at menopause was slightly higher in cases (50.2 years) compared with controls (49.1 years), 
p-value = 0.03. The remaining variables, alcohol and fat consumption, folic acid intake, age at 
menarche, menopausal status, ever pregnant, age at first birth, parity, ever oral contraceptive 
(OC) use, and ever HRT use, all showed no associations with case-control status.  
  
Table 5.1 – Baseline characteristics and breast cancer risk factors of the study population  
Characteristic  Cases (n=162) Controls (n=162) p-value* 
Centre n (%)   1.00 
   Florence  28 (17.3) 28 (17.3)  
   Varese  29 (17.9) 29 (17.9)  
   Ragusa  6 (3.7) 6 (3.7)  
   Turin  88 (54.3) 88 (54.3)  
   Naples  11 (6.8) 11 (6.8)  
Age at recruitment mean (range), years 52.4 (35.0 – 70.0) 52.4 (34.0 – 70.0) 0.95 
Height mean (range), cm 158.6(141.5 – 177.5) 159.1 (139.5 – 175.5) 0.47 
Weight mean (range), kg 64.5 (44.3 – 106.0) 66.1 (42.8 – 104.6) 0.20 
BMI n (%)   0.49 
   Underweight  2 (1.2) 2 (1.2)  
   Normal  65 (40.1) 77 (47.5)  
   Overweight  68 (42.0) 55 (34.0)  
   Obese  26 (16.1) 27(16.7)  
   Missing  1(0.6) 1 (0.6)  
Physical activity  n (%)   0.04 
   Inactive  24 (14.8) 9 (5.6)  
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   moderately inactive  35 (21.6) 39 (24.1)  
   moderately active  87 (53.7) 101 (62.3)  
   Active  14 (8.7) 13 (8.0)  
   Missing  2 (1.2) 0 (0.0)  
Smoking status n (%)   0.02 
   Never  106 (65.5) 85 (52.5)  
   Former  23 (14.2) 41 (25.3)  
   Current  31 (19.1) 36 (22.2)  
   Missing  2 (1.2) 0 (0.0)  
Educational level n (%)   0.75 
   None  3 (1.9) 5 (3.1)  
   Primary  88 (54.3) 97 (59.9)  
   Technical/professional 16 (9.9) 16 (9.9)  
   Secondary  38 (23.4) 30 (18.5)  
   College/University  15 (9.3) 14 (8.6)  
   Missing  2 (1.2) 0 (0.0)  
Alcohol 
consumption  
median (gr/d) 0.91 (0.00-68.0) 2.78 (0.00 – 85.9) 0.35 
Folic acid intake median (µr/d) 268.2 (97.4 – 637.8) 262.4 (50.8- 599.0) 0.82 
Fat consumption median (gr/d) 77.6 (26.6 – 15.2) 79.4 (19.0 – 208.7) 0.61 
Age at menarche mean (range), years   0.16 
   <12   26 (16.1) 35 (21.6)  
   12-14  121 (74.7) 107 (66.1)  
   ≥15  13 (8.0) 20 (12.3)  
   missing  2 (1.2) 0 (0.0)  
Age at menopause mean (range), years 50.2 (38.0 – 57.0) 49.1 (39.0 – 59.0) 0.03 
Menopausal status n (%)   0.99 
   Premenopausal  60 (37.0) 62 (38.3)  
   Postmenopausal  99 (61.1) 100 (61.7)  
   missing  3 (1.9) 0 (0.0)  
Ever pregnant n (%)   0.67 
   Yes  16 (9.9) 13 (8.0)  
   No  144 (88.9) 149 (92.0)  
   Missing  2 (1.2) 0 (0.0)  
Age first birth mean (range), years 26.0 (17.0 – 44.0) 25.4 (17.0 – 39.0) 0.23 
Parity n (%)   0.25 
   0  23 (14.2) 19 (11.7)  
   1  52 (32.1) 38 (23.5)  
   2  62 (38.3) 77 (47.6)  
   3  16 (9.9) 24 (14.8)  
   4  4 (2.4) 2 (1.2)  
   5  3 (1.9) 2 (1.2)  
   missing  2 (1.2) 0 (0)  
Ever OC use n (%)   0.48 
   Yes  59 (36.4) 67 (41.4)  
   No  101 (62.3) 95 (58.6)  
   Missing  2 (1.2) 0 (0.0)  
Ever HRT use n (%)   0.56 
   Yes  23 (14.2) 28 (17.3)  
   No  137 (84.6) 133 (82.1)  
   missing  2 (1.2) 1 (0.06)  
&Missing values category is omitted from the analyses 
*OC: oral contraceptive  #HRT: hormone replacement therapy 
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5.1 Most strongly associated CpG sites 
Conditional logistic regression analysis highlighted 6,334 CpGs associated with an FDR<5% (i.e. 
a q-value<0.05). The smallest p-value observed was 5.91x10-9. Figure 5.1 is a Manhattan plot 
showing all CpGs from the analysis according to their –log10 p-value, coloured by chromosome. 
The horizontal line represents the cut-off value of 1.03x10-7 (genome-wide significance).  
 
 
Figure 5.1 Manhattan plot – Association between DNA methylation and breast cancer Chromosomes are 
displayed along the x-axis (all CpGs on the same chromosome have the same colour, a different colour for each 
chromosome), with the negative logarithm of the association p-value for each CpG displayed on the y-axis. The 
horizontal threshold indicates the genome-wide significance level (1.03x10-7), CpGs above this threshold have 
reached this level. 
 
Out of the 6,334 CpGs with a q-value<0.05, a total of 1,443 were not annotated and 2,803 were 
associated with unique genes (i.e. the gene appeared only once in the list of 6,334 CpGs). 
However, several of these 6,334 CpGs were associated with the same genes. Table 5.2 reports 
the number of CpGs per gene. It shows that, for example, 22 out of the 6,334 CpGs were located 
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on the PTPRN2 gene. Because of the prospective design of the study, genes that were observed 
more often than expected (depending on the number of CpGs for the same gene on the HM450), 
possibly play a role in breast carcinogenesis.  
 
Table 5.2 – Observed and expected number of CpGs per gene in the 6,334 strongest associations (q-value 
<0.05) between DNA methylation and breast cancer, based on the number of CpGs per gene on the HM450 
Gene name Number of CpGs 
(%) in top 6,334 
Number of CpGs 
(%) on HM450 
Expected number 
of CpGs 
Observed / expected 
number of CpGs 
PTPRN2 22 (0.35) 1127 (0.28) 17.7 1.2 
MAD1L1 17 (0.27) 618 (0.15) 9.5 1.8 
TNXB 16 (0.25) 441 (0.11) 7.0 2.3 
PRDM16 14 (0.22) 588 (0.14) 8.9 1.6 
HDAC4 13 (0.21) 385 (0.09) 5.7 2.3 
EHMT2 11 (0.17) 162 (0.04) 2.5 4.4 
COL11A2 11 (0.17) 226 (0.06) 3.8 2.9 
ARHGEF10 11 (0.17) 200 (0.05) 3.2 3.4 
MCF2L 10 (0.16) 271 (0.07) 4.4 2.3 
KCNQ1 10 (0.16) 264 (0.06) 3.8 2.6 
ADAMTS2 10 (0.16) 126 (0.03) 1.9 5.3 
RASA3 9 (0.14) 299 (0.07) 4.4 2.0 
PRKCZ 9 (0.14) 238 (0.06) 3.8 2.4 
DIP2C 9 (0.14) 415 (0.10) 6.3 1.4 
CBFA2T3 9 (0.14) 198 (0.05) 3.2 2.8 
RPTOR 8 (0.13) 384 (0.09) 5.7 1.4 
INPP5A 8 (0.13) 329 (0.08) 5.1 1.6 
 
The PTPRN2, PRKCZ, and DIP2C genes were found approximately as many times, as was 
expected. The ADAMTS2 (ADAM metallopeptidase with thrombospondin type 1 motif, 2) gene 
however, was found 5.3 times more often as would be expected by chance, the EHMT2 
(Euchromatic histone-lysine N-methyltransferase 2) gene 4.4 times more often, and the 
ARHGEF10 (Rho guanine nucleotide exchange factor (GEF) 10) gene 3.4 times more often. 
The gene ADAMTS2 plays a crucial role in the processing of procollagen proteins (the precursors 
of collagens)295 but has not been associated with breast cancer in the literature. EHMT2 is part 
of a larger group of histone methyltransferases which catalyse the transfer of methyl groups 
from S-adenosylmethionine (SAM) to histones. The exact function of ARHGEF10 remains still 
largely unknown although it has been found to play a role in cellular processes that are initiated 
by extracellular stimuli. Both EHMT2 and ARHGEF10 have not been associated with breast 
cancer in the literature. 
 
When looking at the CpGs on these genes in more detail, it appears that all CpGs on the 
ADAMTS2, EHMT2, and ARHGEF10 genes are located in the body of the gene, except one on the 
ARHGEF10 gene which is found in the 5’UTR region. The location in relation to the CpG islands is 
varying, mostly north shores, but also two north shelves, two south shelves and one CpG was 
located at the island itself. The direction of the effect for all CpGs on these three genes is the 
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same: hypomethylation is observed in cases. Only the one CpG located at the 5’UTR region on 
the ARHGEF10 gene showed hypermethylation in cases compared with controls. To date it is 
unknown what the effect is of the location of the CpGs in relation to the gene or the CpG island. 
 
Out of the 6,334 strongest signals, 26 CpGs reached the Bonferroni corrected, genome-wide 
significance level of 1.03x10-7. These CpGs are detailed in Table 5.3, sorted on their effect size, 
which represents the percentage of methylation difference between cases and controls. The 
effect sizes ranged from -0.038 to -0.008, with the strongest observed for a CpG on the 5’UTR of 
gene C12orf50. Annotation was missing for five CpGs and no clear pattern relating to the 
physical or functional location emerged. 
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Table 5.3 – 26 strongest associations from conditional logistic regression analysis between DNA methylation and breast cancer (n=324), sorted on effect size 
Target ID p-value 
crude 
p-value FDR 
adjusted* 
Average β-value 
cases 
Average β-value 
controls 
Effect 
size 
CHR 
 
Gene Functional 
region 
Relation to 
CGI 
cg17824939 7.30E-08 0.001486 0.6572 0.6911 -0.03809 12 C12orf50 5’UTR  
cg12486486 9.04E-08 0.001486 0.7635 0.7979 -0.03787 4 YTHDC1 Body  
cg05455393 8.22E-09 0.001124 0.6913 0.7226 -0.03097 X FHL1 TSS1500 N_Shore 
cg00124920 9.45E-08 0.001486 0.7716 0.7993 -0.03079 1 C1orf220 Body S_Shelf 
cg18038361 1.25E-08 0.001124 0.5463 0.5748 -0.03050 18 TTR TSS1500  
cg03509901 1.01E-08 0.001124 0.8334 0.8607 -0.02767 17 NLK 1stExon S_Shore 
cg04798824 6.72E-08 0.001486 0.7707 0.7996 -0.02761 12 ANKS1B Body  
cg06531158 3.01E-08 0.001340 0.8044 0.8314 -0.02570 13 MIR548F5 Body  
cg17424007 8.42E-08 0.001486 0.7862 0.8078 -0.02469 1 MYOG TSS1500  
cg20235510 5.91E-09 0.001124 0.5060 0.5288 -0.02459 6 ZNF311 Body  
cg13140465 5.82E-08 0.001486 0.7399 0.7594 -0.02241 15 NIPA1 Body N_Shore 
cg16659470 1.37E-08 0.001124 0.6329 0.6564 -0.02208 8 RBM12B 3’UTR  
cg05343548 2.31E-08 0.001340 0.7651 0.7847 -0.02176 20   N_Shore 
cg05567435 3.07E-08 0.001340 0.6763 0.6986 -0.02015 12 METTL7B TSS1500  
cg24504843 8.29E-08 0.001486 0.7798 0.7980 -0.01934 4 CEP135 3’UTR  
cg10133171 4.86E-08 0.001450 0.8040 0.8268 -0.01871 4   N_Shore 
cg26772788 3.61E-08 0.001340 0.7984 0.8182 -0.01773 18   N_Shelf 
cg03338924 7.57E-08 0.001486 0.8365 0.8510 -0.01720 6 PHACTR1 Body Island 
cg04343242 8.25E-08 0.001486 0.7560 0.7737 -0.01611 4 BDH2  ’UTR S_Shelf 
cg20640749 7.84E-08 0.001486 0.7209 0.7374 -0.01439 6 GLP1R  ’UTR  
cg01341572 3.28E-08 0.001340 0.9040 0.9147 -0.01384 12 HNF1A TSS200 Island 
cg04599941 9.40E-08 0.001486 0.9264 0.9390 -0.01316 5 SEMA5A Body  
cg00962707 8.57E-08 0.001486 0.8728 0.8841 -0.01254 16   S_Shore 
cg23494338 4.11E-08 0.001401 0.9061 0.9180 -0.01106 10   N_Shore 
cg01836096 2.99E-08 0.001340 0.8930 0.9009 -0.00918 8 C8ORFK29 TSS200 S_Shore 
cg04187814 4.97E-08 0.001450 0.8978 0.9050 -0.00846 15 KIAA1199 5’UTR  
* p-value adjusted for multiple testing using FDR 
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5.2 Time to diagnosis 
The median time to diagnosis was 3.8 years. In order to exclude the possibility of reverse 
causality (the disease causing changes in DNA methylation rather than DNA methylation 
causing changes in disease risk), samples with a time to diagnosis of less than one year were 
excluded from the analysis and the conditional logistic regression model was run again.  
In this dataset 22 breast cancer cases with a time to diagnosis of less than one year were 
identified and excluded, together with their matched control. The analysis on the remaining 280 
samples resulted in four CpGs reaching a genome-wide significance level of 1.03x10-7 and 1,981 
CpGs with a q-value <0.05. These four CpGs are found in the top 26 CpGs identified in section 5.1 
(ranked as the first (cg17824939, C12orf50), second (cg12486486, YTHDC1), fourth 
(cg00124920, C1orf220), and sixth (cg03509901, NLK) most significant CpGs in Table 5.3).  
These fewer associations are possibly explained by the lower power due to fewer subjects, but 
another possible explanation is that part of the CpGs identified were indicators of preclinical 
phases of the disease, rather than indicators of susceptibility to the disease. However, four CpGs 
(cg17824939, C12orf50, cg12486486, YTHDC1, cg00124920, C1orf220, and cg03509901, NLK, 
Table 5.3) consistently reach genome-wide significance, which makes them stronger candidates 
for biomarkers of breast cancer detection. 
 
5.3 Stratification by menopausal status  
In addition, logistic regression analyses were performed, stratifying the population by 
menopausal status. For clarity, only the 20 strongest associations of these stratified analyses are 
summarized in Table 5.4 for pre-menopausal women and in Table 5.5 for post-menopausal 
women. The p-values for post-menopausal women (n=199) are lower than for pre-menopausal 
women (n=122), at least partly because of the smaller sample size in the latter group. However, 
none of the CpGs in either group had q-values <0.05. Across the 20 strongest signals, only one 
CpG (cg20235510, ZNF311) was consistently found in both pre- and post-menopausal strata 
(Table 5.4 and Table 5.5). The lack of consistency across both groups could indicate biological 
heterogeneity, meaning that pre- and post-menopausal breast cancer pathophysiologically are 
two different diseases.  
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Table 5.4 – 20 strongest associations from logistic regression analysis between DNA methylation and breast cancer in pre-menopausal women (n=122),  
sorted on difference β-value  
Target ID p-value 
crude 
p-value FDR 
adjusted* 
Average β-value 
cases 
Average β-value 
controls 
Difference 
average β-value 
CHR 
 
Gene Functional 
region 
Relation 
to CGI 
cg20235510 0.000288 0.621609 0.5022 0.5234 -0.0212         6 ZNF311 Body  
cg20277670 0.000396 0.621609 0.5022 0.5234 -0.0212         5 HRH2 Body  
cg01956472 0.000329 0.621609 0.8547 0.8742 -0.0195         6 MIR1275 TSS200  
cg14359606 0.000421 0.621609 0.8295 0.8469 -0.0174         2 SNED1 Body Island 
cg16533336 0.000224 0.621609 0.7506 0.7677 -0.0171         7 WBSCR17 Body  
cg12583199 0.000411 0.621609 0.6032 0.6190 -0.0158         10 RPS24 Body  
cg27508180 0.000385 0.621609 0.8937 0.9073 -0.0136         7 COL1A2 Body  
cg01341572 9.99E-05 0.621609 0.9016 0.9136 -0.0120         12 HNF1A TSS200 Island 
cg15744963 0.000219 0.621609 0.9083 0.9196 -0.0113         15 HERC2 Body  
cg08240881 0.000419 0.621609 0.9312 0.9408 -0.0096         13    
cg07026599 0.000364 0.621609 0.0567 0.0473 0.0094         16 MAF TSS200 Island 
cg01836096 0.000438 0.621609 0.8907 0.9000 -0.0093         8 C8ORFK29 TSS200 S_Shore 
cg10805645 0.000268 0.621609 0.9054 0.9147 -0.0093         14 RNASE11 5UTR  
cg01182973 0.000297 0.621609 0.0903 0.0813 0.0090         22 ANKRD54 TSS1500 S_Shore 
cg24264674 0.000395 0.621609 0.0557 0.0479 0.0078         11 LMO1 TSS200 S_Shore 
cg20749008 0.000223 0.621609 0.0438 0.0367 0.0071         17 FLJ35220 TSS200 Island 
cg05801872 0.000335 0.621609 0.9617 0.9684 -0.0067         6    
cg21662326 0.000387 0.621609 0.0563 0.0502 0.0061         11 COPB1 TSS200  
cg13318091 0.000131 0.621609 0.9623 0.9682 -0.0059         8 TRIM35 Body Island 
cg08204155 0.00018 0.621609 0.9493 0.9547 -0.0054         22 ZDHHC8 3UTR N_Shore 
* p-value adjusted for multiple testing using FDR 
 
  
97 
 
Table 5.5 – 20 strongest associations from logistic regression analysis between DNA methylation and breast cancer in post-menopausal women (n=199),  
sorted on difference β-value  
Target ID p-value 
crude 
p-value FDR 
adjusted* 
Average β-value 
cases 
Average β-value 
controls 
Difference 
average β-value 
CHR 
 
Gene Functional 
region 
Relation 
to CGI 
cg05455393 6.95E-07 0.091412 0.6866 0.7289 -0.0423 X FHL1 TSS1500 N_Shore 
cg12486486 5.42E-06 0.091412 0.7599 0.8041 -0.0442 4 YTHDC1 Body  
cg10488199 3.42E-06 0.091412 0.7921 0.8317 -0.0396 6 MIR133B Body  
cg01264298 4.54E-06 0.091412 0.7461 0.7823 -0.0362 6    
cg18038361 2.34E-06 0.091412 0.5445 0.5801 -0.0356 18 TTR TSS1500  
cg03509901 4.38E-06 0.091412 0.8287 0.8611 -0.0324 17 NLK 1stExon S_Shore 
cg04798824 6.12E-06 0.091412 0.7656 0.7979 -0.0323 12 ANKS1B Body  
cg17377797 6.88E-06 0.091412 0.7056 0.7353 -0.0297 12 OR6C1 TSS200  
cg16659470 3.63E-06 0.091412 0.6308 0.6602 -0.0294 8 RBM12B 3UTR  
cg10133171 5.04E-06 0.091412 0.8012 0.8293 -0.0281 4   N_Shore 
cg15149117 3.83E-06 0.091412 0.6764 0.7030 -0.0266 11 OR52H1 TSS1500  
cg20235510 7.09E-06 0.091412 0.5070 0.5322 -0.0252 6 ZNF311 Body  
cg11718780 4.48E-06 0.091412 0.6154 0.6369 -0.0215 1 CAMSAP1L1 Body  
cg20460388 7.02E-06 0.091412 0.5581 0.5774 -0.0193 12 IRAK4 3UTR  
cg03338924 3.14E-06 0.091412 0.8344 0.8533 -0.0189 6 PHACTR1 Body Island 
cg14580443 6.70E-06 0.091412 0.8908 0.9066 -0.0158 9 FGD3 TSS1500  
cg00771653 2.38E-06 0.091412 0.6977 0.7132 -0.0155 22 CHCHD10 TSS1500 S_Shore 
cg13574945 3.40E-06 0.091412 0.7102 0.7241 -0.0139 X OTUD5 5UTR Island 
cg09356193 2.45E-06 0.091412 0.9175 0.9289 -0.0114 14 PACS2 Body N_Shore 
cg09912005 5.44E-06 0.091412 0.8937 0.9030 -0.0093 4 ADAD1 5UTR Island 
* p-value adjusted for multiple testing using FDR 
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5.4 Stratification by MTHFR genotype 
Stratified analyses have also been performed by a common polymorphic variant of the 
methylene-tetrahydrofolate reductase (MTHFR) gene (MTHFR C677T). This gene has been 
associated with breast cancer in a recent meta-analysis by Yu et al.296 In addition, it has been 
shown to play a critical role in DNA methylation; MTHFR converts 5,10-methylene-
tetrahydrofolate to 5-methylene-tetrahydrofolate, which leads to the production of methionine 
(through the addition of a methyl group to homocysteine). Methionine can in turn function as a 
methyl donor which can be used for DNA methylation.43 Polymorphisms in this gene can cause a 
reduction in the efficiency of the protein which inhibits the production of methionine. This 
lower efficiency has been shown for the T allele studied in this chapter, and similar frequencies 
of the three genotypes were observed in this chapter compared with previous studies.297  
The 20 strongest associations for subjects with the TT variant (n=58) are displayed in Table 5.6 
and the 20 strongest associations for subjects with the CT or CC variants (n=266) are displayed 
in Table 5.7.  
The results in the TT stratum do not reach genome-wide significance, which is potentially due to 
the small sample size (smallest p-value = 0.000214). In the CT and CC stratum, no CpGs reach 
genome-wide significance either (smallest p-value = 5.71E-07), however 104 CpGs had a q-
value<0.05. No overlap was observed in the top CpGs of both strata, and only nine CpGs 
overlapped between the CT and CC strata and the 26 most strongly associated CpGs displayed in 
Table 5.3 (cg12486486, cg05455393, cg03509901, cg06531158, cg17424007, cg20235510, 
cg13140465, cg16659470, cg23494338). This is possibly due to the higher numbers in the CT 
and CC stratum. 
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Table 5.6 – 20 strongest associations from logistic regression analysis between DNA methylation and breast cancer in MTHFR TT women (n=58),  
sorted on difference average β-value 
Target ID p-value 
crude 
p-value FDR 
adjusted* 
Average β-value 
cases 
Average β-value 
controls 
Difference 
average β-value 
CHR 
 
Gene Functional 
region 
Relation to 
CGI 
cg05757007 0.000371 0.858849 0.683627 0.710583 -0.02696 6 ASCC3 Body  
cg07189673 0.000386 0.858849 0.929221 0.952780 -0.02356 10    
cg05835241 0.000305 0.858849 0.498646 0.518733 -0.02009 8 PSD3 Body  
cg21762935 0.000314 0.858849 0.372768 0.391961 -0.01919 X IL1RAPL2 TSS1500 Island 
cg23735003 0.000214 0.858849 0.679586 0.691315 -0.01173 X IL2RG TSS1500  
cg13257129 0.000558 0.858849 0.845485 0.855844 -0.01036 3    
cg13964726 0.000509 0.858849 0.832586 0.841298 -0.00871 9 PGM5 Body  
cg23951816 0.000353 0.858849 0.923973 0.932538 -0.00856 10 TCF7L2 Body  
cg17299412 0.000482 0.858849 0.959676 0.967517 -0.00784 1    
cg00127505 0.000556 0.858849 0.068219 0.062702 0.00551 10   Island 
cg01702347 0.000528 0.858849 0.938353 0.945298 -0.00695 12 IFFO1 Body N_Shelf 
cg08165083 0.000355 0.858849 0.895761 0.901957 -0.00620 1 PEX14 Body  
cg12356859 0.000604 0.858849 0.978111 0.982967 -0.00486 2 LOC150622 Body  
cg27373220 0.000472 0.858849 0.970146 0.974895 -0.00475 10 DIP2C Body N_Shore 
cg06142108 0.000607 0.858849 0.830582 0.826291 0.00429 16 SYT17 Body Island 
cg18258502 0.000400 0.858849 0.963060 0.967045 -0.00398 3 MASP1 Body  
cg23229604 0.000636 0.858849 0.937962 0.941705 -0.00374 1 GPR61 TSS1500  
cg06993494 0.000416 0.858849 0.953549 0.957076 -0.00353 11 OR5A1 1stExon  
cg23458341 0.000523 0.858849 0.042697 0.039478 0.00321 20 OVOL2 TSS1500 S_Shore 
cg02197923 0.000333 0.858849 0.969890 0.972087 -0.00220 4    
* p-value adjusted for multiple testing using FDR 
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Table 5.7 – 20 strongest associations from logistic regression analysis between DNA methylation and breast cancer in MTHFR CT and CC women (n=266),  
sorted on difference average β-value 
Target ID p-value 
crude 
p-value FDR 
adjusted* 
Average β-value 
cases 
Average β-value 
controls 
Difference 
average β-value 
CHR 
 
Gene Functional 
region 
Relation to 
CGI 
cg12486486 1.63E-06 0.048311 0.763460 0.797942 -0.03448 4 YTHDC1 Body   
cg05455393 3.13E-06 0.048311 0.691298 0.722572 -0.03127 X FHL1 TSS1500 N_Shore 
cg03509901 5.79E-07 0.048311 0.833421 0.860667 -0.02725 17 NLK 1stExon S_Shore 
cg06531158 1.31E-06 0.048311 0.804394 0.831444 -0.02705 13 MIR548F5 Body  
cg12847986 2.07E-06 0.048311 0.541082 0.565897 -0.02482 3 MECOM Body  
cg15341575 1.89E-06 0.048311 0.819502 0.844049 -0.02455 10 CPEB3 Body  
cg16659470 2.18E-06 0.048311 0.632852 0.656376 -0.02352 8 RBM12B 3UTR  
cg20235510 1.12E-06 0.048311 0.505978 0.528801 -0.02282 6 ZNF311 Body  
cg17424007 2.96E-06 0.048311 0.786212 0.807755 -0.02154 1 MYOG TSS1500  
cg13140465 1.41E-06 0.048311 0.739893 0.759375 -0.01948 15 NIPA1 Body N_Shore 
cg12332536 5.71E-07 0.048311 0.861068 0.877050 -0.01598 3 CCRL2 3UTR  
cg03976754 3.23E-06 0.048311 0.783252 0.798839 -0.01559 1 FNDC5 Body  
cg01048203 8.94E-07 0.048311 0.806145 0.821069 -0.01492 14 RNASE9 5UTR  
cg03567262 3.36E-06 0.048311 0.818742 0.832329 -0.01359 12    
cg13049992 1.57E-06 0.048311 0.807856 0.819901 -0.01204 5 GRAMD3 Body  
cg26948596 2.10E-06 0.048311 0.906058 0.917989 -0.01193 14 RIN3  N_Shore 
cg22457668 1.67E-06 0.048311 0.864886 0.875818 -0.01093 8   N_Shelf 
cg07227769 1.34E-06 0.048311 0.462415 0.473255 -0.01084 11   Island 
cg23494338 2.10E-06 0.048311 0.915237 0.922227 -0.00699 10  Body  
cg02753511 3.46E-06 0.048311 0.958510 0.963242 -0.00473 11 CCND1 3UTR N_Shore 
* p-value adjusted for multiple testing using FDR 
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5.5 Cluster analyses 
 
5.5.1 PCA 
The results presented above suggest differential methylation between cases and controls at 
several locations. These potential candidates may act as epigenetic markers of disease risk. 
However, these require further investigation to understand how they correlate with each other 
and ultimately disentangle how their effect is mediated. To this end, principal component 
analysis was performed on the 6,334 CpGs with a q-value<0.05. The scree plot (Figure 5.2) 
displays the variance explained by each PC (A) and the cumulative percentage of variance 
explained (B). The first three principal components yield a cumulative variance explained of 
around 20%. The inclusion of any subsequent components resulted in low increases in the 
fraction of variance explained. Nevertheless, 90% of the variance is explained by considering 
224 PCs. 
Figure 5.2 Scree plots of 6,334 CpGs with a q-value<0.05  
Number of PCs on x-axis, % variance explained on y-axis – (A) percentage variance explained by each PC (B) 
cumulative scree plot – cumulative percentage explained by each PC, Approximately 20% of the variance is explained 
by the first three PCs and 224 PCs explain 90% of the variance. 
 
 
Score plots (Figure 5.3), show the projection of the 6,334 CpGs on the first, second, or third PC. 
It becomes clear that two groups of CpGs can be distinguished along the first PC (Figure 5.3 A: x-
axis and Figure 5.3 B: x-axis), which indicates strong clustering.  
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Figure 5.3 Score plots of 6,334 CpGs with a q-value<0.05 
A:x-axis displays first PC, y-axis displays second PC, B:x-axis displays first PC, y-axis displays third PC, C:x-axis 
displays third PC, y-axis displays second PC. A clear distinction between CpGs is observed along the first PC (x-axis in 
both A and B) 
 
In an attempt to investigate which factors are highly associated with the first component and 
therefore explain this unsupervised classification, the same score plot was created, colouring 
observations by probe type (Infinium I or II), relation to the CGI (island, north and south shelf 
and shore), gene group (1st exon,  ’UTR, 5’UTR, body, TSS200, TSS1500), and CpG class (HC, IC, 
IC shore, LC, see also section 5.5.2). In addition, coloured plots by technical variables (such as 
batches or position on the chip), lifestyle, reproductive or hormone-related variables (such as 
smoking status, menopausal status, HRT use etc.) and for hyper- or hypomethylated CpGs 
(hypermethylated meaning cases have higher methylation compared with controls, 
hypomethylated meaning cases have lower methylation compared with controls) were 
produced. Figure 5.4 shows that the clustering can be explained fully by the sign of the effect 
size estimate. Overall, more CpGs were hypomethylated than hypermethylated, which is in line 
with the results presented in Chapter 4. 
 
     A                B                      C 
 
     A             B                  C 
Figure 5.4 Score plot of 6,334 CpGs with 
a q-value<0.05.  
First PC (x-axis) and second PC (y-axis), 
coloured by hypomethylation (red) and 
hypermethylation (black).  
The clustering between the CpGs can 
entirely be explained by the sign of the 
effect size estimate. 
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5.5.2 Consensus clustering 
An additional supervised method was used to identify potential functional clustering of the 
6,334 candidate CpGs. Specifically, consensus clustering analysis was run, setting the a priori 
number of clusters to seven. The consensus matrices of these analyses are shown in Figure 5.5. 
The optimal number of clusters (k) as well as their stability, was determined, based on these 
consensus matrices, in combination with the consensus cumulative distribution function (CDF) 
plot and the delta area plot (which can both be found in supplementary Figure S5.1). CpGs 
belonging to the same cluster are arranged next to each other in the consensus matrix (the 
order of CpGs is the same in the rows and columns), and the colour gradient (dark blue 
indicates CpGs always cluster together and white indicates CpGs never cluster together) aid in 
the decision of the optimal number of CpGs. Well defined block structures specify perfect 
clustering. These analyses showed that 5 clusters provided good separation of the clusters and 
to interpret these five clusters, their composition was summarized in Table 5.8 
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Figure 5.5 Heatmap of the consensus matrices of 6,334 CpGs with a q-value<0.05 for k = 2-7 Heatmap A-F 
display consensus matrices for k = 2-7, respectively. The consensus clustering is shown as a dendrogram above the 
heatmap. The cluster memberships are shown by coloured rectangles between the dendrogram and the heatmap and 
the legend of the right of each graphic depicts the legend for each cluster membership. Dark blue indicates probes 
always cluster together and white indicates probes never cluster together. Based on these heatmaps, in combination 
with the CDF plot and delta area plot it was decided that k=5 was the optimal number of clusters. 
 
A B 
C D 
E F 
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In order to investigate if CpGs with certain features cluster together, the cluster membership 
and several CpG characteristics were tabulated, as can be seen in Table 5.8. 
 
Table 5.8 – Cluster memberships versus CpG characteristics of the 6,334 CpGs with a q-value<0.05 
  Cluster membership 
CpG characteristic 
(n=6,334) 
 1 
(n=4,846) 
2 
(n=1,000) 
3 
(n=330) 
4 
(n=157) 
5 
(n=1) 
Effect size estimate  n(%)      
   Hypomethylation (n=5,314)      4,821 (90.72) 33 (0.62) 328 (6.17) 131 (2.47) 1 (0.02) 
   Hypermethylation (n=1,020) 25 (2.45) 967 (94.80) 2 (0.20) 26 (2.55) 0 (0.0) 
       
Infinium design type n(%)      
   Infinium I (n=1,747)              1,255 (71.84) 369 (21.12) 80 (4.58) 43 (2.46) 0 (0.0) 
   Infinium II (n=4,587)              3,591 (78.29) 631 (13.76) 250 (5.45) 114 (2.49) 1 (0.02) 
       
Functional region n(%)      
   1st exon (n=226)  76 (33.63) 134 (59.29) 8 (3.54) 8 (3.54) 0 (0.0) 
    ’UTR (n=383)  352 (91.91) 3 (0.78) 22 (5.74) 6 (1.57) 0 (0.0) 
   5’UTR (n=475)  282 (59.37) 140 (29.47) 32 (6.74) 20 (4.21) 1 (0.21) 
   Body (n=2,657)              2,372 (89.27) 142 (5.34) 101 (3.80) 42 (1.58) 0 (0.0) 
   TSS1500 (n=686)  400 (58.31) 202 (29.45) 61 (8.89) 23 (3.35) 0 (0.0) 
   TSS200 (n=464)  143 (30.82) 288 (62.07) 18 (3.88) 15 (3.23) 0 (0.0) 
       
Relation to CGI n(%)      
   Island (n=1,452)  572 (39.39) 768 (52.89) 72 (4.96) 40 (2.75) 0 (0.0) 
   North shelf (n=486)  438 (90.12) 5 (1.03) 36 (7.41) 7 (1.44) 0 (0.0) 
   North shore (n=756)  613 (81.08) 81 (10.71) 30 (3.97) 32 (4.23) 0 (0.0) 
   South shelf (n=397)  374 (94.21) 2 (0.50) 16 (4.03) 5 (1.26) 0 (0.0) 
   South shore (n=616)  484 (78.57) 81 (13.15) 29 (4.71) 22 (3.57) 0 (0.0) 
       
HM27 probe n(%)      
   yes (n=260)  85 (32.69) 149 (57.31) 16 (6.15) 10 (3.85) 0 (0.0) 
   no (n=6,074)              4,761 (78.38) 851 (14.01) 314 (5.17) 147 (2.42) 1 (0.02) 
       
HIL CpG class n(%)      
   HC (n=1,220)  260 (21.31) 839 (68.77) 63 (5.16) 58 (4.75) 0 (0.0) 
   IC (n=2,078)              1,913 (92.06) 62 (2.98) 77 (3.71) 26 (1.25) 0 (0.0) 
   IC shore (n=301)  195 (64.78) 69 (22.92) 16 (5.32) 21 (6.98) 0 (0.0) 
   LC (n=2,735)              2,478 (90.60) 30 (1.10) 174 (6.36) 52 (1.90) 1 (0.04) 
 
Cluster 5 contains only one probe (Infinium II), which is hypomethylated in cases compared 
with controls, located at the 5’UTR region, not part of the HM27 array and part of the LC HIL 
CpG class. The heatmaps in Figure 5.5 show that this CpG is in a separate cluster irrespective of 
the number of clusters, which means this CpG never clusters together with any of the other 
CpGs and therefore can be considered as an outlier.  
The vast majority of hypomethylated CpGs (90.72%) is part of cluster 1 and the majority of 
hypermethylated CpGs (94.80%) is part of cluster 2. For the different Infinium type probes the 
discrimination is not so obvious. Most of Infinium I probes (87.84%) are allocated to cluster 1, 
but the same is true for most of Infinium II probes (78.29%). CpGs on the 1st exon and TSS200 
seem primarily divided over cluster 2 (59.29% and 62.07% for 1st exon and TSS200, 
respectively) and to a lesser extent cluster 1 (33.63% and 30.82% for 1st exon and TSS200, 
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respectively), with similar percentages in each cluster, while more than 90% of the CpGs at the 
 ’UTR region (91.91) are part of cluster 1. In addition, a high percentage of the CpGs found on 
the gene body belong to cluster 1 (89.27%). The percentages of CpGs at the 5’UTR region that 
are classified as cluster 1 and 2 are similar to the percentages CpGs at the TSS1500 that are 
classified as cluster 1 and 2 (cluster 1: 59.37% and 58.31% for 5’UTR and TSS1500, respectively 
– cluster 2: 29.47% and 29.45% for 5’UTR and TSS1500, respectively).   
Looking at CpGs in relation to the CpG island, the most remarkable observation is the high 
percentage of north shelf (90.12%) and south shelf (94.21%) CpGs in cluster 1. Also CpGs on the 
shores have similar percentages in cluster 1 (north: 81.08%, south: 78.57%) and cluster 2 
(north: 10.71%, south: 13.15%). The highest percentage of CpGs on the CpG islands are found in 
cluster 2, with slightly more than half of the CpGs (52.89%) allocated to this cluster, and the 
second highest percentage of the CpGs allocated to the first cluster (39.39%). No clear clustering 
was observed of HM27 probes.  
Finally, Price et al. categorized the HM450 probes into four classes, based on the CpG island 
density: HC probes (located on high-density CpG islands), IC probes (located on isolated 
intermediate-density CpG islands, IC shore probes (located in areas with borderline high 
density), and LC probes (probes that were not located on a CpG island).258 The majority of IC 
(92.06%) and LC (90.60%) probes were part of cluster 1. The separation of HC probes (68.77% 
in cluster 2 and 21.31% in cluster 1) and IC shore probes (67.78% in cluster 1 and 22.92% in 
cluster 2) was less pronounced. 
 
These results indicate that CpGs with certain common features seem to cluster together and 
confirm the functionally relevant classification of these 6,334 CpGs.  
 
5.6 Cell types 
In an attempt to deal with the issue of different white blood cells in each blood samples, the 
same approach was used as for the global methylation analysis in Chapter 4 (section 4.5). CpGs 
whose DNA methylation differed significantly between the different cell types and PBMCs 
(n=11,196) were excluded from the analyses and the analyses were rerun on the remaining 
397,533 CpGs. The results of the analyses without these CpGs were not drastically different 
from the results displayed here, however, one CpG (cg00124920) disappeared from the 
strongest 26 CpGs suggesting its genuine association with different cell types. (See 
supplementary Table S5.1 – S5.3).  
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5.7 Discussion 
In this chapter, locus-by-locus analysis of the association between DNA methylation at 408,749 
CpGs and breast cancer was performed among 162 matched case-control pairs using a 
prospective nested case-control design. DNA was obtained from blood samples, collected on 
average 3.8 years before diagnosis, and 26 CpGs reaching genome-wide significance were 
discovered to be differentially methylated among women who later went on to develop the 
disease, compared with women who remained disease free. All 26 CpGs were hypomethylated 
in cases compared with controls. Excluding case-control pairs with a time to diagnosis of less 
than one year did not substantially change the results indicating reverse causality is unlikely to 
play a role in these findings.  
Some other studies have used an Infinium array by Illumina to investigate genome-wide, locus-
specific DNA methylation in relation to breast cancer, as was done in this chapter, but this is the 
first study using the HM450. Most studies investigating breast cancer have used the HM27 
BeadChip, which is the predecessor of the HM450. Some of these studies reported associations 
between DNA methylation and hormone receptor status in breast cancer298;299, other tumour 
characteristics300, breast cancer metastasis301, and breast cancer subtypes302.  
These studies all used tumour tissue, rather than blood samples and Widschwendter et al. 
showed that DNA methylation measured in blood samples could serve as a good predictor of 
breast cancer risk. 285 
One study by Xu et al. had a very comparable design to this chapter. They used the HM27 
BeadChip to measure DNA methylation in prospectively collected blood samples from 298 
breast cancer cases and 612 disease free control women.303 They reported 250 (9% of 27,578 
CpGs assessed) differentially methylated CpGs that reached an FDR cut-off of 0.05, of which 188 
(75.2%) CpGs were hypomethylated in cases compared with controls. These results are fairly 
similar to the 6,334 FDR corrected top hits identified here (14% of 408,749 CpGs assayed), of 
which 83.9% were hypomethylated in cases compared with controls. Looking at the CpGs 
specifically, only one CpG overlapped in the 250 CpGs reported by Xu et al. and the 6,334 CpGs 
identified in this chapter. Cg08360728 is located on chromosome 1 and associated with the 
GPATCH3 gene, of which the function is unknown. 
When Xu et al. compared the methylation values of the cases with a time to diagnosis of more 
than one year to methylation values of both the cases and controls with a time to diagnosis of 
less than one year, they observed intermediate methylation values in 71.6% of the 250 
identified CpGs. This is much higher than the 34% of all CpGs on the HM27. These results 
suggest that across these signals some may relate to epigenetic effects of the disease itself. 
When the analyses of this chapter were rerun, excluding samples with a time to diagnosis of less 
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than one year, fewer significant associations were found, which could partly be due to reverse 
causality, or to a smaller sample size. The difference between the findings by Xu et al. and this 
chapter can also possibly be explained by the much shorter average time to diagnosis reported 
by Xu et al. (1.3 years) compared with the average time to diagnosis found in this chapter (3.8 
years). 
 
Moreover, Xu et al. investigated the performance of the methylation of 57 CpGs in 
discriminating breast cancer cases from controls, using receiver operating characteristic (ROC)-
analysis. The area under the curve (AUC) for the CpGs was 65.8% (95% CI = 61.0 – 70.5%), 
while adding the Gail model score increased this to 65.9% (95% CI = 60.9 – 70.9%) and adding 
nine single nucleotide polymorphisms (SNPs) which have been associated with breast cancer 
risk increased the AUC to 66.1% (95% CI = 61.0 – 71.3%). The Gail model is aimed at prediction 
of breast cancer risk. It was developed304, modified to include invasive breast cancer, and 
validated in the US305 and later also in a European population306, and remains to be widely used 
for breast cancer risk prediction until today. Xu et al. did not assess the AUC after the addition of 
CpGs to the Gail model, with and without the SNPs, which means they could not estimate what 
the CpGs could add to the prediction of the already existing Gail model. Unfortunately, it was not 
possible to estimate the AUC of the Gail model using the data described in this chapter, and the 
possible increase in AUC by adding the top 26 CpGs identified here. This is due to a lack of 
information regarding several of the factors of the Gail model, among which family history of 
breast cancer (first degree), and information on breast biopsies. 
 
The number of subjects is an important strength of the study by Xu et al., however, some 
limitations lie in the fact that it remains unclear what form of pre-processing and/or 
normalization was performed, and that all women in the study have a positive family history of 
breast cancer (which makes it difficult to generalize the findings). 
 
Numerous other studies have assessed DNA methylation and breast cancer using a candidate 
gene approach. Genes that were identified in these studies are detailed in Chapter 2 (section 
2.3) (and summarized in Table S2 of the Supplementary tables). No overlap was observed in the 
genes that were associated with the 26 CpGs in this chapter and the genes mentioned in these 
reviews.150-153 However, seven genes (ATM, BIN1, BRCA1, MGMT, RARB, RASSF1, RUNX3) were 
found in the strongest 6,334 associations (annotated to 4,891 genes) with a q-value<0.05, and 
were reported by some of these studies. These genes were found between the 704th and 4,913th 
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position of the top 6,334 CpGs (sorted on p-value), with effect sizes ranging from -0.0135 to 
0.0461.  
 
Breast cancer is a heterogeneous disease. Molecular subtypes have been defined on the basis of 
the oestrogen, progesterone, and human epidermal growth factor receptor 2 status. Other 
classifications of breast cancer are based on lymph node status, or tumour behaviour, grade, or 
stage. Unfortunately there were too many missing values for these variables (hormone 
receptors, tumour grade and stage), the numbers in the subgroups were too small (tumour 
behaviour), or there was no information available at all (lymph node status), to enable analysis 
of these subtypes in this chapter.  
Some evidence suggests that pre- and postmenopausal breast cancer might be two different 
diseases.307 Stratified analysis by menopausal status (section 5.3) showed largely different 
results. Because of the lower power, due to the smaller samples sizes, none of the CpGs for 
either menopausal status reached genome-wide significance, but one signal was consistently 
found in both strata (cg20235510, ZNF311). However, the lack of overlap for most signals 
strengthens the suggestion that both diseases are pathophysiologically heterogeneous and 
studies with more subjects should be performed to investigate this potential difference. 
 
Stratified analysis by MTHFR status showed differential methylation at completely different 
CpGs for the TT variant compared with the CT and CC variant. The MTHFR genotype can result 
in changes in methionine production, which leads to changes in DNA methylation, which can 
result in changes in disease risk. Despite the different CpGs found for the different MTHFR 
genotypes in this study it is premature to draw conclusions. These differences can most likely be 
explained by the lack of power because frequency of the MTHFR genotype was similar among 
cases and controls (cases: 27 TT, 135 CT or CC – controls: 31 TT, 131 CT or CC), which means 
confounding is unlikely. Nevertheless, because another study observed interaction (high plasma 
folate was associated with a higher risk of breast cancer among post-menopausal women who 
were carriers of the 677T allele) it remains important for future studies to stratify the analyses 
by MTHFR genotype.308 More studies, with bigger sample size, are needed to investigate the 
potential causal relationship between MTHFR, via DNA methylation, and breast cancer risk. 
 
Clustering analyses of the 6,334 strongest associations (q-value<0.05) showed that a distinction 
could be made based on hypo/hypermethylation. In addition, consensus clustering seemed to 
indicate that CpGs can cluster together based on similar characteristics, as was shown in Table 
5.8. This table showed again the discrimination between signals with a positive and negative 
effect size estimate and in addition the functionally relevant clustering of CpGs located at the 
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 ’UTR, the south shelves (and to a lesser extent north selves), as well as CpGs from the IC HIL 
CpG class. Other studies have successfully used clustering techniques on DNA methylation data 
to discriminate breast cancer cases from controls or subtypes of breast cancer309;310, which is 
why future studies, with a bigger sample size, could explore the possibilities of these and other 
methods to identify functionally relevant clusters and DNA methylation markers. 
 
An increasing number of studies are aware of the necessity to adjust for white blood cell 
composition. In this chapter the CpGs that were associated with methylation in certain cell types 
were excluded from the analyses, which did not change the results to a large extent. Therefore it 
is thought this cannot have confounded the results presented here. This is one of the strengths 
of this study. Others include the larger number of CpGs assessed, the subjects included being 
part of the general population, the matching of the cases and controls, the prospectively 
collected samples, and the elaborate pre-processing of the data. 
 
In conclusion, this is the first study using the HM450 to assess methylation differences in pre-
diagnostic blood samples of breast cancer cases and controls, at over 400,000 CpGs across the 
genome. The results presented here showed various CpGs to be associated with case-control 
status, however, the effect sizes were very small. Before these results can be interpreted they 
need to be replicated and validated in independent populations. Nevertheless, these preliminary 
findings suggest that the HM450 can be used in studies with bigger samples sizes to potentially 
identify biomarkers of breast cancer risk. 
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Chapter 6 – Replication of global DNA methylation results using the 
EGM dataset 
 
6.1 Samples and study population 
In an attempt to replicate global methylation analyses, the EnviroGenoMarkers (EGM) dataset 
was used. It consists of 95 female breast cancer cases and 95 matched controls, of which DNA 
methylation data are available. After excluding SNPs (n=65) and 64,818 CpGs whose 
methylation levels were missing in >20% (n=38) of the samples, 420,694 CpGs remained. Of the 
total population, 27 samples were excluded because they had missing values for >5% (n= 
21,035) of the CpGs. Another 15 subjects were excluded because the matched pair was not 
located on the same chip. Finally, the non-specific CpGs (n=38,431) were excluded, resulting in 
382,263 CpGs and 148 subjects (74 cases, 74 controls) to be analysed.  
The median time to diagnosis was 5.6 years (range: 2.0 – 9.9). Demographic, lifestyle and 
reproductive features of the study participants, stratified by case-control status, are 
summarized in Table 6.1. The last column displays the significance level of the t-test (or 
Wilcoxon test for not normally distributed variables) or the chi2-test, assessing differences in 
the variables between cases and controls. Age at recruitment and centre were similar in cases 
and controls. No significant differences were observed between cases and controls for 
anthropometric variables such as height (p-value = 0.72), weight (p-value = 0.10), and body 
mass index (BMI) (p-value = 0.21), nor for educational level (as proxy for socio-economic 
status) (p-value = 0.10) or lifestyle factors such as physical activity level (p-value = 0.61), 
smoking status (p-value = 0.54) and alcohol (p-value = 0.42) and fat consumption (p-value = 
0.99). Regarding the hormone-related and reproductive factors, none of the variables showed 
an association with case-control status, apart from a borderline statistically significant 
association for ever vs. never OC use (p-value = 0.06). 
  
Table 6.1 – Baseline characteristics and breast cancer risk factors of the EGM study population  
Characteristic  Cases (n=74) Controls (n=74) p-value& 
Centre n (%)   1.00 
   Sweden  31 (41.9) 31 (41.9)  
   Florence  24 (32.4) 24 (32.4)  
   Naples  4 (5.4) 4 (5.4)  
   Ragusa  1 (1.4) 1 (1.4)  
   Turin  2 (2.7) 2 (2.7)  
   Varese  12 (16.2) 12 (16.2)  
Age at recruitment mean (range), years 51.2 (37.1 – 64.6) 51.3 (37.1 – 64.6) 0.38 
Height mean (range), cm 161.6 (149.0 – 180.0) 161.9 (150.0- 179.0) 0.72 
Weight mean (range), kg 62.9 (48.2 – 84.0) 65.5 (45.3 – 92.0) 0.10 
BMI n (%)   0.21 
   Normal  48 (64.9) 37  
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   Overweight  21 (6.7) 30  
   Obese  5 (28.4) 6  
   Missing  0 (0.0) 1  
Physical activity  n (%)   0.61 
   Inactive  22 (29.7) 15  
   moderately inactive  28 (37.8) 33  
   moderately active  16 (21.6) 17  
   Active  8 (10.8) 7  
   Missing  0 (0.0) 2  
Smoking status n (%)   0.54 
   Never  41 37 (50.0)  
   Former  16 15 (20. 3)  
   Current  16 22 (29.7)  
   Missing  1 0 (0.0)  
Educational level n (%)   0.10 
   None  1 (1.4) 0 (0.0)  
   Primary  35 (47.3) 38  
   Technical/professional 16 (21.6) 6  
   Secondary  11 (14.9) 19  
   College/University  11 (14.9) 10  
   Missing  0 (0.0) 1  
Alcohol 
consumption  
median (gr/d) 0.67 (0.00-36.5) 1.08 (0.00 – 23.8) 0.42 
Fat consumption median (gr/d) 69.2 (31.5 – 155.2) 68.5 (21.6 – 147.6) 0.99 
Age at menarche mean (range), years   0.60 
   <12   14 12  
   12-16  57 51  
   ≥16  0 1  
   missing  3 8  
Age at menopause mean (range), years 49.4 (42.0 – 60.0) 50.2 (40.0 – 58.0) 0.26 
Menopausal status n (%)   0.87 
   Premenopausal  28 29  
   Postmenopausal  34 31  
   missing     
Ever pregnant n (%)   0.76 
   Yes  63 58  
   No  9 6  
   Missing  2 10  
Age first birth mean (range), years 24.7 (19.0 – 36.0) 25.6 (18.0 – 35.0) 0.09 
Parity n (%)   0.23 
   0  9 6  
   1  13 14  
   2  23 28  
   3  20 7  
   4  5 4  
   5  2 3  
   6  0 1  
   7  0 1  
   missing  2 10  
Ever OC use* n (%)   0.06 
   Yes  39 24  
   No  33 41  
   Missing  2 9  
Ever HRT use# n (%)   0.60 
   Yes  19 13  
   No  53 49  
   missing  2 12  
&Missing values category is omitted from the analyses 
*OC: oral contraceptive  #HRT: hormone replacement therapy 
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6.2 Results 
The estimated difference in mean beta values across all CpGs between matched breast cancer 
cases and controls was 0.000075 (lower in controls compared with cases, p-value paired 
Wilcoxon test = 0.80). This difference is considerably smaller than the difference found in the 
HuGeF study (difference = 0.002) and non-significant, while the p-value found in the HuGeF 
study was highly significant (p-value = 8.01e-06).  
Table 6.2 shows the associations between quartiles of global methylation and breast cancer. 
From the distribution of cases and controls in the different quartiles it becomes apparent there 
are more cases (n=32) than controls (n=18) in the third quartile, however, this is not 
statistically significant (OR = 2.27, 95% CI = 0.94 – 5.48, p-value = 0.07). The analysis of one 
standard deviation change resulted in an OR of 1.11, with a 95% CI of 0.73 – 1.69 and p-value of 
0.62, indicating no significant association between global methylation and case-control status. 
While the HuGeF data showed hypomethylation among cases compared to controls, the EGM 
data show more of a tendency towards the opposite association, i.e. hypermethylation in cases 
compared to controls, although this only seems to be the case for the third quartile and the 
paired Wilcoxon test, however both are not statistically significant. 
 
Table 6.2 – Association between average methylation and breast cancer risk 
  Cases  
(n) 
Controls 
(n) 
OR  (95% CI) p-value 
       
By quartiles Q1  [0.537 – 0.544) 14 19 1.00   
 Q2  [0.544 – 0.546) 14 18 1.07 (0.40 – 2.84) 0.90 
 Q3  [0.546 – 0.549) 32 18 2.27 (0.94 – 5.48) 0.07 
 Q4  [0.549 – 0.560) 14 19 1.12 (0.42 – 3.00) 0.82 
       
 Per 1 SD   1.11 (0.73 – 1.69) 0.62 
       
Time to Diagnosis <5.6  37 - 0.90 (0.51 – 1.61) 0.72 
(years) >5.6 34 - 1.57 (0.81 – 3.04) 0.18 
       
Menopausal status Premenopause 28 29 1.11 (0.51 – 2.38) 0.80 
 Postmenopause 34 31 1.27 (0.65 – 2.48) 0.49 
 Missing*  12 14    
       
ER status Negative  39 - 1.56 (0.81 – 2.99) 0.18 
 Positive 35 - 0.85 (0.48 – 1.50) 0.58 
       
*missing values category is omitted from the analyses 
 
The results were further investigated by performing stratified analyses by time to diagnosis, 
menopausal status and oestrogen receptor (ER) status. Time to diagnosis was dichotomized 
above and below the median of 5.6 years and was, unlike the findings in the HuGeF dataset, not 
associated with global methylation (Table 6.2, Figure 6.1.). A Kolmogorov-Smirnov test was 
performed to test for equality of distributions in cases and controls and the results confirmed 
114 
 
no difference in global methylation between cases and controls either below the median (p-
value = 0.98), or above the median (p-value = 0.11) time to diagnosis.   
 
 
Figure 6.1 Density plots of the mean β-values for cases and controls stratified below and above the median of 
time to diagnosis (5.6 years) Cases are displayed in red, controls in black. The density plot including subjects with a 
time to diagnosis below the median does not show any difference between cases and controls, while the density plot 
including subjects with time to diagnosis above the median seems to shows lower methylation among controls (black 
line) compared with cases (red line) although this difference is not statistically significant. 
 
Performing stratified analyses for menopausal status and ER-status did not show any 
associations with global methylation (Table 6.2). In the HuGeF dataset hypomethylation was 
found in ER positive tumours (p-value = 0.05) and among cases in both pre-menopausal (p-
value = 0.03) and post-menopausal (p-value = 0.002) women, however ER positive tumours 
were no longer associated with DNA methylation after adjustment for age at menopause. 
Potential confounding factors were assessed by running linear regression models of global 
methylation versus baseline variables and breast cancer risk factors and results are shown in 
Table 6.3.  
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Table 6.3 – Association between global methylation and breast cancer risk factors 
Characteristic  p-value 
Centre Naples 0.80 
 Ragusa 0.29 
 Turin 0.58 
 Varese 0.96 
 Sweden 0.53 
Age at recruitment years 0.17 
Height cm 0.36 
Weight kg 0.07 
BMI  overweight 0.17 
 obese 0.26 
Physical activity moderately inactive 0.07 
 moderately active 0.07 
 active 0.58 
Smoking status former 0.21 
 current 0.16 
Educational level primary 0.16 
 technical/professional 0.20 
 secondary 0.38 
 college/university 0.35 
Alcohol consumption gr/d 0.61 
Fat consumption gr/d 0.57 
Age at menarche  12-14 years 0.46 
 ≥15 years 0.62 
Age at menopause  years 0.40 
Menopausal state pre/post-menopausal 0.61 
Ever pregnant yes/no 0.55 
Age first birth years 0.45 
Parity 1 0.79 
 2 0.58 
 3 0.47 
 4 0.99 
 5 0.76 
 6 0.77 
 7 0.17 
Ever OC use* yes/no 0,46 
Ever HRT use# yes/no 0.65 
*OC: oral contraceptive  #HRT: hormone replacement therapy 
 
Because none of the variables in Table 6.1 are significantly associated with case-control status 
and equally, no variables from Table 6.3 are associated with global methylation, it was decided 
there is most likely no confounding by any of the variables. 
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Results of the stratified analyses according to the location or function of the CpG sites are shown 
in Table 6.4. 
 
Table 6.4 – Association between global methylation and breast cancer risk by CpG genomic feature per 1 SD 
     # CpG OR (95% CI) p-value 
      
All Including SNP probes 382,263 1.11 (0.73 – 1.69) 0.62 
 Excluding SNP probes 314,433 1.04 (0.69 – 1.57) 0.87 
      
CpG Island Island 107,588 0.83 (0.54 – 1.27) 0.39 
 Shores 95,247 1.01 (0.65 – 1.55) 0.98 
 Shelves 37,688 1.31 (0.86 – 2.00) 0.22 
 None 141,740 1.47 (0.96 – 2.26) 0.08 
      
Regulatory feature  Gene   2,879 1.30 (0.84 – 2.02) 0.24 
category NonGene 1,083 0.81 (0.54 – 1.22) 0.32 
 Promoter 69,248 0.69 (0.42 – 1.12) 0.13 
 Unclassified 56,705 0.90 (0.61 – 1.33) 0.59 
 None 252,348 1.48 (0.94 – 2.31) 0.09 
      
 Promoter 69,248 0.69 (0.42 – 1.12) 0.13 
 Other 313,015 1.29 (0.86 – 1.93) 0.22 
      
Gene Region Feature  TSS1500 55,477 0.96 (0.64 – 1.44) 0.84 
category TSS200 36,729 0.68 (0.43 – 1.07) 0.10 
 5’UTR 33,750 0.89 (0.61 – 1.30) 0.54 
 1st exon 16,609 0.77 (0.51 – 1.17) 0.23 
 Body 132,395 1.52 (0.95 – 2.44) 0.08 
 3’UTR 14,429 1.37 (0.88 – 2.12) 0.16 
      
Associated RNA  Coding 280,612 1.00 (0.66 – 1.52) 0.99 
Transcript NonCoding 8,777 1.25 (0.80 – 1.94) 0.32 
 Intergenic 92,874 1.35 (0.87 – 2.09) 0.19 
      
Repetitive elements Rmsk 68,269 1.35 (0.90 – 2.04) 0.14 
 NoRmsk 313,994 0.97 (0.65 – 1.46) 0.90 
      
Type of repetitive  Rmsk.Sat_SimRep 4,762 0.78 (0.49 – 1.22) 0.28 
element Rmsk.LTR 10,845 1.34 (0.89 – 2.01) 0.17 
 Rmsk.LINE 18,647 1.50 (0.96 – 2.33) 0.08 
 Rmsk.SINE 21,226 1.47 (0.96 – 2.23) 0.08 
 Rmsk.OtherRep 12,789 1.11 (0.72 – 1.70) 0.63 
 
None of the associations, at any functional or physical location on the genome, were associated 
with case-control status. Whereas in the HuGeF study all associations seemed inverse (lower 
methylation was associated with an increased risk of the disease), in the EGM cohort some of 
the associations seem positive, albeit not statistically significant.  
 
6.3 Conclusion 
In conclusion, the association between global hypomethylation and breast cancer that was 
found in the HuGeF dataset was not found in the EGM dataset. In addition, the stratified analyses 
by time to diagnosis, tumour characteristics or location of the CpGs were not replicable, nor the 
associations found with principal component analysis. This is possibly due to the low power of 
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the EGM study (far fewer subjects than the HuGeF study) and potentially the lower quality of 
the data of the EGM samples.  
However, in collaboration with a research group in Australia, Severi et al. performed the same 
analyses on their dataset of 438 breast cancer cases-control pairs (submitted for publication) 
and found very similar results as the results described in Chapter 4 of this thesis, which can 
serve as a replication of these findings. 
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Chapter 7 – Exposures and DNA methylation 
 
The analyses reported in section 7.1 (exposure to endocrine disrupting chemicals and DNA 
methylation) were performed using a subset (n=368) off all subjects from the EGM cohort 
(n=1,235), of which DNA methylation data was available. Section 7.2 summarizes the results of 
other hormone-related or reproductive factors in relation to DNA methylation in 324 subjects 
from the HuGeF (Breast II) cohort. Finally section 7.3 describes the outcomes of analyses 
estimating the association between 13 hormone levels in blood and their effect on DNA 
methylation, again using HuGeF samples. 
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7.1 EDC exposure and DNA methylation 
For the analyses between exposures and DNA methylation, all lymphoma controls from the EGM 
study of which DNA methylation data and exposure data was available (male and female, 
n=247) were included, in addition to the 95 breast cancer cases and 95 controls, resulting in an 
initial study population of 437 subjects. During pre-processing, 65 SNPS were excluded, as well 
as 55,110 CpGs because of missing values in >20% (87.4) of the samples. Subsequently, 61 
samples with missing values for >5% (21,520.1) of the CpGs we excluded, as well as seven 
samples because they were located as the only sample on a chip, which prevents ComBat 
(preprocessing method to reduce batch effect) from working. One Swedish, male control was 
considered as an outlier because of exposure levels for all PCBs well above the 99th percentile, 
and was excluded from the analyses. Finally, non-specific CpGs (n=38,994) were removed, 
leading to a final study population of 368 subjects and 391,408 CpGs.  
 
7.1.1 Population characteristics 
The median time to diagnosis was 5.5 years. Baseline characteristics of the subjects used in this 
part of the study are described in Table 7.1.  
  
Table 7.1 – Baseline characteristics of study population  
Characteristic   n = 368 
Cohort n (%)   
   EPIC-Italy   150 (40.8%) 
   NSHDS   218 (59.2%) 
Sex    
   Male n (%)  110 (29.9%) 
   Female   258 (70.1%) 
Age at recruitment mean (range),years  51.97 (29.77 – 74.91) 
Height mean (range), cm  166.0 (1.46 – 1.94) 
Weight mean (range), kg  70.9 (45.3 – 138.0) 
BMI  n (%)   
   Normal   171 (46.4%) 
   Overweight   152 (41.3%) 
   Obese   40 (10.9%) 
   Missing   5 (1.4%) 
Smoking status n (%)   
   Never   187 (50.8%) 
   Former   94 (25.5%) 
   Current   79 (21.5%) 
   Missing   8 (2.2%) 
Educational level n (%)   
   None   2 (0.5%) 
   Primary   149 (40.5%) 
   Technical/professional  68 (18.5%) 
   Secondary   83 (22.6%) 
   University/college   55 (14.9%) 
   Missing   11 (3.0%) 
Physical activity n (%)   
   Inactive   106 (28.8%) 
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   moderately inactive   141 (38.3%) 
   moderately active   84 (22.8%) 
   Active   34 (9.3%) 
   Missing   3 (0.8%) 
Alcohol consumption median (gr/d)  2.7 (0.0 – 87.5) 
Fat consumption median (gr/d)  71.3 (21.6 – 200.8)) 
Age at menarche mean (range), years   
   <12    25 (6.8%) 
   12-16   114 (31.0%) 
   ≥16   1 (0.3%) 
   missing   228 (61.9%) 
Age at menopause mean (range), years  49.8 (40.0 – 60.0) 
Menopausal status n (%)   
   Premenopausal   61 (16.6%) 
   Postmenopausal   64 (17.4%) 
   missing   243 (66.0%) 
Ever pregnant n (%)   
   Yes   159 (43.2%) 
   No   16 (4.3%) 
   Missing   193 (52.5%) 
Age first birth mean (range), years  25.5 (18.0 – 37.0) 
Parity n (%)   
   0   16 (4.3%) 
   1   38 (10.3%) 
   2   70 (19.0%) 
   3   33 (8.9%) 
   4   11 (3.0%) 
   5   5 (1.4%) 
   6   1 (0.3%) 
   7   1 (0.3%) 
   missing   193 (52.5%) 
Ever OC use* n (%)   
   Yes   67 (18.2%) 
   No   75 (20.4%) 
   Missing   226 (61.4%) 
Ever HRT use# n (%)   
   Yes   42 (11.4%) 
   No   129 (35.1%) 
   missing   197 (35.5%) 
*OC: oral contraceptive  #HRT: hormone replacement therapy 
 
More subjects are part of the NSHDS cohort (59.2%), and the majority of the subjects are female 
(70.1%) which is unsurprising since most subjects come from breast cancer studies which only 
contain females and only lymphoma controls from the EGM study contain males. In addition, 
these males partly explain the large percentage of missing values reported for several 
reproductive and hormone-related variables. 
 
7.1.2 Cadmium and PCBs  
A summary (median and range) of the levels of exposure variables for the entire cohort 
(n=368), and for the EPIC-Italy (n=150) and NSHDS (n=218) cohort separately, are displayed in 
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Table 7.2. The p-value in the last column refers to the significance of the Wilcoxon rank sum test, 
testing differences in exposure levels between the EPIC-Italy and NSHDS cohorts.  
 
Table 7.2 – Blood serum concentrations of cadmium and PCBs in the entire EGM cohort, the EPIC-Italy cohort 
and the NSDHS cohort 
Exposures 
(µg/L) 
EGM (n=369)  EPIC-Italy (n=150)         NSHDS (n=218)   
 
Median  Median (range)  Median (range)       p-value 
Cadmium  
 
0.53  0.62 (0.17 – 3.90) 0.50 (0.11 – 5.22)  0.009 
PCB118 
 
152.2  152.7 (11.6 – 832.1) 151.9 (16.5 – 753.3)  0.75  
PCB138 
 
544.1  514.5 (51.2 – 1739.0) 585.6 (66.7 –2675.0)  0.002 
PCB153 
 
1023.0  961.9 (120.6 – 2992.0) 1107.0 (139.0 – 4334.0)  0.001 
PCB156 
 
89.5  83.6 (24.5 – 257.5) 93.2 (15.5 – 394.0)  0.01  
PCB170 
 
335.5  300.7 (84.0 – 1167.0) 353.4 (50.4 – 1212.0)  0.004  
PCB180 
 
697.1  684.2 (180.3 – 3577.0) 719.0 (100.1 – 2160.0)  0.25 
Dioxin-like 
PCBs 
242.7  263.80 (81.1 – 934.7) 228.40 (36.16 – 1463.0)  0.0006 
Non-dioxin-
like PCBs 
2002.0  1908.0 (616.8 – 6019.0) 2057.0 (271.7 – 16080.0) 0.08 
Immunotoxic 
PCBs 
1121.0  1102.0 (364.5 – 3712.0) 1160.0 (161.3 – 8838.0)  0.42 
Σ-PCBs 2853.0  2826.0 (956.1 – 8839.0) 2885.0 (400.4 – 21981.0) 0.72 
 
From these data it is apparent that there are substantial differences in exposure levels for the 
EPIC-Italy and NSHDS cohort. Levels of cadmium, PCB138, PCB153, PCB156, PCB170, and 
dioxin-like PCBs are statistically significantly different between the EPIC-Italy and NSHDS 
samples. Levels of PCB118 and PCB180, as well as the combinations of non-dioxin-like PCBs, 
immunotoxic PCBs, and the sum of all PCBs did however not show any differences across 
cohorts. Cadmium, PCB118, and dioxin-like PCB levels are higher in the EPIC-Italy cohort, while 
levels of all other PCBs are higher in the NSHDS cohort. To account for these discrepancies, 
analyses were performed on the entire EGM cohort, and on each country separately.  
 
7.1.3 Exposures and DNA methylation 
Table 7.3 shows the number of CpGs with a p-value <1.03e-07 (genome-wide significance level) 
and a q-value <0.05, together with the smallest observed p-value for the association between 
each (log-transformed) exposure and DNA methylation (at a locus-by-locus level), in the entire 
EGM cohort (adjusted for age, sex, chip, case-control status, and centre).  
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Table 7.3 – Summary of CpGs with a p-value<1.03e-07 and q-value<0.05 for the association between 
exposures and DNA methylation in the EGM cohort (n=369) 
Exposures  Number of CpGs Smallest p-value 
  p-value <1.03e-07 q-value<0.05  
Cadmium  62 232 9.04e-46 
PCB118  0 0 7.74e-06 
PCB138  0 0 1.56e-06 
PCB153  0 0 1.53e-06 
PCB156  0 0 9.94e-07 
PCB170  0 0 3.35e-06 
PCB180  0 0 8.64e-06 
Dioxin-like PCBs  0 0 7.89E-06 
Non-dioxin-like PCBs  0 0 1.02E-06 
Immunotoxic PCBs  0 0 2.43E-06 
Σ-PCBs  0 0 1.46E-06 
 
Apart from cadmium exposure, none of the exposures reach genome wide significance. There is 
great overlap in the CpGs associated with exposure to the different PCBs (albeit not statistically 
significant). When comparing the strongest 50 CpGs associated with each PCB, many duplicates 
are found. PCB118 has the fewest overlapping CpGs with other PCBs (n=4), and three CpGs 
occur in the top 50 strongest associations of five PCBs (cg21216543, cg04065108, and 
cg01917721, located on the PRH1, TTLL8, and NSMCE2 gene respectively) (see supplementary 
Table S7.1). None of these genes have been associated with exposure to PCBs in the literature. 
Cadmium exposure however is associated with DNA methylation levels at 62 CpGs and the 
smallest p-value = 9.04e-46. An overview of the top 62 CpGs is given in Table 7.4.  
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Table 7.4 – 62 strongest associations from logistic regression analysis between cadmium exposure levels in blood and genome-wide DNA methylation  
(n=324), sorted on effect size 
Target ID p-value crude p-value FDR 
adjusted* 
Estimate CHR Gene name Functional region Relation to CGI 
cg05575921 9.04E-46 3.54E-40 -0.0661 5 AHRR Body N_Shore 
cg05951221 3.70E-33 7.23E-28 -0.0456 2   Island 
cg03636183 1.29E-30 1.68E-25 -0.0396 19 F2RL3 Body N_Shore 
cg01940273 4.24E-28 4.15E-23 -0.0455 2   Island 
cg21161138 4.80E-27 3.76E-22 -0.0272 5 AHRR Body  
cg26703534 2.14E-21 1.40E-16 -0.0216 5 AHRR Body S_Shelf 
cg25648203 2.71E-21 1.52E-16 -0.0204 5 AHRR Body  
cg19859270 6.30E-21 3.08E-16 -0.0103 3 GPR15 1stExon  
cg03329539 1.01E-19 4.38E-15 -0.0209 2   N_Shore 
cg06126421 2.42E-19 9.45E-15 -0.0398 6    
cg14817490 1.06E-18 3.78E-14 -0.0269 5 AHRR Body  
cg15342087 1.74E-18 5.67E-14 -0.0158 6    
cg25189904 2.82E-17 8.48E-13 -0.0372 1 GNG12 TSS1500 S_Shore 
cg12803068 5.61E-15 1.57E-10 0.0479 7 MYO1G Body S_Shore 
cg22132788 1.12E-14 2.93E-10 0.0283 7 MYO1G Body Island 
cg20295214 5.54E-14 1.36E-09 -0.0145 1 AVPR1B Body S_Shelf 
cg24859433 1.55E-13 3.57E-09 -0.0137 6    
cg21611682 2.59E-13 5.64E-09 -0.0145 11 LRP5 Body  
cg12806681 3.62E-13 7.16E-09 -0.0105 5 AHRR Body N_Shore 
cg23576855 3.84E-13 7.16E-09 -0.0690 5 AHRR Body N_Shore 
cg27241845 3.84E-13 7.16E-09 -0.0172 2   N_Shore 
cg09935388 6.45E-13 1.15E-08 -0.0309 1 GFI1 Body Island 
cg08709672 4.80E-12 8.17E-08 -0.0142 1 AVPR1B 5UTR S_Shore 
cg03991871 1.84E-11 2.99E-07 -0.0171 5 AHRR Body N_Shore 
cg23916896 2.32E-11 3.63E-07 -0.0263 5 AHRR Body N_Shore 
cg12876356 2.56E-11 3.86E-07 -0.0204 1 GFI1 Body Island 
cg00310412 7.75E-11 1.12E-06 -0.0137 15 SEMA7A Body N_Shore 
cg19572487 8.36E-11 1.16E-06 -0.0222 17 RARA 5UTR S_Shore 
cg02657160 8.62E-11 1.16E-06 -0.0098 3 CPOX Body N_Shore 
cg11902777 
 
 
9.47E-11 
 
 
1.24E-06 
 
 
-0.0082 
 
 
5 
 
 
AHRR 
 
 
Body 
 
 
N_Shore 
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Continuation Table 7.4 – 62 strongest associations from logistic regression analysis between cadmium exposure levels in blood and genome-wide DNA 
methylation (n=324), sorted on effect size 
 
 
Target ID p-value crude p-value FDR 
adjusted* 
Estimate CHR Gene name Functional region Relation to CGI 
cg18146737 1.71E-10 2.16E-06 -0.0122 1 GFI1 Body Island 
cg11207515 2.13E-10 2.61E-06 0.0216 7 CNTNAP2 Body  
cg18316974 6.10E-10 7.23E-06 -0.0099 1 GFI1 Body Island 
cg19089201 1.12E-09 1.29E-05 0.0226 7 MYO1G 3UTR Island 
cg13184736 1.29E-09 1.44E-05 -0.0297 1 GNG12 TSS1500 S_Shore 
cg04885881 1.53E-09 1.67E-05 -0.0184 1   S_Shelf 
cg20059012 1.58E-09 1.67E-05 -0.0261 12 RARG Body N_Shore 
cg02637282 1.74E-09 1.79E-05 0.0161 12    
cg18754985 2.98E-09 2.97E-05 -0.0054 3 CLDND1 Body N_Shelf 
cg13039251 3.03E-09 2.97E-05 0.0217 5 PDZD2 Body  
cg23161492 4.60E-09 4.39E-05 -0.0216 15 ANPEP 5UTR N_Shore 
cg26963277 5.03E-09 4.69E-05 -0.0106 11 KCNQ1OT1 TSS1500 S_Shore 
cg16219322 5.99E-09 5.41E-05 -0.0080 5 AHRR Body  
cg04180046 6.08E-09 5.41E-05 0.0235 7 MYO1G Body Island 
cg11660018 6.32E-09 5.50E-05 -0.0172 11 PRSS23 TSS1500 N_Shore 
cg24049493 1.09E-08 9.14E-05 0.0266 1 HIVEP3 TSS1500 S_Shore 
cg26361535 1.10E-08 9.14E-05 -0.0172 8 ZC3H3 Body  
cg17287155 1.15E-08 9.39E-05 -0.0124 5 AHRR Body  
cg07178945 1.30E-08 0.000104 0.0131 12 FGF23 5UTR  
cg07123182 1.77E-08 0.000139 -0.0057 11 KCNQ1OT1 TSS1500 S_Shore 
cg02451831 2.52E-08 0.000193 -0.0100 7 KIAA0087 Body  
cg08035323 2.67E-08 0.000201 0.0167 2    
cg08595501 2.88E-08 0.000212 -0.0174 5 IQGAP2 Body  
cg26764244 3.15E-08 0.000225 -0.0161 1 GNG12 TSS1500 S_Shore 
cg03274391 3.16E-08 0.000225 0.0376 3   N_Shore 
cg25949550 4.55E-08 0.000318 -0.0080 7 CNTNAP2 Body S_Shore 
cg23771366 5.36E-08 0.000368 -0.0152 11 PRSS23 TSS1500 N_Shore 
cg23973524 5.90E-08 0.000398 0.0170 19 CRTC1 Body Island 
cg04551776 6.06E-08 0.000402 -0.0128 5 AHRR Body  
cg27537125 8.40E-08 0.000548 -0.0093 1    
cg21756476 9.09E-08 0.000583 0.0143 15 RORA Body  
cg11229399 9.51E-08 0.0006 0.0080 1    
* p-value adjusted for multiple testing using FDR 
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CpG sites on the Aryl Hydrocarbon Receptor repressor (AHRR) represented 21% of the 
strongest associations with cadmium exposure (13 out of 62 CpGs), corresponding to a 65-fold 
overrepresentation compared with a random model. The estimated effect size suggests 
hypomethylation related to increased cadmium exposure, for all CpGs on the AHRR gene. All 
CpGs are located on the gene body, and six are located at the north shore, while one CpGs is 
found at the south shelf of a CpG island.  
 
Four CpGs from the 62 strongest associations are found on the growth factor independent 1 
transcription repressor (GFI1) gene, another four on the myosin 1 G (MYO1G) gene, and three on 
the guanine nucleotide binding protein (G protein), gamma 12  (GNG12) gene.  
Most of the strongest 62 CpGs are located at the body of the gene (n=35), eight CpGs at the 
TSS1500 region, four at the 5’UTR region, one at the first exon and another one at the  ’UTR 
region.  In addition, 16 CpGs are located at the north shore of the CpG island, 10 at the CpG 
island itself, 10 at the south shore, three at the south shelf and one at the north shelf. No clear 
pattern emerges with regards to the location of the CpGs and to date it remains unknown if this 
is of importance. 
 
7.1.4 The AHRR gene 
The aryl hydrocarbon receptor repressor (AHRR) gene is located on the short arm of 
chromosome 5 (5p15.3) of the human genome and represses transcription of the Aryl 
Hydrocarbon Receptor (AHR). AHRR and AHR are part of a feedback loop where AHR (in 
combination with ARNT) stimulates expression of the AHRR gene, while the expressed AHRR 
gene inhibits the function of the AHR.311  
 
AHR has been identified to play a role in the development of different types of cancer, because 
of its involvement in regulation of cell growth and differentiation.312;313 One study showed that 
increased expression of AHRR in the MCF-7 breast cancer cell line lead to growth inhibition314, 
and another study by Zudaire et al. demonstrated that AHRR can function as a tumour 
suppressor gene for a variety of different cancers, among which breast cancer.315 Moreover, the 
latter showed AHRR gene silencing was caused by increasing DNA methylation.315 Increased 
methylation of the AHRR gene leads to decreased expression (down-regulation) of this gene, 
which can result in an increased risk of cancer through changes in the regulation of cell cycle 
control and supressed apoptosis.315  
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In addition, AHRR has been shown to be an important factor in metabolizing environmental 
contaminants (both synthetic as well as naturally occurring) such as dioxins. Papoutsis et al. 
studied gestational exposure to the dioxin TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin), an AHR 
agonist, and found compromised normal mammary gland development and reduced BRCA-1 
expression in the offspring.316 These changes coincided with increased CpG methylation at the 
BRCA-1 gene and stimulation of various factors involved in breast cancer development.316 A link 
between TCDD exposure and increased risk of breast cancer has also been shown by Brown et 
al.317 Moreover, AHRR is involved in metabolizing environmental pollutants such as 
benzo(a)pyrene, polycyclic aromatic hydrocarbons (PAHs), and tobacco smoke.318-320 Tobacco 
smoke is a significant source of PAHs and cadmium15 and smoking has been associated with 
differing methylation levels at the AHRR gene.321 This makes smoking status a potential 
confounding factor. For this reason and because several of the CpGs from the top 62 associated 
CpGs has been reported before in relation to smoking status and/or behaviour, analyses 
correcting for smoking status (never, former, and current smokers) were performed. 
 
7.1.5 Smoking status 
Adjusting the analysis of cadmium exposure and DNA methylation for smoking status resulted 
in eight CpGs with a p-value<1.03e-07 (see Table 7.5). All eight CpGs were found significant in 
the unadjusted analysis (Table 7.4) and four of these CpGs are located on the AHRR gene. Five 
CpGs are located on the gene body and in relation to the CGI three are found on the north shore, 
two on the island itself and one on the south shelf. As expected, adjustment for smoking status 
results in fewer hits reaching genome-wide significance and overall lower p-values. 
Nevertheless, all candidates showed a consistent inverse association resulting in 
hypomethylation in subjects exposed to cadmium. 
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Table 7.5 –8 CpGs reaching genome-wide significance for the association between cadmium and DNA methylation in the EGM cohort,  
adjusted for smoking status 
Target ID p-value crude p-value FDR 
adjusted* 
Estimate CHR Gene name Functional 
region 
Relation to CGI 
cg05575921 1.09E-15 4.26E-10 -0.0427 5 AHRR Body N_Shore 
cg05951221 2.51E-12 4.91E-07 -0.0322 2   Island 
cg21161138 7.56E-12 9.87E-07 -0.0216 5 AHRR Body  
cg03636183 8.77E-11 8.58E-06 -0.0273 19 F2RL3 Body N_Shore 
cg01940273 2.10E-09 0.000165 -0.0304 2   Island 
cg25648203 7.91E-09 0.000516 -0.0160 5 AHRR Body  
cg26703534 1.58E-08 0.000886 -0.0162 5 AHRR Body S_Shelf 
cg03329539 2.86E-08 0.001400 -0.0163 2   N_Shore 
* p-value adjusted for multiple testing using FDR 
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It is possible however, that adjustment for smoking status is not completely successful when the 
exposure (in this case cadmium), is highly correlated with the confounder (in this case smoking 
status). This seems to be the case, because many of the CpGs in Table 7.5 are associated with the 
AHRR gene, which is related to smoking, and for that reason it was decided to additionally 
stratify by smoking status. The current dataset consist of 187 never smokers, 94 former 
smokers, and 79 current smokers. Table 7.6 summarizes the number of CpGs below a p-value of 
1.03e-07, below a q-value of 0.05 and the smallest p-value identified in the analysis stratified by 
smoking status.  
 
Table 7.6 - Summary of CpGs with a p-value<1.03e-07 and q-value<0.05 for the association between cadmium 
and DNA methylation in never (n=187), former (n=94), and current (n=79) smokers in the EGM cohort 
  CADMIUM 
  Number of CpGs 
Smallest p-value 
  p-value <1.03e-07 q-value <0.05 
Never (n=187)  0 0 1.07E-06 
Former (n=94)  2 2 7.05E-09 
Current (n=79)  0 0 8.26E-07 
 
Only among former smokers did two CpGs reach genome-wide significance (cg05575921, 
cg05951221). For clarity, an overview of only the 10 strongest associations for never, former, 
and current smokers are displayed in Table 7.7, Table 7.8, and Table 7.9, respectively.  
 
None of the CpGs in the 10 strongest associations of never smokers were found in the 62 
strongest and significant associations in the entire EGM cohort, nor is there overlap between the 
10 strongest associations of never smokers and the 10 strongest associations of former or 
current smokers.  
 
Five CpGs of the 10 strongest associations in former smokers (cg05575921, cg05951221, 
cg01940273, cg11902777, cg03636183) and three CpGs of the 10 strongest associations in 
current smokers (cg05575921, cg05951221, cg03636183) are also found in the 62 strongest 
and significant associations of the entire EGM cohort. In former smokers, two CpGs are found on 
the AHRR gene and one on the F2RL3 gene (cg03636183). Among current smokers, none of the 
CpGs are significant and the AHRR gene is not found among the 10 strongest associations, 
however, the same CpG (cg03636183) on the F2RL3 gene is. This CpG has been reported to be 
differentially methylated among smokers compared with non-smokers321;322  
Among former smokers, six out of seven CpGs associated with any gene are located at the body 
of the gene and one is found at the  ’UTR region of the RUSC2 gene. The relation to the CGI 
varies between island, north shore and south shelf and all estimates of the linear model are 
negative. The 10 strongest CpGs among current smokers are found on the body,  ’URT, 5’URT 
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and TSS1500 regions of genes and six out of seven are found on the north shore of a CpG island. 
The effect size estimate of two CpGs is positive, while the other eight are negative. No 
consistency was observed regarding the functional or physical location of the CpGs, nor 
regarding the effect size estimate. 
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Table 7.7 –10 strongest associations between cadmium and DNA methylation in never smokers (n=187), sorted on p-value 
Target ID p-value crude p-value FDR 
adjusted* 
Estimate  CHR Gene name Functional 
region 
Relation to CGI 
cg02986692 1.07E-06 0.419829 -0.0085 6       
cg04869379 9.35E-06 0.999988 -0.0089 13 MYO16 Body   
cg16844818 1.53E-05 0.999988 -0.0117 2 FARP2 5UTR  
cg15646919 2.07E-05 0.999988 -0.0133 18   Island 
cg08913261 2.11E-05 0.999988 -0.0070 1 PRCC Body S_Shelf 
cg11399415 2.47E-05 0.999988 -0.0056 10 TAF3 Body   
cg24526669 2.48E-05 0.999988 -0.0105 4   Island 
cg19320505 2.87E-05 0.999988 0.0109 11 ELMOD1 TSS200 N_Shore 
cg03484267 2.90E-05 0.999988 -0.0059 2 KLF7 Body  
cg16241932 3.68E-05 0.999988 -0.1890 6 ZDHHC14 Body   
* p-value adjusted for multiple testing using FDR 
 
 
Table 7.8 – 10 strongest associations between cadmium and DNA methylation in former smokers (n=94), sorted on p-value 
Target ID p-value crude p-value FDR 
adjusted* 
Estimate CHR Gene name Functional 
region 
Relation to CGI 
cg05575921 7.05E-09 0.002759 -0.0594 5 AHRR Body N_Shore 
cg05951221 2.24E-08 0.004382 -0.0531 2   Island 
cg01940273 6.44E-06 0.839962 -0.0419 2   Island 
cg11902777 1.53E-05 0.993978 -0.0134 5 AHRR Body N_Shore 
cg24113274 1.90E-05 0.993978 -0.0182 3 RYBP Body  
cg14001518 2.02E-05 0.993978 -0.0068 9 RUSC2 3UTR  
cg27344090 2.22E-05 0.993978 -0.0069 18 ZBTB7C Body S_Shelf 
cg03003335 2.44E-05 0.993978 -0.0158 1 ACAP3 Body Island 
cg03636183 2.97E-05 0.993978 -0.0385 19 F2RL3 Body N_Shore 
cg11470063 3.10E-05 0.993978 -0.0360 4   N_Shore 
* p-value adjusted for multiple testing using FDR 
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Table 7.9 – 10 strongest associations between cadmium and DNA methylation in current smokers (n=79), sorted on p-value 
Target ID p-value crude p-value FDR 
adjusted* 
Estimate CHR Gene name Functional 
region 
Relation to CGI 
cg08216808 8.26E-07 0.323414 -0.0280 2 ARPC2 TSS1500 N_Shore 
cg03636183 3.00E-06 0.442061 -0.0435 19 F2RL3 Body N_Shore 
cg05575921 5.80E-06 0.442061 -0.0645 5 AHRR Body N_Shore 
cg02734358 7.23E-06 0.442061 -0.0363 4 GPRIN3 5UTR N_Shore 
cg24718710 7.82E-06 0.442061 0.0092 10 DIP2C Body  
cg00805193 8.24E-06 0.442061 -0.0270 20 SAMD10 Body N_Shore 
cg22672639 8.57E-06 0.442061 -0.0148 5 FAT2 3UTR  
cg11031737 1.07E-05 0.442061 0.0159 11    
cg05951221 1.19E-05 0.442061 -0.0408 2   Island 
cg00708426 1.20E-05 0.442061 -0.0285 5 SNCB Body N_Shore 
* p-value adjusted for multiple testing using FDR 
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Moreover, there is some evidence for cross-talk between AhR and the oestrogen receptor323-325, 
however, unfortunately the number of participants with available information on ER status in 
this study (ER-positive, n=37; ER-negative, n=38) were too small (number of missing values too 
high) to perform stratified analyses by ER-status. 
 
7.1.6 Stratified analyses per cohort 
Because the exposure levels were different in the EPIC-Italy and NSHDS cohort it was decided to 
additionally perform stratified analyses by cohort. Table 7.10 shows the number of CpGs with a 
p-value<1.03e-07, with a q-value<0.05 and the smallest p-value per exposure, stratified by 
cohort.  
 
Table 7.10 – Summary of CpGs with a p-value<1.03e-07 and q-value<0.05 for the association between 
exposures and DNA methylation, stratified by EPIC-Italy (n=150) and NSHDS (n=218) 
  EPIC-Italy (n=150)  NSHDS (n=218) 
  Number of CpGs 
Smallest p- 
value 
 Number of CpGs 
Smallest p- 
value 
Exposures  p-value 
<1.03e-07 
q-value 
<0.05 
 p-value 
<1.03e-07 
q-value 
<0.05 
Cadmium  4 10 1.29e-11  39 115 1.21e-34 
PCB118  0 0 1.47e-05  0 0 1.99e-06 
PCB138  0 0 9.92e-07  0 0 2.04e-05 
PCB153  0 0 1.29e-07  0 0 2.08e-05 
PCB156  0 0 2.28e-07  0 0 1.80e-06 
PCB170  1 1 1.06e-08  0 0 4.86e-06 
PCB180  1 1 5.12e-09  0 0 7.18e-06 
Dioxin-like PCBs 0 0 9.48E-07  0 0 1.86E-06 
Non-dioxin-like PCBs 1 7 1.35E-08  0 0 1.66E-05 
Immunotoxic PCBs 1 1 9.02E-08  0 0 1.22E-05 
Σ-PCBs  2 78 1.75E-09  0 0 1.41E-05 
 
Again, cadmium exposure is associated with several significant CpGs, especially in the NSHDS 
cohort, where the median exposure is lower than in the EPIC-Italy cohort (0.50 vs. 0.62), but the 
maximum value is higher (5.22 vs. 3.90).  
The 20 strongest associations between cadmium exposure and DNA methylation in the EPIC-
Italy cohort are displayed in Table 7.11 and the 20 strongest associations in the NSHDS cohort 
are displayed in Table 7.12. Despite the higher p-values among the samples of the EPIC-Italy 
cohort, which can possibly be explained by the lower number of subjects, the AHRR gene is 
found four times in the 20 strongest associations, and the F2RL3 gene once, which has the 
lowest p-value in this cohort. AHRR is found seven times in the 20 strongest associations of the 
NSHDS cohort, which is very similar to the strongest associations of the entire cohort. In both 
cohorts, 18 out of the 20 CpGs have a negative estimate. Stratifying the results for cadmium 
exposure by cohort does not seem to affect these conclusions.  
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Table 7.11 – 20 strongest associations between cadmium and DNA methylation in the EPIC-Italy cohort (n=150), sorted on p-value 
Target ID p-value crude p-value FDR 
adjusted 
Estimate CHR Gene name Functional 
region 
Relation to CGI 
cg03636183 1.29E-11 5.06E-06 -0.0540 19 F2RL3 Body N_Shore 
cg05575921 6.09E-11 1.19E-05 -0.0757 5 AHRR Body N_Shore 
cg19859270 2.35E-09 0.000307 -0.0159 3 GPR15 1stExon  
cg25648203 7.08E-08 0.006925 -0.0296 5 AHRR Body  
cg21611682 1.18E-07 0.008582 -0.0258 11 LRP5 Body  
cg08709672 1.32E-07 0.008582 -0.0252 1 AVPR1B 5UTR S_Shore 
cg23576855 3.16E-07 0.017653 -0.1166 5 AHRR Body N_Shore 
cg03294124 3.98E-07 0.018729 0.0041 2 RNF25 TSS1500 S_Shore 
cg06126421 4.31E-07 0.018729 -0.0573 6    
cg21161138 8.31E-07 0.032545 -0.0298 5 AHRR Body  
cg25069010 1.64E-06 0.058207 -0.0059 20 C20orf4 Body S_Shelf 
cg05951221 3.31E-06 0.107945 -0.0428 2   Island 
cg15621988 4.13E-06 0.124337 -0.0114 22 SYNGR1 Body Island 
cg25189904 4.61E-06 0.128762 -0.0463 1 GNG12 TSS1500 S_Shore 
cg12760573 6.01E-06 0.155614 -0.0085 6 KCNK17 Body Island 
cg15342087 6.36E-06 0.155614 -0.0201 6    
cg10944833 7.01E-06 0.157056 0.0177 6 NUP153 Body N_Shelf 
cg20295214 7.22E-06 0.157056 -0.0212 1 AVPR1B Body S_Shelf 
cg04640971 1.45E-05 0.286882 -0.0194 2   Island 
cg01940273 1.48E-05 0.286882 -0.0438 2   Island 
* p-value adjusted for multiple testing using FDR 
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Table 7.12 – 20 strongest associations between cadmium and DNA methylation in the NSHDS cohort (n=218), sorted on p-value 
Target ID p-value crude p-value FDR 
adjusted 
Estimate CHR Gene name Functional region Relation to CGI 
cg05575921 1.21E-34 4.73E-29 -0.0711 5 AHRR Body N_Shore 
cg05951221 9.02E-29 1.76E-23 -0.0546 2   Island 
cg01940273 8.06E-24 1.05E-18 -0.0534 2   Island 
cg21161138 1.70E-20 1.66E-15 -0.0297 5 AHRR Body  
cg14817490 6.84E-20 4.92E-15 -0.0335 5 AHRR Body  
cg03636183 7.54E-20 4.92E-15 -0.0392 19 F2RL3 Body N_Shore 
cg26703534 9.88E-18 5.53E-13 -0.0260 5 AHRR Body S_Shelf 
cg03329539 3.42E-17 1.67E-12 -0.0246 2   N_Shore 
cg25648203 6.53E-15 2.84E-10 -0.0205 5 AHRR Body  
cg19859270 2.63E-13 1.03E-08 -0.0101 3 GPR15 1stExon  
cg06126421 3.96E-13 1.41E-08 -0.0405 6    
cg15342087 4.39E-13 1.43E-08 -0.0163 6    
cg12803068 3.43E-12 1.03E-07 0.0508 7 MYO1G Body S_Shore 
cg25189904 6.05E-12 1.69E-07 -0.0384 1 GNG12 TSS1500 S_Shore 
cg11902777 2.60E-11 6.44E-07 -0.0103 5 AHRR Body N_Shore 
cg09935388 2.63E-11 6.44E-07 -0.0362 1 GFI1 Body Island 
cg22132788 4.15E-11 9.55E-07 0.0299 7 MYO1G Body Island 
cg27241845 7.12E-11 1.55E-06 -0.0192 2   N_Shore 
cg23916896 1.12E-10 2.31E-06 -0.0324 5 AHRR Body N_Shore 
cg19572487 1.68E-09 3.30E-05 -0.0257 17 RARA 5UTR S_Shore 
* p-value adjusted for multiple testing using FDR 
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The only significant CpG in the EPIC-Italy cohort for exposure to PCB170 is the same as the only 
CpG for exposure to PCB180 and for the non-dioxin-like and immuno-toxic PCBs: cg12503717 
on chromosome 11, which is not associated with any gene. This is also the CpG with the smallest 
p-value in association with the sum of all PCBs. The second most significant CpG (p-value=5.63e-
08) in the EPIC-Italy cohort, associated with exposure to the sum of all PCBs is cg05672569, 
which is associated with the PTPRN2 (protein tyrosine phosphatase, receptor type, N 
polypeptide 2) gene, located on chromosome 7. The function of this gene is related to pancreatic 
endocrine cells, and has been associated with type I diabetes326. In addition, two studies have 
linked DNA hypermethylation of loci on this gene to lung cancer327;328, but no literature exists 
linking this gene to PCB exposure. 
DNA methylation was not associated with exposure to any of the PCBs in the NSHDS cohort, nor 
to any of the combinations of PCBs. 
 
7.1.7 Cell types 
In an effort to deal with the issue of different white blood cells in each blood samples, the same 
approach was used as for the global association analysis. CpGs that differed significantly 
between the different cell types and PBMCs (n=11,196) were excluded from the analyses and 
the analyses were rerun on the remaining 380,212 CpGs. This was only done for the significant 
associations: cadmium exposure in the entire cohort and the NSHDS cohort, and for cadmium, 
PCB170, PCB180, and for non-dioxin-like and immuno-toxic PCBs as well as the sum of all PCBs, 
in the EPIC-Italy cohort. The results of the analyses without these CpGs were very similar to the 
results displayed here. The top 62 hits were almost identical (see supplementary Table S7.2) 
and the same top hit was found for PCB170 and PCB180 in the EPIC-Italy cohort. Cadmium 
exposure in the EPIC-Italy cohort, after exclusion of cell type specific CpGs resulted in the same 
four significant CpGs. Cadmium exposure in the NSHDS cohort resulted in 38 CpGs reaching 
genome-wide significance (versus 39 in the analysis including cell type specific CpGs), but the 
most significant associations remained the same. 
 
7.1.8 Discussion 
In this section, 62 CpGs were differentially methylated after cadmium exposure in the entire 
EGM cohort. None of the other exposures reached genome-wide significance, but great overlap 
was observed in the CpGs with the smallest p-values for most PCBs (in the entire cohort).  
The smallest p-value for cadmium exposure was 9.04e-46 for a CpG on the AHRR gene, and 
another 12 CpGs were found in the top 62 that were also located at this same gene. AHRR plays a 
role in cell growth, cell differentiation and metabolizes various environmental contaminants, 
among which tobacco smoke. After adjusting the analysis for smoking status only eight CpGs 
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remained statistically significant. Stratified analysis by smoking status showed two CpGs whose 
methylation levels were associated with cadmium exposure among former smokers, but no 
CpGs reached genome-wide significance in current or never smokers. However, overlap was 
observed in the 10 strongest associations in current and former smokers.  
Stratified analysis by cohort did not change the results substantially, apart from one CpG that 
came up in the EPIC-Italy cohort after both PCB170 and PCB180 exposure. This CpG was not 
found to be statistically significant in the entire EGM cohort and because it was not annotated it 
could not be interpreted.  
 
In Chapter 2 of this thesis various studies investigating the association between cadmium 
exposure and DNA methylation have been described. Most studies focused on global 
methylation, but four studies reported specific genes that were differentially methylated after 
cadmium exposure. Three of these studies were performed in humans or using human cells or 
cell lines, but Wang et al. investigated the effect of chronic, low-dose cadmium exposure on DNA 
methylation in rats. They assessed methylation levels of CpG islands at the promoter region of 
15,398 genes after exposure to 20 nmol/kg of Cd every other day for four weeks and found 675 
genes to be hypermethylated, 899 genes to be hypomethylated, and 55 genes of which the 
promoter CpG islands were both partly hyper- and hypomethylated.133 Despite the fact that 
Wang et al. used a different method to analyse DNA methylation (MeDIP chip) from the HM450 
array used in this thesis and these results are based on an animal model, there still is one gene 
that was also found to be differentially methylated in this chapter: RARG. The retinoic acid 
receptor gamma (RARG) gene is located on chromosome 7 in rats and chromosome 12 in 
humans and is reported as hypomethylated in the paper by Wang et al. as well as in this chapter 
(in the entire cohort, Table 7.4). RARG is part of the family of nuclear hormone receptors and 
can regulate gene expression by binding as heterodimers to their target response elements. It is 
involved in several biological processes, such as limb bud development and skeletal growth and 
can influence the differentiation of various cell types.329 No other papers report this gene in 
relation to cadmium exposure.  
Benbrahim-Tallaa et al. compared methylation of CpG islands on the promoters of RASSF1A and 
p16 of cadmium exposed CTPE cells with control (non-exposed) RWPE-1 cells. Both tumour 
suppressor genes were hypermethylated among the exposed cells, leading to reduced 
expression of the genes. In addition, they observed re-expression of RASSF1A and p16 after 
treating the cells with 5-aza-2’-deoxycytidine, a DNA demethylating agent. The p16 gene was 
also investigated by Yuan et al. They exposed human B lymphoblast HMy2.CIR cells to a low 
dose (<0.1µM) of Cd for three months and, like Benbrahim-Tallaa et al. observed 
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hypermethylation of p16 which was followed by reduced expression, while 5-aza-2’-
deoxycytidine reversed these effects.137 However, in this chapter, methylation of p16 (or 
CDKN2A) was not statistically significantly associated with blood cadmium levels, which is in 
concordance with a study by Hossain et al.140 They were the only group investigating dietary 
cadmium exposure, measured in human blood and urine samples of 202 individuals, and its 
effect on methylation of p16 and MLH1.140 The blood cadmium levels measured in this thesis 
(median: 0.53, 5th and 95th percentile: 0.26 – 2.75) are fairly comparable to the blood cadmium 
levels of their study (median: 0.36, 5th and 95th percentile: 0.20 – 0.76), however, the 95th 
percentile in this chapter is much higher. This can possibly be explained by the fact that the 
current study population was older and included more smokers compared with the population 
of Hossain et al. which only included four smokers (Cd levels increase with age and are higher in 
cigarette smokers). Another reason why the different studies find different results is because of 
the different methods that have been used to measure DNA methylation and the different 
models that were used to investigate this in. 
Finally, a study by Sanders et al. assessed cadmium levels in blood leukocytes of 17 mother-
newborn pairs in relation to DNA methylation changes. They observed 61 genes in newborn 
DNA whose methylation was associated with cadmium levels, and 92 genes in maternal DNA. 
Interestingly, there was no overlap between the two gene sets. Importantly, they compared the 
discovered genes with known differentially methylated regions that are associated with 
leukocyte cell types and found no overlap, suggesting that blood cell composition of the samples 
has not influenced the results. Despite the fact that the median cadmium level in their study 
(0.44) is closer to the median reported in this chapter (0.53), and their maximum (1.05) is 
closer to the maximum reported in this chapter (5.22), compared with the study by Hossain et 
al., outliers in the samples used in this chapter are causing the maximum levels to be quite 
different. In addition, the mean age of the mothers included in the study by Sanders et al. was 28 
years (range: 19-42), which is considerably younger than the age of the subjects described in 
this chapter. This might explain why, when comparing the 153 genes identified by them, to the 
62 genes identified in this chapter, no overlap was observed. Other reasons could be the 
duration of exposure, the type of assay used to measure methylation, or additional exposures or 
confounding factors that were not adjusted for.  
Out of the 62 CpGs whose DNA methylation levels are most strongly associated with blood 
cadmium levels in this chapter, all four CpGs located on the GFI1 gene, and all four CpGs located 
on the MYO1G, as well as three CpGs located on the AHRR gene and one CpG located on the 
CNTNAP2 gene have been reported in a paper by Joubert et al. which identified differentially 
methylated CpGs in newborns related to maternal smoking during pregnancy.330  
138 
 
Moreover, cg06126421 (closest TSS gene name is IER3) and another two CpGs that are not 
associated with any gene (but of which the closest TSS gene name is ALPPL2), as well as three 
CpGs located on the AHRR gene and one CpG on the F2RL3 gene are also described by Shenker et 
al. who found nine CpGs to be associated with smoking in a genome-wide association study.321 
The same CpG on the F2RL3 gene was also revealed in a study by Breitling et al. who used the 
HM27 array by Illumina to discover differentially methylated CpGs associated with smoking 
behaviour.322 Zhang et al. found a strong association between F2RL3 methylation and smoking 
status after adjustment for confounding.331 In addition, they observed an inverse dose-response 
relation between F2RL3 methylation and current, as well as former (lifetime pack-years) 
smoking intensity which makes methylation of this gene a promising biomarker for both 
current and long-term past tobacco exposure.331  
This, together with the fact that most significant associations did not survive adjustment for 
smoking status indicates that most genes identified in this chapter are associated with cigarette 
smoking. The reason why two CpGs are associated with cadmium levels and DNA methylation in 
former smokers, but not in current or never smokers is possibly due to some former smokers 
being heavy smokers until very recently or classification bias (them not being honest about 
their smoking habits). However, it is not possible to conclude that cadmium in the cigarettes is 
causing these results, because never smokers have never been exposed to cadmium in 
cigarettes, but also not to other chemicals in cigarettes, while smokers are exposed to cadmium 
through cigarette smoking, but also to the other chemicals found in cigarettes. For this reason it 
is likely that cigarette smoking is causing these findings, but which chemicals in cigarettes 
exactly cannot be concluded from these results.  
Strengths of the analyses described in this chapter include the relatively large number of study 
participants (n=369) compared to previous studies and the adjustment for age, sex, chip, case-
control status and study centre. However, it is possible there is still some form of residual 
confounding. An attempt was made to exclude the possibility of different cell types influencing 
the results by removing the CpGs that were associated with WBC composition. 
These results are based on clinically relevant levels of cadmium, like the results published by 
Hossain et al. and Sanders et al. It remains important to focus on the potential long term effects 
of chronic, low doses of cadmium exposure at levels found in the general population as studies 
are still reporting associations between cadmium and adverse health effects.  
 
In conclusion, the results of this chapter indicate that clinically relevant levels of cadmium 
measured in blood are associated with changes in DNA methylation, however, these changes can 
largely be explained by smoking status. Further research, including larger sample sizes is 
needed to see if it is cadmium, or other chemical in cigarettes smoke that cause these changes in 
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DNA methylation, and subsequently, if these changes in DNA methylation lead to changes in 
gene expression and possibly other molecular changes which could result in the development of 
adverse health effects.  
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7.2 Other exposures and DNA methylation 
 
7.2.1 Reproductive and hormone-related questionnaire data 
Various reproductive and hormone-related variables are associated with breast cancer risk.332 
In order to investigate whether changes in DNA methylation are potential intermediate events 
in this relationship, this section describes the results of the association between various 
reproductive and hormone-related data from the questionnaires and locus-by-locus DNA 
methylation. The HuGeF (Breast II) study was used to analyse this, including 324 subjects and 
DNA methylation was measured at 408,749 CpGs (see for more information about exclusion of 
samples and CpGs section 4.1). 
 
Table 7.13 gives an overview of the number of CpGs with a p-value<1.03e-07 and a q-value<0.05 
and the smallest p-value observed per reproductive or hormone-related variable. 
 
Table 7.13 – Number of CpGs with significant p-value or q-value and the smallest p-value per variable 
Variables 
 Number of CpGs 
Smallest p-value  p-value  
<1.03e-07 
q-value 
<0.05 
BMI     
underweight  0 0 0.274087 
overweight  0 0 0.911431 
obese  0 1 6.71e-07 
Smoking     
current  11 43 5.77e-39 
former  4 18 5.22e-19  
Physical activity     
moderately inactive  0 0 0.090165 
moderately active  0 0 0.023527 
active  0 0 0.555787 
Alcohol consumption  0 0 1.91e-05 
Fat consumption  0 0 5.56e-06 
Age at menarche (continuous)  0 0 6.20e-07 
Age at menarche (categorical)     
12-14 years  0 0 0.100998 
≥ 15 years  0 0 0.533918 
Age at menopause  0 0 9.33e-06 
Menopausal status     
postmenopausal  0 0 1.11e-05 
Reproductive years  0 0 9.95e-06 
Ever pregnant     
yes  0 0 5.38e-07 
Ever liveborn     
yes  0 0 4.56e-07 
Number of liveborn  0 0 3.67e-07 
Age 1st liveborn  0 0 5.50e-06 
Age 2nd liveborn  0 0 2.60e-06 
     
Age 3rd liveborn  0 0 2.41e-06 
Age at last liveborn  0 0 1.41e-06 
Breastfed after 1st pregnancy     
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yes  0 0 2.12e-06 
Breastfed after 2nd pregnancy     
yes  0 0 3.18e-06 
Breastfed after 3rd pregnancy     
yes  0 0 2.27e-06 
Duration breastfeeding 1st pregnancy            0 0 1.25e-05 
Duration breastfeeding 2nd pregnancy            0 0 5.15e-06 
Duration breastfeeding 3rd pregnancy            0 0 7.49e-06 
Total duration breastfeeding  0 0 3.38e-06 
Ever OC use*     
yes  0 0 3.43e-06 
Age start OC use*  0 2 2.30e-07 
Duration OC (continuous)*  0 0 3.59e-05 
Duration OC (categorical)*     
1 year  0 0 0.999946 
2 years  0 0 0.146504 
3 years  0 1 0.003083 
>3 years  0 0 0.999937 
Current HRT use#     
yes  1 1 8.05e-08 
Age start HRT use#  0 0 3.98e-06 
Duration HRT use (continuous)#  0 0 5.50e-06 
Duration HRT use (categorical)#     
1 year  0 0 0.257944 
2 years  0 0 0.001382 
3 years  0 0 0.582882 
>3 years  0 0 0.117697 
Hysterectomy     
yes  0 0 2.05E-06 
Ever ovary surgery     
yes  0 0 3.72E-06 
*OC: oral contraceptive  #HRT: hormone replacement therapy 
 
7.2.2 Lifestyle factors 
For completeness, the following lifestyle variables have been included in the analyses as well: 
BMI, smoking status, physical activity, alcohol consumption and fat consumption. All CpGs with 
a p-value<1.03e-05 for the association between methylation levels and any of the lifestyle 
variables in Table 7.13 are summarized in supplementary Table S7.3, including their p-values, 
the effect size estimate, and their annotation. 
 
Any level of physical activity and alcohol consumption are not associated with changes in DNA 
methylation at any of the CpGs. Being obese was associated (q-value<0.05) with the methylation 
level of one CpG; cg09610891 (p-value = 6.71E-07). The effect size estimate was positive 
indicating higher levels of methylation for this CpG among obese individuals. The CpG is located 
on chromosome 16, but is not annotated.  
 
Smoking status is associated with methylation at various CpGs. This is described in more detail 
in our paper by Shenker et al.321, and was also reported by Breitling et al, using the HM27 array 
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by Illumina.322 All CpGs that are associated with former smokers are also associated with 
current smokers. All CpGs associated with current smokers had a negative effect size estimate, 
meaning that methylation is lower at these specific CpGs among current smokers compared to 
never smokers.  
 
Fat consumption is not associated with methylation levels of any CpG.  
 
7.2.3 Reproductive factors 
Reproductive factors include variables related to menarche, pregnancy, and menopause. These 
variables have been associated with an increased risk of breast cancer in the literature332, and 
DNA methylation is a possible mechanism through which the effect of these factors is mediated. 
All CpGs with a p-value<1.03e-05 for the association between methylation levels and any of the 
reproductive variables in Table 7.13 are summarized in supplementary Table S7.4. 
 
Age at menarche as a continuous variable was borderline associated (smallest p-value=6.20e-
07) with methylation of one CpG: cg26523005, located on gene ZNF662. The function of this 
gene is still largely unknown. Results for age at menarche were also reported as a categorical 
variable in order to assess early age at menarche (often defined at ≤11 years333) but no 
associations with methylation levels of any of the CpGs were observed.  
Age at menopause was also not association with methylation (smallest p-value=9.33e-06), nor 
was menopausal status (smallest p-value=1.11e-05). The number of years between age at 
menarche and age at menopause (here defined as ‘reproductive years) did also not reach 
genome-wide significance (smallest p-value=9.95e-06). 
 
Having ever been pregnant was borderline associated (p-value=5.38e-07) with the methylation 
level of one CpG (cg11491504), located at the gene UNC5A, suggesting hypermethylation for 
women who have ever been pregnant. This gene plays an important role in neuronal 
development and p53-dependent apoptosis334, but has not been associated with pregnancy or 
any other reproductive factor in the literature. Women who ever gave birth to a liveborn child 
have borderline higher methylation at cg04058752 (p-value=4.56e-07), located at the gene 
B3GNT6. This gene is involved in cellular processes in the digestive organs and has been 
associated with colon cancer335, but not with given birth to liveborn children. The number of 
liveborn children was borderline associated with methylation at two CpGs (cg23908407, p-
value=3.67e-07, and cg24027061, p-value=8.41e-07), suggesting hypermethylation at both 
CpGs with an increasing number of liveborns. One of these CpGs is not annotated and the other 
CpG is, located at the gene CSNK1D. This gene plays an important role in the mammalian 
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circadian clock336, but has not been associated with the number of live born children or any 
other reproductive factor in the literature.  
 
The age of a woman when she gave birth to her first, second, third, or last liveborn, was not 
associated with methylation levels. 
  
 
7.2.4 Hormone-related factors 
Hormone-related factors include actions which change a woman’s exposure to hormones (such 
as breastfeeding, hysterectomy or ovary surgery, which all change hormone levels337), but also 
the use of oral contraceptives (OC), or hormone replacement therapy (HRT). All CpGs with a p-
value<1.03e-05 for the association between methylation levels and any of the hormone-related 
variables in Table 7.13 are summarized in supplementary Table S7.5. 
 
Information about breastfeeding (yes/no) after several pregnancies, and the duration of 
breastfeeding, was available in the dataset but none of these variables reached genome-wide 
significance (nor a q-value<0.05). 
 
Oral contraceptive (OC) use was not associated with methylation, but the age at which OC use 
started was borderline significantly associated with methylation levels at two CpGs 
(cg00831970, p-value=2.30e-07, and cg01532487, p-value=2.37e-07). Methylation at both CpGs 
decreases with age. Only one of these CpGs is annotated: cg00831870 is located at the gene 
FCGR2B. This gene has not been associated in the literature with OC use specifically, however, 
Sarvari et al. observed increased expression of the FCGR2B gene in rats after ovariectomy, which 
did not reverse after E2 replacement.338 They concluded that FCGR2B is likely to be regulated by 
E2 and progesterone, which are the main components of oral contraceptives. Therefore it is 
possible that the association between methylation of this CpG and the age at which OC use 
started is a novel finding (albeit not statistically significant). 
 
Using hormone replacement therapy (HRT) is associated with methylation at one CpGs. 
Cg13768445, located at the gene SLC28A3 (chromosome 9), is the only hit reaching genome-
wide significance (p-value=8.05e-08). The effect size estimate is extremely high (0.6751), 
indicating methylation increases greatly among women who use HRT, compared with those 
who do not. This gene (also called CNT3) is part of the concentrative nucleoside transporter 
family, and mediates transport of purine and pyrimidine nucleosides and synthetic anticancer 
nucleoside analog drugs.339;340 Transcriptional upregulation of CNT3 has been shown during 
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lactation341;342 and an endocrine regulation has been shown for two family members of CNT3 
(CNT1 and CNT2)343, but no literature was available relating SLC28A3 (CNT3) to endocrine 
regulation or HRT use. The age at which a woman starts to use HRT was not associated with 
methylation of any CpG. Finally, having had a hysterectomy or ovary surgery did not lead to any 
significant associations.  
 
7.2.5 Discussion 
The exploratory analyses in this section show a number of lifestyle, reproductive and hormone-
related variables to be borderline associated with changes in DNA methylation, while only one 
CpG, associated with HRT use, reached genome-wide significance.  
 
Age at menarche as a continuous variable was borderline associated with DNA methylation at 
one CpG. As early as 1973 a decrease in age at menarche was observed by Tanner et al., a trend 
which seems to be continuing in present times.344 Age at menarche is determined by genetic, 
environmental, nutritional and lifestyle factors.345 Earlier menarche means a longer time of 
exposure to endogenous hormones, which increases the risk of breast cancer.332 Therefore it is 
most likely that age at menarche is a proxy for other breast cancer risk factors, such as hormone 
levels. Terry et al. investigated global DNA methylation and observed an increase in methylation 
among adults who had a later age at menarche.346  Only one study has investigated age at 
menarche in relation to locus-specific DNA methylation changes, using part of the same subjects 
as were used in this chapter.347 They identified one CpG (cg01339004), associated with the 
SMAD6 gene, whose DNA methylation was associated with age at menarche, however, they were 
unable to replicate this finding by pyrosequencing (using an independent dataset), which might 
indicate a false positive finding.347  
 
Age at menopause was not associated with DNA methylation in this study and no other studies 
have investigated age at menopause and DNA methylation. A late age at menopause (like an 
early age at menarche) means longer exposure to reproductive hormones, which increases 
breast cancer risk.332 A recent study however reported that early age at menarche has a greater 
impact on breast cancer risk than late menopause, which suggests the increase in risk can not 
only be explained by years of exposure to hormones.348 A possible explanation comes from the 
finding that oestrogen levels in urine are higher in girls with early age at menarche compared to 
girls with a normal age at menarche, and these higher levels seem to persist throughout the 
woman’s reproductive years, suggesting overall higher exposure to endogenous hormones 
during development and adulthood among women with early menarche.349 
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Having ever been pregnant and ever given birth to a liveborn child were both associated with 
one CpG. Only one study reported nulliparity (never having given birth) to be associated with 
higher levels of genome-wide DNA methylation346 but this was not confirmed in subsequent 
studies.80 No other studies, investigating the association between having ever been pregnant or 
ever given birth and DNA methylation, could be identified.  
The number of liveborn children (parity) was borderline associated with DNA methylation at 
two CpGs, of which only one was annotated to CSNK1D. Only two studies investigated parity in 
relation to DNA methylation and both found no association.80;350 The gene is not found in a 
literature search about parity or number of live born children. It is believed however, that 
having given birth to at least one child decreases the risk of breast cancer, although some 
studies suggest it depends on the number of children, it might be different for breast cancer 
subtypes, and it might be protective for postmenopausal breast cancer, but associated with an 
increased risk of premenopausal breast cancer.332;351;352 More research is needed to determine 
whether it is perhaps a proxy for other socio-economic or lifestyle related factors.332 Other 
studies suggest the age at which the first child is born is a more important determinant of breast 
cancer risk. When a woman gives birth after the age of 35, her risk of breast cancer is higher 
compared to a woman who gave birth before she was 25 years old.332;352 Age of the woman at 
first, second, third, or last liveborn were not associated with DNA methylation in this study. 
However, Terry et al. found an association between later age at first birth and increased DNA 
methylation levels.346 A study by Asztalos et al. reported differential expression of several genes 
(lower expression of ERα, ESR1, PGR, ERBB2, and increased expression of ESR2) among parous 
women, compared with nulliparous women, however none of these genes were found to be 
differentially methylated in this section.353 
Breast feeding reduces the risk of breast cancer, although this also appears to be different for 
different types of breast cancer352;354 and in this study DNA methylation was not associated with 
breast feeding after any of the pregnancy, nor with the duration of breastfeeding. No studies 
have investigated breast feeding or the duration of breast feeding in relation to DNA 
methylation.  
Use of OC, but not duration, seems to increase the risk of breast cancer slightly among current 
and recent users.332 In this study, DNA methylation of none of the CpGs was associated with ever 
vs. never OC use and DNA methylation of two CpGs was borderline associated with the age at 
which the first OC use started. Two studies have assessed the effects of OC use on DNA 
methylation. Christensen et al. did not find an association between OC use and methylation in 
162 breast tumours.350 However, Campesi et al. measured global DNA methylation in WBC and 
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found significantly higher levels among 162 healthy adult women who used OC.355 No studies 
have focused on locus-specific DNA methylation in relation to OC use or duration. 
Another important hormonal factor is the use of hormone replacement therapy (HRT), of which 
the use is associated with an increased risk of breast cancer.332 Current HRT use was in this 
study associated with DNA methylation of one CpG. The age at which a person started using 
HRT and the duration of HRT was not associated with DNA methylation. Three studies have 
investigated HRT use in relation to DNA methylation. A study by Choi et al. did not observe an 
association between ever vs. never HRT use and global methylation.80 Friso et al. performed a 
placebo-controlled, double-blind, randomized, cross-over study among post-menopausal 
women, with a conjugated equine oestrogen (CEE) phase, and a placebo phase. They observed 
statistically significantly higher levels of global DNA methylation after the CEE phase. Despite 
this finding, they did not show any difference in methylation of the ERα, ERβ and p16 
promoters.356 Another study assessed DNA methylation of seven genes (ESR1, ESR2, PGR, MLH1, 
CDKN2A, MGMT and MYOD1) in both healthy colon tissue (n=234) as well as in colon cancer 
tissue (n=280).357 They found higher DNA methylation at MGMT among HRT users in healthy 
tissue but none of the genes were significantly differently methylated in the cancer tissues.357 
The genes that were associated with the significant CpGs in this study were not found by any of 
the studies.  
Finally, surgeries of the reproductive organs, such as hysterectomy or oophorectomy decrease 
the exposure to endogenous hormones, which decreases the risk of breast cancer.358 In this 
study however, methylation was not associated with hysterectomy or with ovary surgery. This 
last variable may contain many different types of surgery, which makes it difficult to find 
significant results. No other studies have investigated the link between reproductive organ 
surgeries and DNA methylation.  
The many reproductive and hormone-related variables that were assessed is one of the 
strengths of this study. However, these results are only preliminary and further research should 
include bigger sample sizes and more targeted study populations.  
This is the first study to use the HM450 to investigate locus-by-locus changes in DNA 
methylation associated with various reproductive and hormone-related variables. Some of these 
variables have been investigated in other studies in relation to global DNA methylation and one 
study used a candidate gene approach, but no locus-specific studies at a CpG level have been 
performed so far. The results seem to indicate there are potential associations between these 
numerous reproductive and hormonal variables and DNA methylation, however, only one CpG 
reached genome-wide significance (cg13768445, located at the SLC28A3 gene).   
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7.3 Hormone levels in blood and DNA methylation  
 
7.3.1 Samples and study population 
The reproductive factors described in section 7.2 influence the risk of breast cancer through 
changes in endogenous hormone levels. Several studies have shown an association between 
endogenous sex hormones and breast cancer risk in both pre-menopausal and post-menopausal 
women.359;360 For a small group of samples from the EPIC-Turin cohort (n=58) of whom DNA 
methylation data was available, 13 hormone levels in blood were measured. After excluding 19 
males, and two colon cancer cases, 36 females remained, which were included in the analyses. 
Measurements for IGFBP1, IGFBP2, and HbA1c were available for too few samples and these 
measures were therefore excluded from the analyses, leaving 10 hormones to be analysed. 
Despite these low numbers, preliminary analyses were performed to estimate the association 
between several hormone levels in blood and DNA methylation.  
During pre-processing, 65 SNPs were excluded, as well as 34,382 CpGs with missing values for 
more than 20% (n=7) of the samples. No samples had to be excluded because of missing values 
for more than 5% (n=22,557) of the remaining CpGs, however, ComBat identified 3,324 
additional CpGs that were deemed unusable and had to be excluded. Of the remaining 447,806 
CpGs, 40,029 non-specific CpGs were excluded, resulting in 36 samples and 407,777 CpGs to be 
included in the analyses. 
 
7.3.2 Results 
The number of measurements for each hormone is represented in Table 7.14. Only Insulin-like 
growth factor 1 is available for all subjects, there are missing values for all other hormone 
levels. 
 
Table 7.14 – The hormone levels in blood available for this study, the number of samples with measured 
levels and the mean and range per hormone measurement 
Name Abbreviation N samples mean (range) 
Connecting peptide C-peptide 35 4.08 (1.46 – 10.44) ng/ml 
Insulin-like growth factor 1 IGF-1 36 259.0 (129.2 – 470.9) ng/ml 
Insulin-like growth factor-binding protein 3        IGFBP3 34 5,492 (3,179 – 7,258) ng/ml 
Testosterone  Testosterone 34 0.51 (0.22 – 1.81) nmol/l 
Dehydroepiandrosterone sulfate DHEAS 34 129.4 (46.3 – 461.9) µg/dl 
Sex hormone-binding globulin SHBG 34 35.7 (11.8 – 64.5) nmol/l 
Androstenedione D4 34 1.62 (0.33 – 10.0) nmol/l 
Estrone  E1 30 60.7 (27.6 – 178.9) pg/ml 
Estradiol E2 30 53.3 (9.4 – 211.8) pg/ml 
Progesterone Progesterone 14 3.29 (0.19 – 9.68) ng/ml 
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Table 7.15 gives an overview of the baseline characteristics of the 36 subjects of which hormone 
levels were available.  
 
Table 7.15 – Baseline characteristics and breast cancer risk factors of the study population  
Characteristic  Subjects (n=36) 
Age at recruitment mean (range), years 52.3 (35.0 – 63.7) 
Breast cancer n (%)  
      Case  25 (69.4) 
      Control  11 (30.6) 
Height mean (range), cm 160.0 (147.5 – 177.5) 
Weight mean (range), kg 65.7 (44.5 – 89.8) 
BMI n (%)  
   Normal  17 (47.2) 
   Overweight  14 (38.9) 
   Obese  5 (13.9) 
   Missing  0 (0.0) 
Physical activity  n (%)  
   Inactive  5 (13.9) 
   moderately inactive  14 (38.9) 
   moderately active  14 (38.9) 
   Active  3 (8.3) 
   Missing  0 (0.0) 
Smoking status n (%)  
   Never  18 (50.0) 
   Former  7 (19.4) 
   Current  11 (30.6) 
   Missing  0 (0.0) 
Educational level n (%)  
   None  1 (2.8) 
   Primary  16 (44.4) 
   Technical/professional 5 (13.9) 
   Secondary  8 (22.2) 
   College/University  6 (16.7) 
   Missing  0 (0.0) 
Alcohol consumption  median (gr/d) 6.2 (0.00 – 50.6) 
Fat consumption median (gr/d) 82.5 (40.6 – 149.8) 
 
The subjects consisted of 25 female breast cancer cases and 11 female controls. Analyses were 
adjusted for age and case control status. The results are presented in Table 7.16 displaying the 
number of CpGs reaching significant p-values or q-values, per hormone.  
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Table 7.16 – Number of CpGs with significant p-value or q-value and smallest p-value per hormone 
Hormone 
 Number of CpGs 
Smallest p-value  p-value  
<1.03e-07 
q-value 
<0.05 
C-peptide  0 0 1.15e-06 
IGF-1  0 0 2.31e-07 
IGFBP3  0 0 1.88e-05 
Testosterone  2 4 8.57e-09 
DHEAS  0 0 1.18e-06 
SHBG  0 0 1.85e-06 
D4  54 84 4.42e-17 
E1  0 0 2.26e-06 
E2  0 0 1.58e-06 
Progesterone  0 0 1.81e-06 
 
Testosterone and D4 were genome-wide significantly associated with methylation levels at two 
and 54 CpGs, respectively. The strongest association was observed for D4 exposure in relation 
to methylation of cg14498674 (p-value=4.42e-17).  
 
Especially D4 (Androstenedione) was associated with methylation levels at many CpGs (54 
CpGs reach a p-value<1.03e-07). D4 is a steroid hormone which can be converted to 
testosterone by 17β-hydroxysteroid dehydrogenase, or to estrone by aromatase (see Figure 
7.1). Approximately 50% of the D4 production comes from the adrenal glands and the other 
50% from the ovaries. In post-menopausal women the ovaries produce much less D4, resulting 
in a reduction of about 50% compared to pre-menopausal production.  
Also two CpGs in relation to testosterone reached genome-wide significance. Testosterone is, 
like D4, a steroid hormone and the main sex hormone among men. In women it is secreted by 
the ovaries and the adrenal glands and plays an important role in muscle strength and bone 
mass, as well as mood changes, libido, and cognitive functions.361  
IGF-1 levels reached borderline significance. IGF-1 is a hormone mainly produced by the liver 
after stimulation by pituitary growth hormone (GH). It is essential in growth of children, besides 
other physiological processes in adults and is regulated by various factors, such as age, sex, 
nutrition, and oestrogen status, among others.362 IGF-1 has been associated with several 
cancers, including breast cancer.363 Insulin-like growth factor-binding protein 3 (IGFBP3) was 
not associated with DNA methylation at any of the CpGs, nor were c-peptide levels and 
progesterone.  
Estrone (E1) is one of the most frequently occurring oestrogens besides estradiol (E2) and 
estriol (E3). As can be seen in Figure 7.1, aromatase can convert testosterone in estradiol and 
androstenedione (D4) in estrone. Estrone can also be converted in estradiol (and vice versa) 
through 17β-hydroxysteroid dehydrogenases (17β-HSDs). In post-menopausal women estrone 
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is predominantly produced by the ovaries, the placenta and adipose tissue.364 E1 and E2 also did 
not reach genome-wide significance.  
The p-values, the effect size estimates (indicating an increase or decrease in methylation with 
higher hormone levels) and the annotation of the CpGs with a p-value<1.03e-05 are shown in 
Table S7.6 of the supplementary material. 
 
 
Figure 7.1 Steroidogenesis - the relationship between progestagens, androgens, oestrogens, and corticoids (source: 
Wikipedia: http://en.wikipedia.org/wiki/File:Steroidogenesis.svg) Red circles are some of the hormones that have 
been investigated in this section 
 
Out of all CpGs with a p-value<1.03e-05 (n=143), there were two CpGs occurring twice. 
Cg09187107 was found in association with E1 (Estrone) and E2 (Estradiol). This CpG is located 
on the body of the FLJ90757 gene, of which the function is unknown. As mentioned above, 
aromatase can convert testosterone in estradiol, or 17β-HSD can convert estrone in estradiol. 
Estradiol has a stronger oestrogenic effect than estrone, which makes it the main oestrogen 
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during a woman’s reproductive life. After menopause however, circulating levels drop roughly 
to the level of estradiol in males. In pre-menopausal women estradiol is mainly produced by the 
ovaries and the placenta and in post-menopausal women (and men) it is produced by adipose 
tissue. Besides the important role of estradiol on reproductive and sexual health, it is also 
essential for other organs, such as the bones. In addition it has been associated with an 
increased risk of breast cancer.365  
The other CpG occurring twice is cg02143936 which was associated with levels of DHEAS 
(Dehydroepiandrosterone sulfate) and SHBG (Sex hormone-binding globulin) and is located on 
the  ’UTR region of a gene called MICAL2. The function of this protein coding gene is the 
promotion of depolymerisation of F-actin and it has been shown to play a role in the 
development of prostate cancer366 but has not been linked to DHEAS or SHBG levels in the 
literature.  
DHEAS is another steroid hormone, which is secreted by the adrenal cortex. It can be 
transformed into DHEA (by losing its sulphate group), after which it can be converted into 
several androgens and oestrogens (see Figure 7.1). DHEAS has been extensively studied and 
associated with a variety of different health outcomes (such as cardiovascular disease, obesity, 
diabetes, as well as depression), however, the exact function or mechanism by which DHEAS 
and DHEA influence health are still unknown.367  
SHBG is a protein, predominantly produced by the liver, which binds to androgens (higher 
binding affinity for testosterone (T)) and oestrogens (lower affinity for estradiol (E2)) in order 
to transport them through the blood stream.368 It is also important in controlling bioavailability 
of various sex-steroids. High levels of for example IGF-1 cause a decrease in SHBG, while high 
levels of oestrogen increase SHBG levels.369  
 
Taking all CpGs, whose methylation was associated with hormone levels, together they were 
associated with 120 genes. Both the gene PTPRN2 and the gene CCDC88B included three CpGs 
whose DNA methylation was associated with hormone levels. The CpGs associated with PTPRN2 
were related to testosterone levels (cg10736303), and D4 levels (cg00356251 and cg03347095) 
and were all found on the body of the gene. At all three CpGs methylation levels decreased with 
increasing hormone levels. PTPRN2 is involved in the development of the nervous system and 
pancreatic endocrine cells and has been associated with type I diabetes.326 In addition, two 
studies have found hypermethylation of loci on the PTPRN2 gene to be associated with lung 
cancer.327;328 Three CpGs associated with CCDC88B were all related to D4 levels. They were all 
located on the gene body and on the south shelf of a CpG island. The effect size estimate is 
negative for the three CpGs and the function of the gene is unknown. It remains unclear whether 
the location of the CpGs in relation to the CpG island and gene have any meaning. None of the 
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genes mentioned in this section were associated with any hormone-related exposure in the 
literature. 
 
7.3.3 Discussion 
This is the first preliminary study investigating hormone levels in peripheral blood samples in 
relation to locus-specific DNA methylation assessed by the HM450 array by Illumina. These 
exploratory analyses showed that methylation of several CpGs was associated with various 
hormone levels, but only two CpGs related to testosterone levels and 54 CpGs related to D4 
levels reached genome-wide significance. Unfortunately it was not possible to stratify by 
menopausal status due to the small sample size. This would be of interest since certain hormone 
levels (especially the oestrogen oestradiol) are very different during the different menopausal 
states. In addition, it would have been relevant to stratify the analyses by BMI because it has 
been shown that circulating oestradiol levels are much higher among obese post-menopausal 
women, compared with normal weight post-menopausal women, which has been associated 
with an increased risk of breast cancer.370 
Despite the sample-related limitation, these initial results seem to indicate that certain hormone 
levels influence DNA methylation at various CpGs across the human genome.  
 
A few studies have investigated sex-hormones in relation to DNA methylation. Four animal 
studies were performed in which DNA methylation was measured after exposure to estradiol 
(E2). Aniagu et al. exposed the three spine stickleback to estradiol and measured global DNA 
methylation in the liver and the gonads of both male and female fish. They observed no changes 
in the liver, but found hypermethylation (31% increase in global methylation) in the testis of the 
male fish. No difference was reported in methylation levels of the ovaries of the female fish.371 
Ho et al. exposed rats to estradiol and measured methylation in prostate tissue of these rats. 
They observed hypomethylation of several CpGs located at the promoter region of the PDE4D4 
gene, which was associated with increased expression of this gene.372 Kovalchuk et al. also 
studied DNA methylation in rats, after E2-induced breast carcinogenesis, and observed global 
hypomethylation (measured using an assay which measures the proportion of unmethylated 
CCGG sites), as well as decreased LINE-1 methylation.373 Finally, Tang et al. assessed promoter 
methylation of several candidate genes in rat prostates after early life exposure to estradiol. 
They observed perinatal hypomethylation of Nsbp1 which lead to increased gene expression, 
but perinatal hypermethylation of Hpcal1 with concordant lower gene expression. Importantly, 
they demonstrate that, depending on the type of gene, the type of exposure, the moment during 
development on which this exposure takes place, and other life events and exposures later in 
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life, certain epigenetic marks can change during adulthood.374 This remains important to keep in 
mind when evaluating epigenetic signals. 
Besides these animal studies, one study investigated human cells. Aniagu et al. exposed human 
liver cells, as well as hepatocellular carcinoma (HepG2) cells to estradiol and studied global and 
locus-specific DNA methylation. They found no difference in global DNA methylation of 
hepatocytes, but found hypomethylation in HepG2 cells after E2 exposure. Promoter 
methylation of various genes (N-cym, ERα, RB1, p16, C-myc, H-ras, THRα, histone H3, TBK1 and 
TNFRα) was not associated with E2 exposure in hepatocytes, nor in HepG2 cells.375   
None of the genes identified by the studies described above have been found in this section. 
 
Lastly, two recent studies assessed the effects of several sex-hormones on global methylation 
measured in blood samples of women. Ulrich et al. measured LINE-1 methylation in 
lymphocytes of 173 overweight and obese, post-menopausal women and studied the 
association with levels of a variety of sex steroid hormones. Additionally, to account for one-
carbon status, they stratified analyses by folate level and multivitamin use. They found higher 
levels of SHBG to be associated with lower methylation levels. After stratifying the analyses by 
serum folate level they observed inverse associations between D4, E1, E2, SHBG, and 
testosterone and global DNA methylation among women in the lower folate category. 
Stratification by multivitamin use showed similar inverse associations between E1, E2, and 
SHBG levels and DNA methylation among women who did not use any multivitamins. Among 
women who did use multivitamins an inverse association was observed between SHBG 
concentrations and global DNA methylation. These results indicate that one carbon status can 
modify the results, which is an important finding for future epidemiological studies.376  
Iwasaki et al. performed a cross-sectional study assessing global DNA methylation in blood 
samples in relation to endogenous sex-hormones among 185 Japanese post-menopausal 
women. Adjusting for age showed an inverse association between estrone and global DNA 
methylation, but the other hormone levels did not reach statistical significance. After 
additionally adjusting for various hormonal, reproductive and lifestyle related breast cancer 
risk factors, none of the hormones were statistically significantly associated with DNA 
methylation anymore. Stratification by alcohol consumption status demonstrated an inverse 
association between DHEAS levels and DNA methylation among drinkers, but not among non-
drinkers. Stratified analyses by vitamin B2, B6, B12 and five polymorphisms did not result in 
any significant findings.377  
Because both the study by Ulrich et al. and the study by Iwasaki et al. did not assess locus-
specific DNA methylation, it is not possible to compare the results with the results found in this 
section. However, the observations reported here and described by the two other studies 
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indicate the possibility of sex-hormone levels to influence DNA methylation. Future studies 
should include more subjects (higher power), explore stratification by menopausal status, BMI, 
and folate/multivitamin use and take white blood cell count into account. In addition, more 
research is needed to assess the consequences of the DNA methylation changes (such as 
differential gene expression) related to hormone levels. 
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Chapter 8 – Overall discussion 
 
8.1 Meet-in-the-middle 
In this section the meet-in-the-middle principle will be applied on all results described 
throughout this thesis. To do so I will try to identify overlap of CpGs that are associated with 
both breast cancer (Chapter 5) and exposures to EDCs (Chapter 7, section 7.1), and/or exposure 
to other hormone-related or reproductive factors from the questionnaire data (Chapter 7, 
section 7.2), and/or hormone levels in blood (Chapter 7, section 7.3). 
 
8.1.1 Level of significance 
In the current study, the CpGs that are associated with breast cancer reach a genome-wide 
significance level of p<1.03e-07. Equally, the exposure variables (EDC levels in blood, as well as 
questionnaire data) need to have a p-value<1.03e-07 to be deemed statistically significant. 
However, when applying the meet-in-the-middle principle this might be too stringent. Since this 
principle assumes DNA methylation is an intermediate biomarker of exposure which lies on the 
etiological pathway between exposure and disease, twice applying such a strict cut-off seems to 
be overcorrection, potentially leading to overlooking real signals. In addition, other studies have 
reported the potentially too stringent cut-off values for genome-wide significance, and report 
that several borderline significant associations can be reproduced and are possibly genuine.378 
For those reasons, in this section, all CpGs reaching a p-value of 1.03e-05 are also described, 
despite the fact that they do not reach genome-wide significance.  
 
8.1.2 EDC exposure – DNA methylation – breast cancer 
In Chapter 5 the locus-by-locus analyses identified CpGs that are associated with breast cancer: 
6,334 CpGs had a q-value<0.05 and 26 CpGs reached a genome-wide significance level of p-
value<1.03e-07. In section 7.1 62 CpGs were shown to be differentially methylated after 
cadmium exposure. However, none of these 62 CpGs were also found within the 6,334 
associations with breast cancer with a q-value<0.05. In the stratified analysis by cohort, both 
exposure to PCB170 and PCB180 were associated with methylation of cg12503717 in the EPIC-
Italy cohort. However, also this CpG was not found in the top 6,334. It is known from the 
literature that an association exists between cadmium exposure and breast cancer119, however 
the results in this thesis could not identify any direct meet-in-the-middle candidate for the EDC 
exposures, DNA methylation and breast cancer. 
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8.1.3 Questionnaire data – DNA methylation – breast cancer 
In Chapter 7, section 7.2 only one CpG reached genome-wide significance (p-value<1.03e-07). 
DNA methylation at this CpG, cg13768445, was associated with current vs. not current HRT use 
(p-value=8.05e-08). It is located on chromosome 9, on a gene called solute carrier family 28 
(sodium-coupled nucleoside transporter), member3 (SLC28A3). However, when searching for 
this CpG in the results of the locus-by-locus analysis (DNA methylation and breast cancer, 
Chapter 5), it only appeared in the 301,026th position in the ranking (p-value=0.61). No 
literature was available relating SLC28A3 to HRT use or to breast cancer. 
When including also CpGs that reached a q-value<0.05 for the association between breast 
cancer and DNA methylation and a p-value<1.03e-05 for the association between questionnaire 
data and DNA methylation three CpGs are identified as potential meet-in-the-middle candidates.  
 
One CpGs (cg10903132) was found with a p-value<1.03e-05 for the association between DNA 
methylation and age at menarche (p-value = 4.20e-06), and a significant q-value at 5% (p-value 
= 0.0001, q-value = 0.023) for the association with breast cancer.  Methylation at this CpG, 
located on chromosome 10 increased with increasing age of the women at menarche. In view of 
case-control status, cases have lower methylation levels (beta = 0.9522) compared with controls 
(beta = 0.9571) at this CpG, which is not associated with any gene.  
Another CpG (cg01726880) was identified, which had a p-value<1.03e-05 for the association 
between DNA methylation and the number of liveborn children (p-value=4.34e-06), and a 
significant q-value (p-value=0.00047, q-value=0.041) for the association with breast cancer. 
This CpG is located on TMPRSS8 gene (chromosome 16). With each additional liveborn, 
methylation of this gene increases with 0.0061. Among breast cancer cases, methylation of this 
CpG was 0.8916 (beta-value), and among controls it was 0.8980. No information is available 
about this gene (also known as protease, serine, 30, pseudogene (PRSS30P)). 
Finally, the third potential meet-in-the-middle candidate is cg13226362. This CpG had a p-
value<1.03e-05 for the association between DNA methylation and ever vs. never use of oral 
contraceptives (p-value = 3.43e-06), and a significant q-value<0.05 for the association with 
breast cancer (p-value = 0.00030, q-value = 0.034). This CpG is located at the CTDP1 gene on 
chromosome 18. Ever having used OC decreases methylation at this CpG with 0.010 and beta-
values among breast cancer cases are 0.866 compared with 0.873 among controls. This gene 
encodes a protein which interacts with the carboxy-terminus of transcription initiation factor 
TFIIF, and dephosphorylates a subunit of RNA polymerase II (promoting its activity).379 No 
literature exists linking CTDP1 to either the use of oral contraceptives or to breast cancer.  
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These analyses yield weak associations which correspond to extremely weak effect size 
estimates. The consequences of these small differences in DNA methylation need to be further 
assessed in future studies.  
 
8.1.4 Hormone levels in blood – DNA methylation – breast cancer 
The analyses in Chapter 7, section 7.3 showed several hormone levels to be associated with 
CpGs across the genome. In total 143 CpGs (141 unique CpGs) were identified that had a  p-
value<1.03e-05 for the association between DNA methylation levels and hormone levels. When 
comparing these 143 CpGs with the 6,334 CpGs reaching a q-value < 0.05 in the association 
between breast cancer and methylation, no overlap was found. No meet-in-the-middle 
candidate could be identified in the relation between hormone levels in blood, DNA methylation 
and breast cancer, which is possibly due to the small number of samples included in these 
analyses (low power). 
 
Figure 8.1 gives an overview of all associations found in this thesis. 
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Figure 8.1 – Summary of observed associations  
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8.2 Strengths and limitations 
 
As discussed before, one of the main strengths of this thesis concerns the prospective design of 
the study. The blood samples were collected before onset of the disease, which excludes several 
potential sources of bias that can occur in case-control studies, such as variations in collection, 
processing, and storage between samples of cases and controls. In addition, samples that are 
collected after diagnosis might differ from control samples because of diagnostic or treatment 
processes, changes in lifestyle or disease progression. As an extra precaution, cases (and their 
matched controls) with a time to diagnosis of less than one year were excluded from the locus-
by-locus analysis (Chapter 5), which still resulted in four CpGs reaching genome-wide 
significance, indicating reverse causality is unlikely to affect these signals.  
Another advantage of the analyses performed in this thesis is the use of prospective blood 
samples, which are easy, cheap and non-invasive to obtain. In addition, various biobanks and 
prospective studies have blood samples stored, which form a great potential source of valuable 
data to be used in DNA methylation studies. Furthermore, the HM450 array used in this thesis 
only needs a relatively small amount of DNA. Most previous DNA methylation studies have used 
human cell lines or human tissues (i.e. breast tumour tissue vs. healthy breast tissue) but the 
number of studies using body fluids such as urine, breast milk, nipple fluids, ductal fluids, 
plasma, serum, and peripheral blood is growing.380 There has been some debate as to whether 
DNA methylation measured in peripheral blood leukocytes actually reflects methylation of 
target tissue. Concerns exist about differences in leukocyte cell types due to inflammatory 
processes during cancer development, which could result in changes in DNA 
methylation.283;284;381 Nevertheless blood samples have been shown to be useful in the 
assessment of biomarkers of exposure, such as smoking and other environmental 
contaminants.321 Moreover, the potential of DNA methylation assessment in blood samples as a 
tool for detection or risk prediction of cancer has been demonstrated by Teschendorff et al.381  
In addition, SNPs that are known to be associated with the disease studied and with differential 
DNA methylation, such as the MTHFR C667T described in Chapter 5 of this thesis, could thereby 
confound epigenetic studies.296;297 However, because the results did not change substantially 
after excluding the CpGs whose DNA methylation was associated with white blood cell type, and 
because the frequency of the MTHFR genotype were similar among cases and controls, it can 
cautiously be concluded that these two issues did not affect the results reported in this thesis. 
Several studies have confirmed that DNA methylation from peripheral blood can serve as a non-
invasive biomarker for disease, however, some were not able to show this.83 It remains 
important for future studies to sort blood samples into the various WBC types before storing 
them, rather than correcting for this issue at a later stage. This is important when the 
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association between DNA methylation and a disease outcome is assessed and blood cell 
composition is associated with both the disease (for example because of inflammation) and DNA 
methylation (which is known to be true). In that case blood cell composition can be a 
confounder and adjusting or correcting for this confounder, through the method that was used 
in this study has its limitations. It is still possible for CpGs that did not reach genome-wide 
significance in the association with different cell types, and were therefore not excluded from 
the analyses, to influence the results. A possible solution to this issue of cell composition bias is 
suggested by Houseman et al. and should be used by future studies.382  
 
The use of the HM450 array had several strong points, as well as some limitations, all described 
in section 3.2.6. Briefly, the fact it measures DNA methylation at over 480,000 CpGs across the 
genome means it covers a large part of the human epigenome (albeit it not truly genome-wide). 
Unlike other arrays is does not only measure repetitive elements or only CpG Islands, but 
includes different physical locations and functional regions. Furthermore, although there are 
some papers supporting the technical reproducibility and reliability247;248, in practice there is a 
need for careful modelling of nuisance or technical variation. 
The limitations include the differences between Infinium I and II probes, potential batch effects, 
and non-specific CpGs but the elaborate pre-processing and normalization that was performed 
in advance of the analyses means that all limitations were minimized as much as possible.  
The subjects in this study were selected from the general population, which makes it easier to 
generalize the findings to the rest of the Italian and Swedish (European) population. Cases and 
controls were matched on certain crucial variables (such as age, date of recruitment, study 
centre, and chip), making the results less prone to bias with respect to these confounders.  
In an attempt to increase the power of the EDC exposure and DNA methylation analyses, female 
lymphoma controls were included. This seemed to have the desired effect since several CpGs 
were found to be associated with cadmium in this thesis, which have been reported by several 
previous studies in relation to smoking. It was to be expected that results from section 7.4 
would yield underpowered results. Nevertheless the data were explored, resulting in several 
signals reaching genome-wide significance, however a replication in possibly larger studies is 
still crucial. 
Another strength of this thesis resides in the high quality of the exposure measurements: the 
environmental exposures measured in blood and the wide variety of (self-reported) hormone-
related and reproductive questionnaire data. Many studies investigating the risk of 
environmental pollutants used animal models or cell lines. The exposures studied here were 
clinically relevant and involved relatively low levels of exposures, which is more appropriate to 
assess effects in the human population. However, it was not possible to adjust for other 
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unmeasured metals and trace elements which might interact with the exposures under 
investigation and breast cancer risk. Additionally, the exposures are only measured at one point 
in time (at enrolment) which is likely to make the estimate less representative of lifetime 
exposure. This is a common problem in many cohort studies. The same was true for variables 
such as smoking status and other lifestyle and dietary factors. These were measured at 
enrolment and it is possible they have changed during the time between enrolment and breast 
cancer diagnosis or follow-up. Moreover, information on factors such as family history of breast 
cancer and tumour grade and stage were lacking, while other variables such as ER, PR, HER2 
status suffered from a high number of missing values, which might have influenced some of the 
results (residual confounding). If more variables had been available it would have been possible 
to build a risk prediction model for breast cancer, such as the Gail model, additionally including 
methylation values of top CpGs to assess what they add to the discriminative accuracy between 
cases and controls.  
The fact that no results were found for any of the PCBs in relation to DNA methylation (only for 
cadmium) could be due to the fact that cadmium exposure is largely a proxy of cigarette 
smoking. Potentially the adverse health effect of PCBs only occur at much lower levels of 
(chronic) exposure, which means a larger sample size is needed to detect this. 
Lastly, the attempt to replicate the global results from Chapter 4 using the EGM cohort in 
Chapter 6 failed. As described before this is possibly due to the smaller sample size and the 
lower quality of the DNA methylation data of the EGM study. Recently however, another attempt 
was made in collaboration with Severi et al. who independently validated the results presented 
in Chapter 4 in a parallel study. They also observed hypomethylation among breast cancer cases 
compared with controls in blood samples collected before onset of the disease (paper submitted 
for publication). Regarding the locus-specific analyses from Chapter 5, an attempt should be 
made, either to replicate the findings in a larger population or to validate them using alternative 
platforms in a targeted manner (e.g. pyrosequencing). 
No potential sources of bias (information bias, selection bias) could be identified. It is possible 
that there was some form of recall bias among subjects who filled out the questionnaire 
regarding reproductive and hormone-related variables, however, there is no reason to assume a 
systematic differential performance in memory across cases and controls in remembering these 
factors.  
 
8.3 Implications of the findings 
The field of epigenetic epidemiology is still new and developing, and the analytical methodology 
is still very much under construction. A lot of effort and research has gone into developing the 
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pre-processing methods from Chapter 3 (Methods). The various available options have been 
described, including their strengths and limitations, which eventually led to the well-argued 
decision of applying the pre-processing steps described in sections 3.3.4.3 and 3.3.5. Future 
DNA methylation studies, using the same HM450 array can benefit from this and use the same 
techniques. By doing so, studies will become better comparable and thereby meta-analyses 
more feasible. 
In addition, all the analyses performed had not been attempted by any previous studies. Firstly, 
the global methylation analyses resulted in hypomethylation among women who later went on 
to develop breast cancer compared with women who remained disease free. These results were 
confirmed in an independent study by Severi et al. who used similar pre-processing and 
analysing techniques (paper submitted for publication). These findings should encourage future 
studies to assess the possibility of global methylation levels to serve as a biomarker for breast 
cancer risk, by testing the sensitivity and specificity in a larger study which includes white blood 
cell counts and information of the variables that were missing in this thesis, in order to 
potentially add to the Gail prediction model. 
Secondly, the locus-specific analyses resulted in 26 CpGs on the human genome reaching 
genome-wide significance, however, it is unclear how these results should be interpreted and 
what their functional meaning is. The CpGs were associated with genes that were not identified 
in the literature as well-known breast cancer associated genes. It is possible these CpGs are 
novel hits but the fact that they were not replicable in the EGM dataset and the fact that the 
study was under-powered, makes it harder to draw any specific conclusion. Currently, this 
remains one of the biggest challenges of genome-wide studies: how to select true biomarkers 
with high sensitivity and specificity, from the many potential hits. 
Even though DNA methylation was statistically different between cases and controls, the actual 
difference at each CpG was very small, which makes it unclear what the biological implications 
of these differences were and if it would actually lead to changes in gene expression in the 
target tissue and perhaps changes in transcription. 
Thirdly, the exposure analyses, investigating the association between EDCs, reproductive and 
hormone-related factors and hormone levels in blood, and locus-specific DNA methylation, has 
never been performed before. Several of the CpGs whose DNA methylation was found to be 
associated with cadmium exposure, were reported by previous studies in relation to smoking, 
which strengthens the findings. Because smoking has such strong effects, often studies with a 
lower power are still able to demonstrate results. The implications of these findings however, 
also remain unclear. Future research is needed to see what the biological consequences are of 
these changes in DNA methylation and if they lead to any adverse health effects (i.e. gene 
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silencing of a tumour suppressor gene). If this is the case, additional efforts should be made to 
diminish the exposures to cadmium.  
Similarly, the functional effects of the changes in DNA methylation of the numerous CpGs 
identified in relation with reproductive and hormone-related factors need to be further 
addressed before any implications can be recognized.   
Despite the small number of subjects included in the hormone level and DNA methylation 
analyses, these findings show that not only environmentally, but also endogenous factors can 
potentially lead to changes in DNA methylation. Before any further conclusions can be drawn 
the study needs to be repeated with a larger sample size. It would be interesting to investigate if 
some of the reproductive and hormone-related factors from section 7.4 are associated with 
some of the hormone levels and if the DNA methylation changes as a result of these levels lead 
to any other biological changes.  
  
Finally, this was the first study to investigate both various exposures, as well as breast cancer 
risk in association with DNA methylation, using the meet-in-the-middle principle. This was done 
to investigate whether a causal link exists between environmental exposures, DNA methylation 
(as intermediate biomarker) and breast cancer development. Three potential meet-in-the-
middle candidate have been identified, however, future studies are needed to investigate these 
candidates in more depth (see section 8.4) 
 
The potential use of the DNA methylation markers presented here is two-fold:  firstly they can 
be used to investigate the aetiology of breast cancer, such as the causes and biological 
mechanisms of breast cancer development, and secondly, they can be used for clinical purposes, 
such as early diagnosis or prognosis of the disease. Because of some of the limitations of this 
thesis, the second purpose is still unfeasible at this stage. Before the results from this thesis can 
be used as clinical biomarkers in the detection or diagnosis of breast cancer, several steps need 
to be taken, as will be elaborated on in section 8.4. Detection of breast cancer is currently done 
by mammography, however, besides the high sensitivity, the specificity is rather low, which 
emphasizes the need for highly specific biomarkers for early breast cancer diagnosis and DNA 
methylation studies as performed here have shown great potential.  
 
8.4 Conclusion and future work 
This study is the first prospective cohort study, measuring pre-diagnostic DNA methylation 
from peripheral white blood cells using the HM450 by Illumina to assess the association 
between global DNA methylation and locus-specific DNA methylation in relation to breast 
164 
 
cancer, as well as locus-specific DNA methylation in relation to endocrine disrupting chemicals, 
hormone and reproductive questionnaire data, and hormone levels in blood. To the knowledge 
of the author, this is the first study investigating the combination of EDC and 
reproductive/hormone-related exposure, DNA methylation changes and breast cancer. 
 
Reflecting on the hypothesis and aims reported at the start of this thesis, the following 
comments can be made:  
The literature review into the associations between EDC exposures, DNA methylation and 
breast cancer identified seven genes as potential meet-in-the-middle candidates. These genes 
had been reported in the epigenetic literature to be associated with both EDC exposure and 
breast cancer risk. This supported the underlying basic idea of this thesis, namely applying the 
meet-in-the-middle approach (a combination of a prospective study to assess the association 
between exposures and DNA methylation and a retrospective design to assess the association 
between breast cancer and DNA methylation) to identify overlapping markers. 
Chapter 4 and Chapter 5 demonstrated that both global DNA methylation (hypomethylation 
among controls), as well as locus-specific DNA methylation (26 CpGs) measured in peripheral 
blood are associated with breast cancer. Chapter 7, section 7.1 showed that cadmium exposure, 
but not any of the PCB exposures, was associated with DNA methylation at 62 different CpGs. In 
section 7.2 various CpGs were found to be associated with numerous reproductive and 
hormone-related variables and D4 and testosterone levels were shown to be associated with 
DNA methylation in section 7.3.  
In summary, three potential meet-in-the middle candidates were identified:  
 cg10903132 (not associated with any gene) showed association with age at menarche 
and with breast cancer 
 cg01726880 (TMPRSS8 gene) showed association with the number of liveborn children 
and with breast cancer  
 cg13226362 (CTDP1 gene) showed association with the use of oral contraceptives (ever 
vs. never) and breast cancer 
It was hypothesised that conducting combined analyses of exposure data and DNA methylation 
data would lead to meet-in-the-middle markers, relevant to the aetiology of breast cancer. The 
identification of three meet-in-the-middle candidates is evidence that this hypothesis may prove 
to be acceptable.  
 
165 
 
Future studies should include larger sample sizes. This will increase the power and enable the 
possibility of subtype analysis, which is of great importance for a heterogeneous disease such as 
breast cancer. When future studies include repeated measurements, they can assess the speed 
by which environmental exposures lead to changes in DNA methylation. In addition, it will be 
possible to investigate whether these changes accumulate after recurrent or long-term 
exposure and whether they persist after removing the exposure.247;383 Repeated measurements 
also enable studies to better assess intra-individual changes of exposure (for example, 
oestrogen levels vary within one individual throughout the menstrual cycle).384 However, 
repeated measurements also have limitations and draw-backs, such as the costs involved and 
the higher complexity of analysing and interpreting the data. 
In addition, it has been stated before that one of the most important aims of future studies 
should be focussing on the biological consequences of changes in DNA methylation. It is possible 
that certain exposures cause intermediate effects, such as inflammation, which lead (indirectly) 
to changes in DNA methylation. Moreover, DNA methylation might lead to intermediate effects, 
which eventually result in developing the disease. Therefore, it is of value to assess multiple 
epigenetic mechanisms, besides DNA methylation, such as changes in histone modification and 
miRNAs. Because these mechanisms are all closely linked together, studying them together may 
give greater insight in biological processes. Subsequently, it will be interesting to assess the 
association between DNA methylation and gene expression (transcriptomics), and proteins 
(proteomics). As has been stated by Vineis and Perera; usually a combination of biomarkers in 
needed to completely understand the process of (breast) cancer development.21 
Regarding the issue of causality, future studies should attempt to use Mendelian 
randomization.385 This has been especially developed to establish causal associations between 
environmental exposures and diseases and has recently been extended to include epigenetic 
markers.386 After a causal relationship has been established, future epidemiological studies can 
investigate whether changes in lifestyle, such as smoking cessation, changes in factors such as 
OC use, or changes in dietary habits affect DNA methylation and through that perhaps breast 
cancer risk.  
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Appendix 1 - Supplementary tables 
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Table S2.1 Potential DNA methylation biomarkers from reviews 
Wang, 2010 Suijkerbuijk, 2011 Tang, 2012 Ma, 2013 Pubmeth Unique 
APC1 14-3-3σ APC 14-3-3σ ABCB1 14-3-3σ 
BRCA1 APC BIN1 APC APC ABCB1 
BRCA2 ATM BRCA1 BIN1 BRCA1 APC 
CDH1 BRCA1 BRCA2 BMP6 CADM1 ATM 
Cyclin D2 CCND2 CST6 BRCA1 CCND2 BIN1 
Erα CDH1 cyclin D2 CST6 CDH1 BMP6 
Hin1 CDKN2A GSTP1 DKK3 CDKN2A BRCA1 
p16 DAPK1 HIN1 ESR1 CST6 BRCA2 
RARB ESR1 p16 ESR-b DAB2 CADM1 
RASSF1A GSTP1 p21 GSTP1 DAPK1 CCND2 
TWIST1 MGMT RAR3 ITIH5 DLC1 CDH1 
 PRB RARB p16 DSC3 CDKN2A (p16) 
 RARB RASSF1A p21 ESR1 CST6 
 RASSF1 RUNX3 RARB ESR2 Cyclin D2 
 RUNX3 TIMP3 RASSF1 FHIT DAB2 
 SCGB3A1 TWIST1 SLC19A3 GSTP1 DAPK1 
 SLIT2  SOX17 HIC1 DKK3 
 TMS1  TIMP3 ID4 DLC1 
 TWIST1   KLK10 DSC3 
    MGMT ESR1 (Erα) 
    MLH1 ESR2 
    MYOD1 ESR-b 
    PTGS2 FHIT 
    PYCARD GSTP1 
    RARB HIC1 
    RASSF1 HIN1 
    RBP1 ID4 
    RUNX3 ITIH5 
    SCGB3A1 KLK10 
    SFRP1 MGMT 
    SLIT2 MLH1 
    SOCS1 MYOD1 
    SYK p21 
    TIMP3 PRB 
    TWIST1 PTGS2 
     PYCARD 
     RAR3 
     RARB 
     RASSF1 
     RASSF1A 
     RBP1 
     RUNX3 
     SCGB3A1 (HIN-1) 
     SFRP1 
     SLC19A3 
     SLIT2 
     SOCS1 
     SOX17 
     SYK 
     TIMP3 
     TMS1 
     TWIST 
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Table S4.1 – Association between average methylation and breast cancer risk  
  Cases  
(n) 
Controls 
(n) 
OR  (95% CI) p-value 
By quartiles Q1  [0.520 – 0.529) 76 41 1.00   
 Q2  [0.529 – 0.531) 31 40 0.45 (0.24 – 0.84) 0.01 
 Q3  [0.531 – 0.534) 31 40 0.37 (0.20 – 0.71) 0.003 
 Q4  [0.534 – 0.543) 24 41 0.35 (0.18 – 0.67) 0.001 
       
 Per 1 SD   0.61 (0.46 – 0.80) 0.00034 
       
Time to Diagnosis <3.7  79 - 0.66 (0.46 – 0.95) 0.03 
(years) >3.7 83 - 0.55 (0.36 – 0.83) 0.004 
       
Menopausal status Premenopause 60 62 0.61 (0.40 – 0.94) 0.03 
 Postmenopause 99 100 0.57 (0.40 – 0.82) 0.002 
       
ER status Negative  18 - 0.49 (0.19 – 1.24) 0.13 
 Positive 56 - 0.58 (0.36 – 0.95) 0.03 
  Missing*  88 -    
       
PR status Negative 27 - 0.95 (0.44 – 2.01) 0.88 
 Positive 44 - 0.46 (0.26 – 0.82) 0.008 
  Missing* 91 -    
       
HER2 status Negative  20 - 0.77 (0.36 – 1.64) 0.50 
 Positive 6 - 9.71e+14 (0.00 – inf) 1.00 
  Missing* 136 -    
       
Tumour behaviour 
 
Borderline 
malignancy 
23 - 0.63 (0.32 – 1.24) 0.18 
 In situ 119 - 0.63 (0.46 – 0.86) 0.004 
 Missing* 20     
       
Grade Well differentiated 15 - 0.12 (0.02 – 0.87) 0.03 
 
Moderately 
differentiated 
38 - 0.61 (0.32 – 1.14) 0.12 
 
Poorly 
differentiated 
20 - 0.83 (0.40 – 1.71) 0.61 
 Undifferentiated 1 - 1.44e+14   (0.00 – inf) 1.00 
 Missing* 88 -    
       
Stage In situ 8 - 0.88 (0.29 – 2.66) 0.83 
 Localised 45 - 0.39 (0.21 – 0.70) 0.002 
 Metastatic 16 - 1.92 (0.74 – 4.97) 0.18 
 
Metastatic 
regional 
11 - 1.13 (0.45 – 4.22) 0.58 
 Metastatic distant 3 - 2,879 (0.00 – inf) 1.00 
 missing* 79 -    
       
*missing values category is omitted from the analyses 
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Table S4.2 – Association between global methylation and breast cancer risk factors 
Characteristic  p-value 
Center Florence  
 Varese 0.98 
 Ragusa 0.54 
 Turin 0.43 
 Naples 0.91 
Age at recruitment years 0.80 
Height cm 0.59 
Weight kg 0.16 
BMI  underweight 0.56 
 overweight 0.81 
 obese 0.25 
Physical activity moderately inactive 0.32 
 moderately active 0.08 
 active 0.09 
Smoking status former 0.08 
 current 0.35 
Educational level primary 0.83 
 technical/professional 0.91 
 secondary 0.95 
 college/university 0.65 
Alcohol consumption gr/d 0.89 
Folic acid intake µg/d 0.04 
Fat consumption gr/d 0.08 
Age at menarche  12-14 years 0.53 
 ≥15 years 0.49 
Age at menopause  years 0.02 
Menopausal state pre/post-menopausal 0.45 
Ever pregnant yes/no 0.94 
Age first birth years 0.94 
Parity 1 0.41 
 2 0.86 
 3 0.84 
 4 0.56 
 5 0.37 
Ever pill use yes/no 0,21 
Ever HRT use yes/no 0.47 
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Table S4.3 – Association between global methylation and breast cancer risk by CpG genomic feature per 1 SD 
   # CpG ORcrude (95% CI) p-value ORadj* (95% CI)* p-value* 
All  397,553 0.61 (0.46 - 0.80) 0.0003 0.63 (0.42 – 0.92) 0.02 
         
CpG Island Island 121,532 0.76 (0.58 – 0.99) 0.04 0.82 (0.56 – 1.18) 0.28 
 Shores 95,470 0.71 (0.55 – 0.92) 0.01 0.75 (0.53 – 1.08) 0.13 
 Shelves 37,865 0.49 (0.36 – 0.67) 5.90e-06 0.53 (0.35 – 0.79) 0.002 
 None 142,686 0.51 (0.38 – 0.68) 8.01e-06 0.54 (0.36 – 0.82) 0.004 
         
Regulatory feature  Gene   2,907 0.62 (0.47 – 0.83) 0.001 0.62 (0.42 – 0.93) 0.02 
category NonGene 1,212 0.79 (0.57 – 1.09) 0.15 0.83 (0.52 – 1.31) 0.42 
 Promoter 79,783 0.94 (0.65 – 1.34) 0.72 0.92 (0.56 – 1.53) 0.76 
 Unclassified 59,030 0.70 (0.53 – 0.92) 0.01 0.76 (0.52 – 1.10) 0.14 
 None 254,621 0.53 (0.39 – 0.71) 1.84e-05 0.57 (0.38 – 0.85) 0.006 
         
 Promoter 79,783 0.94 (0.65 – 1.34) 0.72 0.92 (0.56 – 1.53) 0.76 
 Other 317,770 0.57 (0.42 – 0.76) 0.0001 0.59 (0.40 – 0.87) 0.009 
         
Gene Region Feature  TSS1500 57,717 0.71 (0.54 – 0.94) 0.02 0.78 (0.54 – 1.13) 0.19 
category TSS200 42,434 0.93 (0.69 – 1.25) 0.64 1.00 (0.67 – 1.52) 0.97 
 5’UTR  35,756 0.72 (0.54 – 0.95) 0.02 0.82 (0.55 – 1.22) 0.33 
 1st exon 18,525 0.85 (0.65 – 1.11) 0.24 0.89 (0.62 – 1.28) 0.54 
 Body 134,724 0.51 (0.38 – 0.69) 1.57e-05 0.49 (0.31 – 0.76) 0.002 
 3’UTR 14,665 0.41 (0.29 – 0.58) 4.41e-07 0.37 (0.22 – 0.62) 0.0001 
         
Associated RNA  Coding 294,935 0.65 (0.50 – 0.84) 0.001 0.68 (0.47 – 0.98) 0.04 
Transcript NonCoding 8,886 0.59 (0.45 – 0.77) 0.0001 0.63 (0.43 – 0.92) 0.02 
 Intergenic 93,732 0.57 (0.43 – 0.75) 6.16e-05 0.64 (0.44 – 0.92) 0.02 
         
Repetitive elements Rmsk 70,365 0.50 (0.37 – 0.68) 1.02e-05 0.57 (0.38 – 0.85) 0.007 
 NoRmsk 327,188 0.63 (0.48 – 0.82) 0.0006 0.65 (0.45 – 0.95) 0.02 
         
Type of repetitive  Rmsk.Sat_SimRep 5,394 0.73 (0.56 – 0.95) 0.02 0.75 (0.52 – 1.08) 0.13 
element Rmsk.LTR 10,842 0.51 (0.38 – 0.69) 9.28e-06 0.58 (0.39 – 0.86) 0.007 
 Rmsk.LINE 18,671 0.52 (0.39 – 0.70) 1.12e-05 0.58 (0.40 – 0.86) 0.006 
 Rmsk.SINE 21,328 0.48 (0.35 – 0.65) 2.60e-06 0.50 (0.32 – 0.76) 0.001 
 Rmsk.OtherRep 14,130 0.72 (0.55 – 0.94) 0.02 0.77 (0.52 – 1.12) 0.17 
*Adjusted for menopausal status 
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Figure S5.1 Consensus CDF plot, delta area plot 
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Table S5.1 – 26 strongest associations from conditional logistic regression analysis between DNA methylation and breast cancer (n=324)  
after exclusion of cell type composition associated CpGs, sorted on effect size 
Target ID P-value 
raw 
P-value FDR 
adjusted* 
Effect size CHR 
 
Gene Functional region Relation to CGI 
cg17824939 7.30E-08 0.001481 -0.03809 12 C12orf50 5UTR  
cg12486486 9.04E-08 0.001495 -0.03787 4 YTHDC1 Body  
cg05455393 8.22E-09 0.001093 -0.03097 X FHL1 TSS1500 N_Shore 
cg18038361 1.25E-08 0.001093 -0.03050 18 TTR TSS1500  
cg03509901 1.01E-08 0.001093 -0.02767 17 NLK 1stExon S_Shore 
cg04798824 6.72E-08 0.001481 -0.02761 12 ANKS1B Body  
cg12847986 1.11E-07 0.001691 -0.02673 3 MECOM Body  
cg06531158 3.01E-08 0.001303 -0.02570 13 MIR548F5 Body  
cg17424007 8.42E-08 0.001481 -0.02469 1 MYOG TSS1500  
cg20235510 5.91E-09 0.001093 -0.02459 6 ZNF311 Body   
cg13140465 5.82E-08 0.001481 -0.02241 15 NIPA1 Body N_Shore 
cg16659470 1.37E-08 0.001093 -0.02208 8 RBM12B 3UTR  
cg05343548 2.31E-08 0.001303 -0.02176 20   N_Shore 
cg05567435 3.07E-08 0.001303 -0.02015 12 METTL7B TSS1500  
cg24504843 8.29E-08 0.001481 -0.01934 4 CEP135 3UTR  
cg10133171 4.86E-08 0.001410 -0.01871 4   N_Shore 
cg26772788 3.61E-08 0.001303 -0.01773 18   N_Shelf 
cg03338924 7.57E-08 0.001481 -0.01720 6 PHACTR1 Body Island 
cg04343242 8.25E-08 0.001481 -0.01611 4 BDH2 3UTR S_Shelf 
cg20640749 7.84E-08 0.001481 -0.01439 6 GLP1R 3UTR  
cg01341572 3.28E-08 0.001303 -0.01384 12 HNF1A TSS200 Island 
cg04599941 9.40E-08 0.001495 -0.01316 5 SEMA5A Body  
cg00962707 8.57E-08 0.001481 -0.01254 16   S_Shore 
cg23494338 4.11E-08 0.001362 -0.01106 10   N_Shore 
cg01836096 2.99E-08 0.001303 -0.00918 8 C8ORFK29 TSS200 S_Shore 
cg04187814 4.97E-08 0.001410 -0.00846 15 KIAA1199 5UTR   
*p-value adjusted for multiple testing using FDR 
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Table S5.2 – 20 strongest associations from logistic regression analysis between DNA methylation and breast cancer in pre-menopausal women  
(n=122), after exclusion of cell type composition associated CpGs, sorted on p-value 
Target ID p-value 
raw 
p-value FDR 
adjusted* 
CHR 
 
Gene Functional region Relation to CGI 
cg01341572 9.99E-05 0.62196 12 HNF1A TSS200 Island 
cg13318091 0.000131 0.62196 8 TRIM35 Body Island 
cg08204155 0.00018 0.62196 22 ZDHHC8 3UTR N_Shore 
cg15744963 0.000219 0.62196 15 HERC2 Body  
cg20749008 0.000223 0.62196 17 FLJ35220 TSS200 Island 
cg16533336 0.000224 0.62196 7 WBSCR17 Body  
cg10805645 0.000268 0.62196 14 RNASE11 5UTR  
cg20235510 0.000288 0.62196 6 ZNF311 Body  
cg01182973 0.000297 0.62196 22 ANKRD54 TSS1500 S_Shore 
cg01956472 0.000329 0.62196 6 MIR1275 TSS200  
cg05801872 0.000335 0.62196 6    
cg07026599 0.000364 0.62196 16 MAF TSS200 Island 
cg27508180 0.000385 0.62196 7 COL1A2 Body  
cg21662326 0.000387 0.62196 11 COPB1 TSS200  
cg24264674 0.000395 0.62196 11 LMO1 TSS200 S_Shore 
cg20277670 0.000396 0.62196 5 HRH2 Body  
cg12583199 0.000411 0.62196 10 RPS24 Body  
cg08240881 0.000419 0.62196 13    
cg14359606 0.000421 0.62196 2 SNED1 Body Island 
cg01836096 0.000438 0.62196 8 C8ORFK29 TSS200 S_Shore 
*p-value adjusted for multiple testing using FDR 
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Table S5.3 – 20 strongest associations from logistic regression analysis between DNA methylation and breast cancer in post-menopausal 
 women (n=199), after exclusion of cell type composition associated CpGs, sorted on p-value 
Target ID p-value 
raw 
p-value FDR 
adjusted* 
CHR 
 
Gene Functional region Relation to CGI 
cg05455393 6.95E-07 0.091914 X FHL1 TSS1500 N_Shore 
cg18038361 2.34E-06 0.091914 18 TTR TSS1500  
cg00771653 2.38E-06 0.091914 22 CHCHD10 TSS1500 S_Shore 
cg09356193 2.45E-06 0.091914 14 PACS2 Body N_Shore 
cg03338924 3.14E-06 0.091914 6 PHACTR1 Body Island 
cg13574945 3.40E-06 0.091914 X OTUD5 5UTR Island 
cg10488199 3.42E-06 0.091914 6 MIR133B Body  
cg16659470 3.63E-06 0.091914 8 RBM12B 3UTR  
cg15149117 3.83E-06 0.091914 11 OR52H1 TSS1500  
cg03509901 4.38E-06 0.091914 17 NLK 1stExon S_Shore 
cg11718780 4.48E-06 0.091914 1 CAMSAP1L1 Body  
cg01264298 4.54E-06 0.091914 6    
cg10133171 5.04E-06 0.091914 4   N_Shore 
cg12486486 5.42E-06 0.091914 4 YTHDC1 Body  
cg09912005 5.44E-06 0.091914 4 ADAD1 5UTR Island 
cg04798824 6.12E-06 0.091914 12 ANKS1B Body  
cg14580443 6.70E-06 0.091914 9 FGD3 TSS1500  
cg17377797 6.88E-06 0.091914 12 OR6C1 TSS200  
cg20460388 7.02E-06 0.091914 12 IRAK4 3UTR  
cg20235510 7.09E-06 0.091914 6 ZNF311 Body  
*p-value adjusted for multiple testing using FDR
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Table S7.1 – Overlap in CpGs for the different PCB exposures (entire cohort) 
 
pcb118 pcb138 pcb153 pcb156 pcb170 pcb180 
cg00164941 
 
x x 
   cg00664205 
  
x 
 
x 
 cg00679711 
 
x x 
   cg01006802 
   
x x 
 cg01917721 
 
x x x x x 
cg02197228 
 
x 
 
x x 
 cg02339793 x 
 
x x 
  cg02340915 
 
x x 
 
x x 
cg03226114 
   
x x 
 cg03490288 
 
x x 
   cg03868770 
    
x x 
cg04065108 
 
x x x x x 
cg04380332 
 
x x x x 
 cg04741128 
 
x x 
 
x x 
cg05240017 
  
x x x 
 cg05404009 
    
x x 
cg05585176 
   
x x 
 cg06080252 
 
x x 
   cg06202802 
    
x x 
cg06214869 
 
x x 
 
x x 
cg06814191 x x 
    cg07020540 
  
x 
 
x 
 cg07338983 
 
x x 
  
x 
cg07916967 
    
x x 
cg07996880 
   
x x x 
cg08108188 
   
x x 
 cg08537751 
    
x x 
cg08710410 
 
x x 
   cg09029959 
 
x x 
   cg09135343 x 
  
x 
  cg09252377 
 
x x 
   cg09259053 
 
x x 
   cg09828010 
 
x x 
   cg09959242 
   
x x 
 cg10172801 
 
x x 
   cg10331500 
    
x x 
cg10572858 
  
x x x 
 cg11058576 
 
x x 
   cg11097842 
    
x x 
cg11422092 
  
x 
  
x 
cg13482814 
 
x x 
   cg13594655 
    
x x 
cg13976370 
   
x x x 
cg14165766 
 
x x 
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cg14243496 
 
x x 
   cg14638957 
 
x x 
   cg14729175 
 
x x 
   cg15603964 
 
x x x x 
 cg15921606 
    
x x 
cg16206480 
 
x x 
   cg16505764 
    
x x 
cg17295053 
    
x x 
cg17341118 
    
x x 
cg17578380 
  
x 
 
x x 
cg17878351 
  
x x x x 
cg18370102 
    
x x 
cg19016171 
    
x x 
cg19024381 
 
x x x 
  cg20107840 
  
x 
 
x x 
cg20201402 
   
x x x 
cg20332088 
 
x x 
   cg20901426 
   
x x 
 cg21216543 
 
x x x x x 
cg21517309 
 
x x 
   cg23427362 
   
x x 
 cg23548670 
    
x x 
cg23625823 
  
x x x x 
cg25756003 
 
x x 
 
x x 
cg25844605 x x 
    cg25868793 
 
x x 
   cg26525091 
 
x x 
    
 
204 
 
Table S7.2 – 62 strongest associations from logistic regression analysis between cadmium exposure levels in blood and genome-wide DNA methylation  
(n=324), after exclusion of cell type composition associated CpGs, sorted on effect size estimate 
Target ID p-value crude p-value FDR 
adjusted* 
Estimate CHR Gene name Functional region Relation to CGI 
cg05575921 9.04E-46 3.44E-40 -0.06610 5 AHRR Body N_Shore 
cg05951221 3.70E-33 7.03E-28 -0.04556 2   Island 
cg03636183 1.29E-30 1.63E-25 -0.03965 19 F2RL3 Body N_Shore 
cg01940273 4.24E-28 4.03E-23 -0.04553 2   Island 
cg21161138 4.80E-27 3.65E-22 -0.02719 5 AHRR Body  
cg26703534 2.14E-21 1.36E-16 -0.02165 5 AHRR Body S_Shelf 
cg25648203 2.71E-21 1.47E-16 -0.02050 5 AHRR Body  
cg19859270 6.30E-21 3.00E-16 -0.01033 3 GPR15 1stExon  
cg03329539 1.01E-19 4.26E-15 -0.02088 2   N_Shore 
cg06126421 2.42E-19 9.18E-15 -0.03979 6    
cg14817490 1.06E-18 3.68E-14 -0.02693 5 AHRR Body  
cg15342087 1.74E-18 5.51E-14 -0.01576 6    
cg25189904 2.82E-17 8.23E-13 -0.03717 1 GNG12 TSS1500 S_Shore 
cg12803068 5.61E-15 1.52E-10 0.04792 7 MYO1G Body S_Shore 
cg22132788 1.12E-14 2.85E-10 0.02825 7 MYO1G Body Island 
cg20295214 5.54E-14 1.32E-09 -0.01454 1 AVPR1B Body S_Shelf 
cg24859433 1.55E-13 3.47E-09 -0.01369 6    
cg21611682 2.59E-13 5.47E-09 -0.01451 11 LRP5 Body  
cg12806681 3.62E-13 6.95E-09 -0.01054 5 AHRR Body N_Shore 
cg23576855 3.84E-13 6.95E-09 -0.06902 5 AHRR Body N_Shore 
cg27241845 3.84E-13 6.95E-09 -0.01722 2   N_Shore 
cg09935388 6.45E-13 1.11E-08 -0.03092 1 GFI1 Body Island 
cg08709672 4.80E-12 7.94E-08 -0.01417 1 AVPR1B 5UTR S_Shore 
cg03991871 1.84E-11 2.91E-07 -0.01712 5 AHRR Body N_Shore 
cg23916896 2.32E-11 3.53E-07 -0.02627 5 AHRR Body N_Shore 
cg12876356 2.56E-11 3.75E-07 -0.02040 1 GFI1 Body Island 
cg19572487 8.36E-11 1.17E-06 -0.02224 17 RARA 5UTR S_Shore 
cg02657160 8.62E-11 1.17E-06 -0.00983 3 CPOX Body N_Shore 
cg11902777 9.47E-11 1.24E-06 -0.00823 5 AHRR Body N_Shore 
cg18146737 1.71E-10 2.17E-06 -0.01219 1 GFI1 Body Island 
cg11207515 2.13E-10 2.62E-06 0.02158 7 CNTNAP2 Body  
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cg18316974 6.10E-10 7.24E-06 -0.00986 1 GFI1 Body Island 
cg19089201 1.12E-09 1.29E-05 0.02265 7 MYO1G 3UTR Island 
cg13184736 1.29E-09 1.44E-05 -0.02968 1 GNG12 TSS1500 S_Shore 
cg04885881 1.53E-09 1.66E-05 -0.01836 1   S_Shelf 
cg20059012 1.58E-09 1.67E-05 -0.02607 12 RARG Body N_Shore 
cg02637282 1.74E-09 1.79E-05 0.01610 12    
cg18754985 2.98E-09 2.96E-05 -0.00543 3 CLDND1 Body N_Shelf 
cg13039251 3.03E-09 2.96E-05 0.02173 5 PDZD2 Body  
cg23161492 4.60E-09 4.37E-05 -0.02156 15 ANPEP 5UTR N_Shore 
cg26963277 5.03E-09 4.67E-05 -0.01059 11 KCNQ1OT1 TSS1500 S_Shore 
cg16219322 5.99E-09 5.38E-05 -0.00805 5 AHRR Body  
cg04180046 6.08E-09 5.38E-05 0.02352 7 MYO1G Body Island 
cg11660018 6.32E-09 5.46E-05 -0.01723 11 PRSS23 TSS1500 N_Shore 
cg24049493 1.09E-08 9.07E-05 0.02660 1 HIVEP3 TSS1500 S_Shore 
cg26361535 1.10E-08 9.07E-05 -0.01719 8 ZC3H3 Body  
cg17287155 1.15E-08 9.32E-05 -0.01239 5 AHRR Body  
cg07178945 1.30E-08 0.000103 0.01313 12 FGF23 5UTR  
cg07123182 1.77E-08 0.000138 -0.00568 11 KCNQ1OT1 TSS1500 S_Shore 
cg02451831 2.52E-08 0.000192 -0.01000 7 KIAA0087 Body  
cg08035323 2.67E-08 0.000199 0.01669 2    
cg08595501 2.88E-08 0.000210 -0.01735 5 IQGAP2 Body  
cg26764244 3.15E-08 0.000222 -0.01614 1 GNG12 TSS1500 S_Shore 
cg03274391 3.16E-08 0.000222 0.03759 3   N_Shore 
cg25949550 4.55E-08 0.000315 -0.00801 7 CNTNAP2 Body S_Shore 
cg23771366 5.36E-08 0.000364 -0.01521 11 PRSS23 TSS1500 N_Shore 
cg23973524 5.90E-08 0.000394 0.01699 19 CRTC1 Body Island 
cg04551776 6.06E-08 0.000397 -0.01282 5 AHRR Body  
cg27537125 8.40E-08 0.000542 -0.00932 1    
cg21756476 9.09E-08 0.000576 0.01432 15 RORA Body  
cg11229399 9.51E-08 0.000593 0.00803 1    
cg23480021 1.03E-07 0.000631  3   N_Shore 
*p-value adjusted for multiple testing using
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Table S7.3 – Lifestyle variables associated (p-value<1.03e-05) with DNA methylation 
Variable Affected CpG p-value Estimate CHR 
Gene 
name 
Functional 
region 
Relation 
to CGI 
Obesity cg09610891 6.71e-07 0.0045 16    
        
Smoker cg05575921* 5.64e-39 -0.1402 5 AHRR Body N_shore 
 cg03636183* 1.50e-26 -0.0991 19 F2RL3 Body N_shore 
 cg01940273* 1.84e-22 -0.0919 2   Island 
 cg05951221 4.29e-19 -0.0921 2   Island 
 cg26703534 1.57e-17 -0.0547 5 AHRR Body S_Shelf 
 cg06126421* 1.20e-16 -0.1101 6    
 cg21161138* 1.20e-16 -0.0656 5 AHRR Body  
 cg09935388 9.62e-10 -0.0861 1 GFI1 Body Island 
 cg24859433* 3.42e-09 -0.0305 6    
 cg25949550 5.75e-08 -0.0234 7 CNTNAP2 Body S_shore 
 cg14817490* 1.45e-07 -0.0526 5 AHRR Body  
 cg25648203 2.85e-07 -0.0405 5 AHRR Body  
 cg11660018 7.15e-07 -0.0508 11 PRSS23 TSS1500 N_shore 
 cg19859270 8.36e-07 -0.0155 3 GPR15 1st Exon  
 cg23576855 8.72e-07 -0.1885 5 AHRR Body N_shore 
 cg13193840 1.40e-06 -0.0248 2   Island 
 cg23771366 3.68e-06 -0.0482 11 PRSS23 TSS1500 N_shore 
 cg01692968 4.14e-06 -0.0551 9   N_shore 
 cg21611682 6.89e-06 -0.0329     
 cg03329539 9.41e-06 -0.0485 2   N_shore 
        
Fat cg16150307 5.56e-06 0.000083 4    
consumption cg00676269 7.23e-06 0.000096 22   N_shore 
 cg01490821 8.74e-06 -0.000086 2 UBR3 1st Exon Island 
*Also associated (p-value<1.03e-05) among former smokers 
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Table S7.4 – Reproductive variables associated (p-value<1.03e-05) with DNA methylation 
Variable Affected CpG p-value Estimate CHR Gene name 
Functional 
region 
Relation 
to CGI 
Age at cg26523005 6.20e-07 0.0081 3 ZNF662 TSS1500 N_shore 
menarche cg27483455 1.75e-06 0.0021 12 ACCN2 Body Island 
(continuous) cg26791488 2.47e-06 -0.0020 16 USP7 Body  
 cg01388757 3.42e-06 0.0031 2 RFX8 TSS200 S_shore 
 cg11764966 3.45e-06 0.0023 20 WFDC10A TSS200  
 cg10903132 4.20e-06 0.0017 10    
 cg02919030 4.42e-06 0.0023 12 KITLG Body Island 
 cg02295509 5.97e-06 -0.0039 17    
 cg02610550 7.75e-06 -0.0032 13 KLF12 TSS1500 Island 
        
Age at 
menopause 
cg01223071 9.33e-06 0.0299 11    
        
Reproductive 
years 
cg01450274 9.95e-06 0.0015 3 PLD1 Body  
        
Ever pregnant cg11491504 5.38e-07 0.0129 5 UNC5A Body  
 cg03861532 3.99e-06 0.0128 20 PMEPA1 5’UTR  
 cg01966425 5.21e-06 -0.0848 6 PSORS1C1 5’UTR  
        
Ever liveborn cg04058752 4.56e-07 0.0652 11 B3GNT6 Body Island 
 cg14182693 3.04e-06 0.0171 1 GPATCH3 Body N_shelf 
        
Number of cg23908407 3.67e-07 0.0016 17 CSNK1D Body N_shore 
liveborn cg24027061 8.41e-07 0.0042 14   N_shore 
 cg01726880 4.34e-06 0.0061 16 TMPRSS8 TSS1500 S_shore 
 cg24842753 5.83e-06 -0.0114 5    
 cg03236180 9.65e-06 -0.0019 10 SGMS1 TSS200 Island 
        
Age first cg27621747 5.50e-06 -0.0046 X RGAG1 Body  
liveborn cg23816737 8.35e-06 -0.0012 6 TULP4 1st Exon  
 cg11391462 9.68e-06 -0.0009 1 LOC648740 Body  
 cg19781814 9.70e-06 -0.0013 5 SPEF2 Body  
        
Age second cg18004003 2.60e-06 -0.0012 13 SPERT Body  
liveborn cg26331122 2.71e-06 -0.0015 4 CTBP1 Body Island 
 cg23540272 5.01e-06 0.0070 14    
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 cg14508904 6.21e-06 0.0013 11 ZNF143 TSS200 Island 
 cg20980494 6.43e-06 -0.0017 1    
 cg24063470 6.90e-06 0.0013 16 FOXC2 TSS1500 Island 
 cg02839029 9.53e-06 -0.0017 17 BAIAP2 Body Island 
 cg09306577 9.72e-06 0.0005 1 MFN2 5’UTR S_shore 
 cg02443062 1.01e-05 0.0004 6 RPL10A TSS200 Island 
        
Age third ch.9.2473665R     2.41e-06 0.0012 9 PMPCA Body N_shore 
liveborn cg00067588 4.67e-06 0.0025 10    
 cg03793778 5.94e-06 0.0039 19 LGALS7 TSS1500 S_shelf 
 cg24659216 9.44e-06 0.0014 19 ZNF416 TSS200 Island 
        
Age last cg08096062 1.41e-06 -0.0336 2 CCDC85A TSS1500 N_Shore 
liveborn cg00731917 7.21e-06 0.0096 18   Island 
 cg25178565 7.40e-06 -0.0080 10 PIP4K2A Body  
 cg12623045 8.85e-06 -0.0094 10    
 
  
209 
 
Table S7.5 – Hormone related variables associated (p-value<1.03e-05) with DNA methylation 
Variable Affected CpG p-value Estimate CHR 
Gene 
name 
Functional 
region 
Relation 
to CGI 
Breastfeeding cg13430898 2.12e-06 -0.0092 9    
after 1st cg16030751 3.51e-06 -0.0075 13 ZMYM2 Body  
pregnancy cg22871298 6.65e-06 -0.0105 14    
        
Breastfeeding cg06531176 3.18e-06 0.0052 5 TERT Body Island 
after 2nd cg12069158 3.27e-06 -0.0074 14    
pregnancy cg13665025 7.03e-06 0.0111 17 RPRML TSS1500 Island 
 cg26683361 1.00e-05 -0.0214 22    
        
Breastfeeding cg19847038 2.27e-06 0.0322 3 ARL13B Body  
after 3rd cg08693337 7.30e-06 0.0282 17 NT5M Body S_Shore 
pregnancy cg16135995 8.24e-06 -0.0107 7 RFC2 TSS200 Island 
        
Duration 
       
breastfeeding 
2nd pregnancy 
cg27024992 5.15e-06 -0.000077 2 FBXO11  ’UTR  
        
Duration 
       
breastfeeding 
3rd pregnancy 
cg00607755 7.49e-06 -0.0004 2 PKDCC TSS1500 
 
        
Total        
duration 
breastfeeding 
cg26230320 3.38e-06 -0.000018 4   S_shore 
        
Ever pill use cg13226362 3.43e-06 -0.0104 18 CTDP1 Body S_shore 
        
Age first pill cg00831970 2.30e-07 -0.0014 1 FCGR2B  ’UTR  
use cg01532487 2.37e-07 -0.0029 1   N_shore 
 cg00838397 2.18e-06 -0.0008 10 HKDC1 Body  
 cg23152572 3.55e-06 -0.0006 10 PHYH Body  
 cg19840133 5.67e-06 0.0064 X TIMM17B Body Island 
 cg05202068 6.17e-06 -0.0015 4    
        
Current HRT cg13768445 8.05e-08 0.6751 9 SLC28A3 TSS1500  
use cg14767647 1.93e-06 0.0459 6 NUP153 TSS1500 Island 
 cg20287230 9.54e-06 0.0896 14 MIR543 TSS200  
 cg24642064 9.96e-06 0.0635 1 PRDM16 Body S_shore 
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Age start HRT cg22484980 3.98e-06 -0.0035 11 TPCN2 TSS1500 N_shore 
 cg07622493 7.86e-06 -0.0059 8   Island 
 cg04516022 9.19e-06 0.0050 7   N_shore 
 cg01833143 9.25e-06 -0.0022 8 RSPO2 Body N_shore 
        
Duration HRT cg22353823 5.50e-06 -0.0199 12    
 cg00695324 7.47e-06 -0.0140 X TEX13B  TSS1500 
        
Ever cg17986469 2.05e-06 0.0084 10 SEC24C  ’UTR N_shore 
hysterectomy cg08966413 9.80e-06 0.0129 16 USP31 Body  
        
Every ovary cg17213074 3.72e-06 0.0529 8 SNX31  ’UTR  
surgery cg24053375 4.49e-06 -0.0083 10 RBP3 TSS1500 S_shelf 
 cg26906642 9.17e-06 -0.0145 16 SMPD3  ’UTR  
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Table S7.6 – Hormone levels in blood associated (p-value<1.03e-05) with DNA methylation 
Variable Affected CpG p-value Estimate CHR Gene name 
Functional 
region 
Relation 
to CGI 
C-peptide cg20213508 1.15e-06 0.0232 20 GNAS 3UTR N_Shore 
        
IGF-1 cg08453926 2.31e-07 0.0002 13 WASF3 TSS200 Island 
 cg00984474 6.54e-07 0.0002 5 C5orf49 Body N_Shore 
 cg18057126 8.42e-07 0.0002 19 ZNF347 5UTR Island 
 cg04656757 8.75e-07 -0.00008 16 CMIP Body  
 cg07427945 9.18e-07 0.0001 17 SP2 5UTR Island 
 cg13088368 1.01e-06 0.0001 20 TOX2 TSS200 Island 
 cg00860379 1.19e-06 0.0002 15   Island 
 cg24923509 3.58e-06 0.0002 10   N_Shore 
 cg23335460 3.78e-06 0.0003 10 CRTAC1 TSS200 Island 
 cg26076750 3.81e-06 0.0001 5 RGMB 5UTR Island 
 cg27267377 4.72e-06 -0.0001 8    
 cg25457956 5.45e-06 0.0002 11 BDNF TSS200 Island 
 cg01431908 5.96e-06 0.0001 1 C1orf190 TSS200 Island 
 cg18051798 6.20e-06 -0.0002 12 LETMD1 3UTR  
 cg04475027 6.41e-06 0.0003 12 TMEM132C Body Island 
 cg17420078 7.11e-06 0.0002 4   Island 
 cg02019774 7.26e-06 0.00007 3   Island 
 cg03732762 7.41e-06 0.0001 21 OLIG1 1stExon Island 
 cg03607359 8.39e-06 0.0001 5 SNCB 5UTR Island 
 cg25841608 8.49e-06 0.0002 3   Island 
 cg13788479 8.53e-06 0.0001 15 CSPG4 TSS200  
 cg03304610 9.33e-06 0.0002 4 GALNTL6 TSS1500 Island 
 cg08217227 9.33e-06 0.0001 5 GHR TSS1500 Island 
 cg23470850 9.47e-06 0.0001 17 C17orf93 TSS200 N_Shore 
 cg01566526 9.49e-06 0.0003 3 ALDH1L1 5UTR Island 
 cg20062401 9.60e-06 0.00009 17 MYOCD TSS200 Island 
 cg15060366 9.90e-06 0.0002 20 PCSK2 TSS1500 Island 
        
Testosterone cg02143936 8.57e-09 0.0002 11 MICAL2 3UTR  
 cg19026811 6.68e-08 0.0017 17 CCDC103 3UTR S_Shelf 
 cg11318906 1.79e-07 0.0009 3 H1FX 1stExon Island 
 cg13680188 3.12e-07 -0.0006 8 GATA4 TSS1500 Island 
 cg25080256 1.62e-06 0.0006 2 GALNT14 Body  
 cg18367529 3.03e-06 -0.0005 1 SDF4 Body N_Shore 
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 cg26889226 4.03e-06 -0.0003 17 NEURL4 Body S_Shelf 
 cg10774282 4.89e-06 -0.0001 1 SLC1A7 1stExon  
 cg10736303 7.22e-06 -0.0007 7 PTPRN2 Body  
        
DHEAS cg02143936 1.18e-06 -0.0005 11 MICAL2 3UTR  
        
SHGB cg18749097 1.85e-06 0.0013 21   N_shelf 
 cg07505680 2.78e-06 0.0005 8 KBTBD11 5UTR  
 cg21719937 4.32e-06 0.0004 12 NTF3 Body  
        
D4 cg14498674 4.42e-17 0.0559 1 SCMH1 5UTR Island 
 cg17030628 2.08e-15 -0.0621 1 IL20 TSS200  
 cg16992599 2.92e-14 -0.0709 15   N_Shore 
 cg23240231 7.44e-13 -0.0324 3   S_Shelf 
 cg24808162 7.70e-13 -0.0730 1 PTPRF Body N_Shelf 
 cg03751055 1.28e-12 -0.0386 10 MGMT Body  
 cg10481534 2.06e-12 -0.0237 15 PARP6 3UTR  
 cg26455386 2.91e-12 -0.0239 17 MPRIP Body  
 cg04517258 4.16e-12 -0.0307    8      LOC100133669          Body  
 cg05337637 5.30e-12 -0.0265 9 NDOR1 3UTR N_Shore 
   cg19484164 5.47e-12 -0.0284 13 ATP11A Body Island 
 cg00699919 5.92e-12 -0.0261 1 GPR161 Body  
 cg11441533 6.03e-12 -0.0239 12 SRGAP1 Body  
 cg12381164 7.71e-12 0.0093 4 SLC39A8 1stExon Island 
 cg26516080 7.71e-12 -0.0299 12 FAM101A 5UTR N_Shelf 
 cg20051314 1.02e-11 -0.0318 11 LRRN4CL 5UTR S_Shore 
 cg17464043 1.64e-11 -0.0215 17 KRT39 Body  
 cg18283386 2.33e-11 0.0436 8 GATA4 1stExon Island 
 cg00356251 5.06e-11 -0.0308 7 PTPRN2 Body  
 cg01942797 5.49e-11 -0.0319 7   N_Shore 
 cg00894344 6.48e-11 -0.0380 13 COL4A2 Body N_Shore 
 cg00549798 7.19e-11 -0.0269 22 MKL1 Body N_Shore 
 cg07928060 8.90e-11 -0.0373 19   N_Shelf 
 cg18376999 1.33e-10 -0.0208 22   S_Shelf 
 cg09392911 1.70e-10 -0.0245 6 ASCC3 3UTR  
 cg25059408 1.71e-10 -0.0326 22   N_Shelf 
 cg01751917 2.69e-10 -0.0311 8 GPR124 Body S_Shelf 
 cg02607124 4.53e-10 -0.0376 8 SLC45A4 Body N_Shore 
 cg24136932 5.15e-10 -0.0334 8 SLC39A14 Body  
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 cg09379492 6.60e-10 -0.0183 10 FAM53B Body  
 cg21010995 6.92e-10 -0.0219 1 NPHP4 Body  
 cg00302587 1.51e-09 -0.0238 10 NCOA4 TSS200 S_Shelf 
 cg03347095 2.37e-09 -0.0103 7 PTPRN2 Body  
 cg20158826 6.29e-09 -0.0390 11 CCDC87 1stExon N_Shore 
 cg24675983 6.79e-09 -0.0375 12   S_Shelf 
 cg22148138 1.21e-08 0.0354 19 BCL2L12 Body S_Shore 
 cg22814023 1.25e-08 -0.0189 6 OR2H2 1stExon  
 cg13372003 1.66e-08 -0.0266 11 NAV2 3UTR  
 cg20481110 1.83e-08 -0.0138 17 SECTM1 5UTR  
 cg14747498 1.94e-08 -0.0348 8 JRK Body  
 cg26340725 2.13e-08 -0.0312 4    
 cg01592350 2.83e-08 -0.0408 2   S_Shelf 
 cg27030352 2.88e-08 -0.0217 18    
 cg16027775 3.01e-08 0.0569 3 MGLL Body  
 cg13008301 3.86e-08 -0.0077 20 CSTF1 Body Island 
 cg06843231 4.45e-08 -0.0195 5 PDZD2 Body  
 cg20039257 4.61e-08 -0.0084 8 NCALD 5UTR  
 cg11893488 5.60e-08 -0.0223 13 COL4A2 Body  
 cg00257187 6.48e-08 -0.0218 10 PANK1 Body N_Shelf 
 cg23261327 9.19e-08 0.0315 17 BAIAP2 Body N_Shore 
 cg17850642 9.52e-08 -0.0328 12 KRT74 TSS200  
 cg14594295 9.53e-08 -0.0303 4 DOK7 Body S_Shelf 
 cg05499376 9.89e-08 -0.0213 5 COL23A1 Body S_Shore 
 cg12608565 1.01e-07 0.0195 17 CHRNE Body Island 
 cg00534343 1.58e-07 -0.0222 11 ABTB2 Body  
 cg04878159 2.14e-07 -0.0456 17   N_Shelf 
 cg12370606 3.00e-07 0.0099 4 C4orf19 TSS1500 N_Shore 
 cg21381525 3.28e-07 -0.0065 10 NSUN6 Body  
 cg12797157 3.55e-07 -0.0129 11 CCDC88B Body S_Shelf 
 cg22295658 4.55e-07 -0.0212 8 BMP1 Body  
 cg06013395 4.57e-07 -0.0275 3 EPHB3 Body Island 
 cg01998806 4.64e-07 -0.0148 11 CCDC88B Body S_Shelf 
 cg01276536 5.06e-07 0.0240 17 BAIAP2 Body N_Shore 
 cg03347050 5.37e-07 0.0089 4 SNHG8 Body S_Shore 
 cg19714454 7.17e-07 -0.0073 2 HDAC4 Body  
 cg06539629 8.28e-07 -0.0450 10 PLCE1 TSS1500 N_Shore 
 cg08118273 9.34e-07 0.0048 4 SLC39A8 TSS200 Island 
 cg01801610 9.42e-07 -0.0250 14    
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 cg19471466 1.19e-06 0.0558 1   Island 
 cg09973852 1.36e-06 0.0060 16 SEPHS2 1stExon Island 
 cg17090593 1.49e-06 0.0181 2 EMX1 TSS200 Island 
 cg13129833 1.70e-06 -0.0110 1 PDE4DIP Body  
 cg17031967 2.25e-06 -0.0286 6 LRRC16A Body  
 cg11592634 2.49e-06 0.0450 19 SH3GL1 Body N_Shore 
 cg12805491 3.19e-06 -0.0293 1 PAQR7 TSS1500 N_Shelf 
 cg03859846 3.60e-06 -0.0125 13 RASA3 Body N_Shelf 
 cg21775007 4.00e-06 0.0137 8 TDH Body Island 
 cg14584177 4.19e-06 -0.0277 6 OR11A1 1stExon  
 cg08074182 4.35e-06 -0.0039 16 LMF1 Body S_Shore 
 cg00490203 6.80e-06 -0.0103 11 CCDC88B Body S_Shelf 
 cg24881202 6.94e-06 0.0103 1 FBXO6 5UTR S_Shore 
 cg09906857 8.31e-06 -0.0286 16   S_Shelf 
 cg26303934 8.65e-06 0.0122 7 C7orf50 Body Island 
        
E1 cg09187107 2.26e-06 -0.0013 17 FLJ90757 Body N_Shore 
 cg18001714 2.36e-06 0.0026 5 ANKH TSS200 N_Shore 
 cg08454507 2.42e-06 -0.0013 17 RPTOR Body  
 cg04083966 3.54e-06 -0.0020 1 MYBPH 1stExon  
 cg04021887 4.14e-06 -0.0008 2 HPCAL1 3UTR Island 
 cg19976235 4.86e-06 -0.0008 14 OTX2 5UTR N_Shore 
 cg23203918 6.48e-06 -0.0020 8    
 cg24876644 6.81e-06 -0.0026 1 MYBPH 3UTR  
 cg08677954 6.93e-06 -0.0010 6 BAT2 Body  
 cg18244487 9.64e-06 -0.0011 4 MFSD7 Body N_Shore 
 cg12030031 9.85e-06 0.0001 6 LOC285780 Body  
        
E2 cg24500711 1.58e-06 -0.0003 21 KRTAP13-3 TSS1500  
 cg12175949 1.60e-06 0.0007 22 TXNRD2 1stExon Island 
 cg09187107 3.04e-06 -0.0008 17 FLJ90757 Body N_Shore 
 cg17701336 6.30e-06 0.0005 19 FBL Body N_Shore 
 cg06034263 8.40e-06 -0.0011 3   S_Shore 
        
Progesterone cg26416766 1.81e-06 0.0036 13   S_Shelf 
 cg11034626 2.10e-06 -0.0034 6 RSPH9 TSS200 Island 
 cg25571184 7.60e-06 -0.0013 12 METTL1 TSS1500 Island 
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van Veldhoven K, Polidoro S, Campanella G, Sacerdote C, Panico S, Mattiello A, Palli D, Masala G, 
Krogh V, Agnoli C, Tumino R, Frasca G, Chadeau-Hyam M, Flanagan JM, Vineis P. Epigenome-
Wide Association Study in the European Prospective Investigation into Nutrition and Cancer 
(EPIC-Italy) cohort reveals decreased average methylation levels years before breast cancer 
diagnosis. Submitted to Lancet oncology 
 
 
Background: Interest in the potential of DNA methylation in peripheral blood as a biomarker of 
cancer risk is increasing. Most previous studies had limitations in study design and 
methodologies. We aimed to assess whether epigenome-wide DNA methylation levels measured 
in peripheral blood samples obtained before onset of the disease are associated with increased 
risk of breast cancer. 
 
Methods: This nested case-control study was part of the Italian cohort of the European 
Prospective Investigation into Cancer and Nutrition (EPIC) study. Average follow-up was 106.8 
months. Since recruitment (1993), 32,157 female volunteers from the general population have 
been included in the study. From these, 164 female incident breast cancer cases (identified 
through cancer registries) and 164 healthy female controls (matched on date of birth, date of 
recruitment, study centre) were randomly selected. All participants had detailed baseline 
questionnaire information on lifestyle, blood samples and anthropometric measurements at 
enrolment. The Illumina HM450 DNA methylation array was used to measure methylation 
levels (β values) at 485,577 cytosines across the genome. Mean β values over all probes were 
calculated as a measurement for epigenome-wide methylation. These values were divided into 
quartiles and compared between cases and controls using conditional logistic regression, 
adjusting for potential confounding factors. In addition, methylation differences were analysed 
based on the observed median in each quartile. Methylation levels at specific classes of CpG sites 
were also assessed. 
 
Findings: Both quartiles of methylation and the pseudo-continuous variable showed a 
statistically significant association between decreasing methylation and an increase in future 
breast cancer risk (OR for 1 SD change 0.52, 95% C.I. 0.37 – 0.72). Moreover, hypomethylation 
in breast cancer cases was observed in CpG island shores (OR 0.60, 95% C.I. 0.43 – 0.83), 
shelves (OR 0.50, 95% C.I. 0.37 – 0.70), and outside these regions (OR 0.58, 95% C.I. 0.43 – 
0.79), but not in islands. Furthermore, hypomethylation at other locations, including repetitive 
elements, was associated with breast cancer risk. 
 
Interpretation: Results indicate that epigenome-wide hypomethylation measured in pre-
diagnostic blood samples may be predictive of breast cancer risk and may thus be useful as a 
clinical biomarker. 
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van Veldhoven K, Rahman S, Vineis P. 2013. Epigenetics and epidemiology: models of study and 
examples. In: V. Zappia. Advances in nutrition and cancer. Berlin: Springer (ahead of print). 
Ch.14 
 
 
Book chapter – no abstract available 
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Vineis P, van Veldhoven K, Chadeau-Hyam M, Athersuch TJ. Advancing the application of omics-
based biomarkers in environmental epidemiology. Environ Mol Mutagen. 2013 Aug;54(7):461-7 
 
The use of omics represents a shift in approach for environmental epidemiology and exposure 
science. In this article, the aspects of the use of omics that will require further development in 
the near future are discussed, including (a) the underlying causal interpretation and models; (b) 
the “meet-in-the-middle” concept, with examples; (c) the role of “calibration” of measurements; 
and (d) the role of life-course epidemiology and the related development of adequate 
biostatistical models.  
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Shenker NS, Polidoro S, van Veldhoven K, Sacerdote C, Ricceri F, Birrell MA et al. Epigenome-
wide association study in the European Prospective Investigation into Cancer and Nutrition 
(EPIC-Turin) identifies novel genetic loci associated with smoking. Human Molecular Genetics. 
2013;22(5):843-51 
 
 
A single cytosine–guanine dinucleotide (CpG) site within coagulation factor II (thrombin) 
receptor-like 3 (F2RL3) was recently found to be hypomethylated in peripheral blood genomic 
DNA from smokers compared with former and non-smokers. We performed two epigenome-
wide association studies (EWAS) nested in a prospective healthy cohort using the Illumina 450K 
Methylation Beadchip. The two populations consisted of matched pairs of healthy individuals (n 
5 374), of which half went on to develop breast or colon cancer. The association was analysed 
between methylation and smoking status, as well as cancer risk. In addition to the same locus in 
F2RL3, we report several loci that are hypomethylated in smokers compared with former and 
non-smokers, including an intragenic region of the aryl hydrocarbon receptor repressor gene 
(AHRR; cg05575921, P 5 2.31 3 10215; effect size 5 14–17%), an intergenic CpG island on 
2q37.1 (cg21566642, P 5 3.73 3 10213; effect size 5 12%) and a further intergenic region at 
6p21.33 (cg06126421, P 5 4.96 3 10211, effect size 5 7–8%). Bisulphite pyrosequencing 
validated six loci in a further independent population of healthy individuals (n 5 180). 
Methylation levels in AHRR were also significantly decreased (P < 0.001) and expression 
increased (P 5 0.0047) in the lung tissue of current smokers compared with non-smokers. This 
was further validated in a mouse model of smoke exposure. We observed an association with 
breast cancer risk for the 2q37.1 locus (P 5 0.003, adjusted for the smoking status), but not for 
the other loci associated with smoking. These data show that smoking has a direct effect on the 
epigenome in lung tissue, which is also detectable in peripheral blood DNA and may contribute 
to cancer risk. 
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Herceg Z, Lambert MP, van Veldhoven K, Demetriou C, Vineis P, Smith MT et al. Towards 
incorporating epigenetic mechanisms into carcinogen identification and evaluation. 
Carcinogenesis. 2013;34(9):1955-67 
 
 
 
Remarkable progress in the field of epigenetics has turned academic, medical and public 
attention to the potential applications of these new advances in medicine and various fields of 
biomedical research. The result is a broader appreciation of epigenetic phenomena in the 
etiology of common human diseases, most notably cancer. These advances also represent an 
exciting opportunity to incorporate epigenetics and epigenomics into carcinogen identification 
and safety assessment. Current epigenetic studies, including major international sequencing 
projects, are expected to generate information for establishing the “normal” epigenome of 
tissues and cell types as well as the physiological variability of the epigenome against which 
carcinogen exposure can be assessed. Recently, epigenetic events have emerged as key 
mechanisms in cancer development, and while our search of the Monograph Volume 100 
revealed that epigenetics have played a modest role in evaluating human carcinogens by the 
International Agency for Research on Cancer (IARC) Monographs so far, epigenetic data might 
play a pivotal role in the future. Here, we review (i) the current status of incorporation of 
epigenetics in carcinogen evaluation in the IARC Monographs Programme, (ii) potential modes 
of action for epigenetic carcinogens, (iii) current in vivo and in vitro technologies to detect 
epigenetic carcinogens, (iv) genomic regions and epigenetic modifications and their biological 
consequences, and (v) critical technological and biological issues in assessment of epigenetic 
carcinogens. We also discuss the issues related to opportunities and challenges in the 
application of epigenetic testing in carcinogen identification and evaluation. Although the 
application of epigenetic assays in carcinogen evaluation is still in its infancy, important data are 
being generated and valuable scientific resources are being established that should catalyze 
future applications of epigenetic testing.  
 
 
 
